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Two D or not two D: that is the question; 
Whether ‘tis nobler in the mind to suffer 
The streaks and blobs of intractable proteins 
Or to take chips against a sea of genes 
And by comparing, find them that 
Hold the bitter taste of disease and death. 
 
        (Fey and Larsen 2001) 
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Abstract 
 
Advances in DNA technology have led to the extremely sensitive and rapid 
analysis methods used in forensic science.   It can often be crucial to a criminal case to 
unequivocally identify the body fluid source of DNA. This is of particular importance in 
rape cases where the defence may argue that the source of a female DNA profile might 
be from a casual touch or from saliva. 
 
 In this study, proteomics has been employed in an attempt to identify potential 
biomarkers that are specific to a range of body fluids. Many publications cite the use of 
proteomics to identify biomarkers of disease such as cancer.  In these reports, 
diseased and healthy tissues or tissues that have been treated or not treated with a 
drug are compared and the expressed proteins are compared by 2D electrophoresis. 
Human body fluids differ in function, composition and protein expression. Proteomics 
therefore seemed an ideal application to isolate the proteins that are characteristic of 
and specific to, different fluid types. 
 
Both saliva and vaginal fluid proteomic methodologies were optimised for 
sample preparation, IPG strip pH range and protein load, and post-electrophoretic 
staining. 
 
Seventeen isolated protein spots from saliva and vaginal fluid samples were 
submitted for LC-MS/MS analysis.  Nine saliva spots and eleven vaginal spots were 
identified as known proteins on the MASCOT database. Of those thought to be specific 
to saliva or vaginal fluid six candidate biomarkers were tested further against a panel of 
body fluids for specificity using ELISA or Dot Blot.  
 
Zinc-α-2 glycoprotein (ZA2G) was detected and present in all body fluid 
samples thus could be used as a human body fluid positive control in a future assay.  
SCC (Squamous cell carcinoma) ELISA was capable of distinguishing samples of 
vaginal origin by detection of SCCA (Squamous cell carcinoma antigen). This antigen 
could be used in conjunction with a menstrual blood marker to distinguish between 
vaginal fluid and menstrual blood. Antibody specificity was a limiting factor in the 
success of the dot blots performed and hence the analysis of Cystatin SA, Cystatin SN 
and SERPIN B1 was inconclusive. 
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Chapter 1. Introduction 
  
 In forensic science it is often of vital importance to know the source of evidence 
such as a body fluid.  For instance, it can make a huge difference if DNA 
(Deoxyribonucleic acid) has come from saliva or vaginal secretion.  However, there is a 
lack of a good biochemical test for the identification of body fluids.  The work described 
in this thesis sets out to discover proteins that may provide unequivocal evidence for 
the source of an unknown fluid. 
 
1.1 Forensic Analysis 
  
 DNA is unique to each individual (except for identical twins). For this reason 
forensic science has exploited DNA as a method to identify and associate victims, 
suspects and pieces of evidence found at crime scenes. Short tandem repeat (STR) 
analysis is the method used to obtain DNA profiles, where short repeated sequences of 
non-coding, highly variable DNA are used to differentiate between individuals (Butler 
2005). The number of criminal cases relying on DNA evidence has dramatically 
increased over the past 10 years. In 1999 the number of crimes with a DNA match on 
the national DNA database (NDNAD) was 21,239 whereas in 2008/09, there were 
36,727 crimes with suspect-to-crime-scene DNA matches, (National Policing 
Improvement Agency (2009a)). The increase in matches is partly due to the expansion 
of the NDNAD. Figures as of the 30th September 2009 show that the number of 
individuals retained on the database is 4,762,033 and 351,461 crime scene samples to 
the database. The NDNAD may hold more than one profile from a given individual as 
samples could be taken from the same individual on more than one occasion.  This 
may happen as a result of a person giving different names, or different versions of their 
name, on separate arrests (National Policing Improvement Agency (2009b)).   
DNA analysis has become routine in forensic laboratories and sample 
submission increases have led to some of the steps of DNA profiling being automated 
to reduce time and labour. Although this has decreased turnaround times for DNA 
analysis it has meant that most of the time on a case is spent performing body fluid 
screening on exhibits, searching for potential stains to sample for DNA analysis. 
Without a confirmatory test for the different biological fluids on exhibits, the time 
involved and associated costs have led to an increase in samples bypassing body fluid 
identification prior to STR typing. DNA profiles are loaded to the NDNAD as quickly as 
possible.  
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DNA evidence can be in the form of body fluid or tissue samples, either swabs 
(from an individual or item taken at the scene) or on a physical article. Although the 
generation of a DNA profile from a piece of evidence implies that biological material is 
present, it is often important to a case to know from which biological fluid the DNA 
profile was obtained. It may also be of importance to identify individual stains.  If 
multiple stained areas are present on an exhibit – they may have originated from more 
than one individual and identifying the type of stain could assist in the investigation of 
the case.  
The most common body fluids encountered in forensic laboratories are blood, 
semen and saliva but others such as vaginal fluid, urine and sweat (Virkler and Lednev 
2009) can also be considered important sources for DNA within certain case 
circumstances. A case submission may also yield a mixed DNA profile (consisting of 
DNA from more than one person) derived from a mixture of body fluid samples. It may 
be important to the case to ascertain the body fluid source for each DNA profile within 
the mixture for example, semen and victim‟s blood in a rape case. Many body fluids are 
difficult to identify visually as they are colourless and therefore not easily discriminated 
from the background material.  
It is important to use a method to identify body fluid samples prior to STR 
profiling, to limit the number of submissions being analysed unnecessarily. It is 
important to ascertain whether a submission is likely to yield a DNA profile, and to ask 
if there is a body fluid stain present and if so if it is of human origin. As well as obtaining 
a DNA profile it could also be of value to prove the identity of the source of the DNA 
profile or even to exclude a particular fluid in any given forensic case.  
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1.2 Body fluids 
  
 Body Fluids have a varied composition related to their function and site of 
secretion or action within the body. The functions of body fluids include transport 
(blood), protection and lubrication (vaginal fluid), digestion (saliva) and excretion (sweat 
and urine). The different components of body fluids provide the basis for current 
identification tests. Frequently encountered forensic body fluids and their main 
components are shown in Table 1.1.  
 
Table 1.1: The main constituents of human body fluids (adapted from Virkler and Lednev 2009 
and Wilson 2005). 
 
Blood Saliva Semen Urine Vaginal fluid 
Haemoglobin 
Fibrinogen 
Erythrocytes 
Albumin 
Glucose 
Ig 
Glycoprotein  
Bicarbonate 
Chloride 
Potassium 
Sodium 
cAMP 
Amylase 
Ig 
Urea 
Phosphate 
Lysozyme 
Calcium 
Amino acids 
Ammonia 
Uric acid 
Lipid 
Thiocyanate 
Glucose 
Peroxidise 
Citrate 
 
Acid phosphatase 
PSA 
Spermatozoa 
Choline 
Spermine 
Putrescine  
Spermidine  
Cadaverine 
Semenogelin 
Zinc 
Citric acid 
Lactic acid 
Fructose 
Urea 
Ascorbic acid 
Ig 
Urea 
Sodium 
Chloride 
Potassium 
Ammonium 
Phosphate 
Calcium 
Creatinine 
Uric acid 
Bicarbonate 
Chlorine 
Glucose 
Mucins 
Albumin 
Ig 
Transferrin 
Lactoferrin 
Glucose 
Glycogen 
Mannose 
Glucosamine 
Fructose 
Neutral lipids 
Phospholipids 
Urea 
Lactic acid 
Acetic acid 
Butanoic acid 
Propanoic acid 
Amino acids 
Sodium 
Potassium 
Chloride 
  
 
 Saliva and vaginal fluid were analysed in this study for their particular relevance 
in ascertaining whether a rape or sexual assault has been committed. The components 
of each of these fluids relate to their function within the human body. The body fluids of 
focus within this study are saliva and vaginal fluid. The composition of these two fluids 
have been described in more detail. Both saliva and vaginal fluid contain epithelial cells 
originating from the oral cavity and vagina respectively and suspended in a liquid 
matrix. It is necessary to know a little about these fluids in order to predict potential 
markers and interpret the importance of characterised proteins. 
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1.2.1 The Epithelium 
 
 The human body is protected from microbes by a continuous tissue known as 
the epithelium, which is present on all surfaces of the body in contact with the external 
environment. There are two types of epithelial surfaces, the dry epithelia of the skin 
(epidermis) and the moist epithelia (mucosae) covering the internal body surfaces. The 
focus of this section will be on mucosal epithelia as it is found in the oral cavity and the 
genital tract. The apical surface of the epithelium is in contact with the external surface 
and the basal surface is in contact with the basal membrane and the underlying 
tissues. The cells of the oral cavity and the vagina are both stratified squamous 
epithelia (Figure 1.1) which is characteristic of the mucosae. Stratified epithelial 
surfaces consist of more than one layer of cells and are characteristic of areas 
subjected to mechanical abrasion.  
 
 
 
                    
Figure 1.1 A Schematic diagram of stratified squamous epithelium (Wilson 2005). 
  
 The epithelium acts as a physical barrier to microbes preventing their 
penetration to the underlying tissues. The epithelial surface contains receptors for the 
microbe adhesion molecules thus trapping them in the mucus. Epithelial cells are 
continually produced and shed along with trapped microbes in the mucus and expelled 
from the body. The epithelium secretes antimicrobial compounds such as, enzymes 
and antibodies capable of either killing microbes or inhibiting their growth. These 
antimicrobial compounds become concentrated in the mucus layer which enhances 
their affectivity.  
 
Apical Surface 
Basal Surface 
Basal Lamina 
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1.2.2 The Physiology of Saliva 
  
 Saliva is an aqueous fluid with a number of functions including lubrication, 
digestion, and host defence. It also acts as a buffer preventing pH fluctuations within 
the oral cavity as well as enhancing the remineralisation of teeth. 
 Saliva is a dilute fluid containing of more than 99% water (Humphrey and 
Williamson 2001) and is produced by both major (90%) and minor (10%) salivary 
glands. The major saliva glands, the parotid, submandibular and the sublingual are 
located outside the oral cavity (Figure 1.2). The parotid glands are located in front of 
the ears with ducts opening next to the upper second molar teeth. The submandibular 
glands are located beneath the tongue with their ducts opening behind the incisors. 
The sublingual glands are located in front of the submandibular glands and open into 
the oral cavity below the tongue. There are an estimated 450-750 minor salivary glands 
which are located in the buccal glands of the oral mucosa, the palate and the tongue 
(Aps and Martens 2005).  
 
 
Figure 1.2 A diagram showing the position of the human salivary glands adapted from The 
Medline Encyclopedia 2009 [online]. 
 
 Salivary glands are composed of acini where the initial isotonic saliva is 
produced. The acini are connected by ducts and the secreted saliva is drained into the 
oral cavity where there are changes in electrolytes giving saliva its hypotonic character. 
The hypotonic nature of saliva allows the taste buds to perceive different tastes without 
 
Sublingual gland 
Parotid duct 
Accessory Parotid gland 
 
 
 
 
 
 
Parotid gland 
Submandibular gland 
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being masked by normal plasma sodium levels (Humphrey and Williamson 2001). The 
pH of saliva is subject to fluctuations and can range from 5.30 (with low flow) to 7.80 
(high flow) (Humphrey and Williamson 2001). The composition of saliva originating 
from these glands differs. The saliva produced by the submandibular and sublingual 
gland has a higher mucus content than that produced by the parotid glands.  
The flow and secretion of saliva is dependent on numerous factors ranging from 
the time of day to the smell or sight of food as well as eating itself. The autonomic 
nervous system plays an important role in salivation, both sympathetic and 
parasympathetic stimulation are capable of causing salivation although the constituents 
of each secretion differs. Sympathetic stimulation leads to secretions containing more 
protein whereas parasympathetic secretions are more watery in composition 
(Humphrey and Williamson 2001). 
 There are two types of saliva, resting saliva (in the absence of a stimulus) and 
stimulated saliva (produced in response to a stimulus). The composition of these types 
of saliva also varies (Table 1.2). Stimulated saliva contributes between 80-90% of 
saliva produced daily. Stimulated saliva production is quicker than resting production 
for this reason; the faster speed that saliva passes through the salivary ducts means 
that there is less time for electrolyte exchange to occur thus a higher bicarbonate 
concentration is produced. This results in a higher buffering capacity of the saliva (Aps 
and Martens 2005). 
 
Table 1.2: The glandular composition and flow rate of resting and stimulated saliva (adapted 
from Wilson 2005). 
 
Type of saliva Composition Flow Rate 
Resting 
(high viscosity and protein rich) 
 
 
 
 
Stimulated 
 
20% Parotid 
65% Submandibular  
7% Sublingual 
8% minor salivary glands 
 
 
Parotid 
Submandibular 
Sublingual 
Minor salivary glands 
 
 
0.30ml/minute 
 
 
 
 
 
2.50-5.00 
ml/minute 
 
 The main components of saliva are proteins and glycoproteins with salivary 
mucins comprising approximately 25% of the total protein complement of saliva. 
Amylase, IgA (immunoglobulin A) and lysozyme are also major contributors to saliva.  
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The concentration of protein in saliva varies according to the abundance of the protein, 
and ranges between 140-640 mg/100ml (Wilson 2005) 
 Saliva also contains electrolytes, nitrogenous compounds and proteins, which 
play a role in the five different functions of saliva (Table 1.3). Although amylase and 
lipase are present in saliva the short time that food remains in the oral cavity may mean 
that limited digestion occurs. Amylase remains active up to 15 minutes after being 
swallowed whereas lipase is able to withstand the high gastric pH. Thus digestion of 
starch and fats may proceed with the aid of salivary enzymes after being swallowed. 
The oral cavity can contain approximately 1.1ml of saliva before the swallowing reflex 
is initiated (Wilson 2005). Swallowing only removes approximately 25% of saliva 
allowing all the surfaces of the oral cavity to remain covered with saliva. Saliva also 
acts as the main source of nutrients for microbes in the oral cavity.  
 
Table 1.3: The constituents of saliva and how they relate to the different functions of saliva 
(data source Wilson 2005). 
 
Function Substance 
 
Lubrication 
 
Digestion 
 
 
Buffer 
 
 
 
 
 
Tooth mineralisation 
 
 
 
Host defence 
 
Mucins 
 
Amylase 
Lipase 
 
Bicarbonate 
Phosphates 
Urea 
Amino acids 
Proteins 
 
Calcium  
Phosphates 
Proteins 
 
Immunoglobulins 
Proteins 
Mucins 
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1.2.3 The Physiology of Vaginal Fluid 
  
 To understand the components of vaginal fluid it is important to understand the 
structure of the vagina and its function.  
 The vagina is a muscular organ comprised mainly of smooth muscle with a 
mucosal epithelial lining.  The three functions of the vagina are; a childbirth canal, an 
outlet for menstrual blood and a receptacle for the penis during sexual intercourse. The 
folded epithelial lining is lubricated by mucus produced by the cervix. The vaginal 
mucosa has three main layers. The inner layer consists of basal cells active in cell 
division, the intermediate layer has glycogen producing cells with intracytoplasmic 
glycogen granules and there is a superficial layer with fewer glycogen granules and 
microfilaments than the intermediate layer which provides rigidity and protection for the 
other layers. The mucosa also contains lymphocytes and Langerhans cells (Wilson 
2005).  
 There are two cycles that make up the commonly described menstrual cycle; 
the ovarian cycle and the menstrual cycle. The ovarian cycle is associated with 
changes leading to ovulation (Figure 1.3B). The menstrual cycle is associated with 
changes in the endometrium leading to menstruation (Figure 1.3D). Both cycles are 
under hormonal control (Figure 1.3A and C).  
Menstrual cycle changes occur in the epithelium stimulated by the hormone 
Oestrogen, involving the proliferation, maturation and desquamation of the cells. 
Conversely progesterone inhibits the maturation of vaginal epithelial cells. The vaginal 
epithelium prior to the onset of menstruation and after menopause is thin due to the low 
Oestrogen levels at these stages. 
The mucus layer, although an important component of the host defense 
mechanism is also a major source of nutrients for microbes in the vagina. The mucus 
secreting cells of the cervix are affected by hormones; the quantity of mucus produced 
increases 10 fold and peaks at ovulation when the levels of Oestrogen are at their 
highest. The viscosity of the mucus also changes throughout the menstrual cycle. Prior 
to ovulation mucus viscosity is low, following ovulation when the level of progesterone 
rises less mucus is produced and it is much more viscous in composition than during 
the follicular phase. 
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Figure 1.3 The menstrual cycle and its relationship to the ovarian cycle. Reference.Queen Mary 
University of London [online]. 
 
The vaginal mucosa contains stores of glycogen which are metabolised 
anaerobically releasing organic acids e.g. lactic acid producing a pH in the vagina of 
approximately pH4. This acidic environment has an inhibitory affect on the growth of 
many bacterial species. Unlike other mucosal fluids the predominant class of antibody 
within vaginal fluid is IgG (Immunoglobulin G) rather than IgA (Wilson 2005).  
 Vaginal fluid is a mixture of fluids derived from a number of different sources; 
transudate from the vaginal mucosa, cervical mucus, endometrial fluid secretions of the 
bartholins glands, desquamated vaginal epithelial cells and leukocytes. Between 1-3 g 
of vaginal fluid are produced daily by women of reproductive age. It contains  water, 
carbohydrates, inorganic ions, proteins and amino acids (Dasari et al. 2007) providing 
the main source of nutrients for vaginal microbiota. Table 1.4 shows the principle 
components of vaginal fluid of pre-menopausal women. 
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Table 1.4: The main components of vaginal fluid (adapted from Wilson 2005). 
 
Type of molecule/ion Examples 
Protein 
 
 
Carbohydrate 
 
 
Lipid 
 
Low molecular weight organic 
compounds 
 
 
 
 
 
Amino acids 
 
Inorganic ions 
Mucins, albumin, Immunoglobulins 
(IgG, IgA, IgM), trasferrin, 
lactoferrin 
 
Glycogen (1.50g/100g) 
Glucose (0.62g/100g) 
 
Neutral lipids  
Phospholipids 
 
Urea 
Lactic acid 
Acetic acid 
Butanoic acid 
Propanoic acid 
 
 
 
Sodium 
Potassium 
Chloride 
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1.3 Current Body Fluid Identification 
 
Body fluid identification relies on two distinct method types. These are physical 
methods such as irradiation at different wavelengths and biochemical methods such as 
chemical presumptive tests.  Presumptive tests are used for preliminary identification of 
the fluid but in order to unambiguously characterise the fluid, a confirmatory test is 
needed. Although presumptive tests are used routinely there is a need for a 
confirmatory test for a range of body fluids. The current identification methods for major 
body fluids encountered at a crime scene or submitted to a forensic laboratory are 
described in further detail below. 
 
1.3.1 Blood 
 
 Blood is one of the few fluids for which both presumptive and confirmatory tests 
are available. 
Ultraviolet (UV) light can be used as a presumptive test to enhance blood stains 
present on dark background fabrics. However, overexposure to UV light is known to 
degrade DNA (Pang and Cheung 2007a) so caution must be used.  
Many of the biochemical tests for blood rely on the peroxidase - like properties 
of haemoglobin reacting with a substrate to create a colour change reaction. The most 
sensitive of presumptive tests currently used is the chemo-luminescent test reagent 
Luminol (Webb et al. 2006)  which has been used for the past 40 years (Barni et al. 
2007). Luminol is oxidised in the presence of hydrogen peroxide to an unstable excited 
state which upon decomposition liberates light. The reaction is catalysed by iron 
present in haemoglobin within blood samples (Figure 1.4).  
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Figure 1.4 A schematic diagram of the chemical reaction of Luminol with blood. Adapted from 
BlueStar Forensic (2004). 
 
Two other popular chemical presumptive tests with similar limits of detection 
(1:10000 blood dilution) are the Kastle-Meyer (KM) test and the Leucomalachite green 
(LMG) test (Virkler and Lednev 2009). These two tests are not as sensitive as Luminol 
which when diluted 1:1,000,000 times can successfully detect the presence of blood 
(Watkins and Brown 2004). Peroxidase in blood catalyses the reduction of hydrogen 
peroxide, liberating oxygen which in turn oxidises either LMG or KM solutions. A colour 
change from clear to either a blue/green colour (LMG) or pink colour (KM) change is 
seen when positive.  
The KM test relies on phenolphthalein causing an alkaline solution to turn pink 
after being oxidised by peroxide in the presence of blood (Figure 1.5) but no false 
positives have been shown with other body fluids.  
LMG also uses the catalytic properties of haemoglobin but in acidic conditions 
to produce a green colour. The heme group responsible for catalysing the reaction 
occurs widely in nature in cytochromes, plant peroxidases and some catalase 
enzymes. For this reason a positive result implies peroxidase activity and the 
presumed identification of blood. Oxidising agents such as copper salts and vegetable 
peroxidases may also yield false positives (Wecht and Rago 2006). 
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Figure 1.5 A schematic diagram of the Kastle Meyer chemical reaction in the presence of blood. 
Diagram adapted from Crosgray, W., 2004. 
 
A blood stain can be confirmed by microscopic analysis with the identification of 
blood cells. A major disadvantage with the luminol, KM, LMG and microscopic 
examination tests is that none of them are species specific.  
This problem can be overcome with immunodiffusion against antibodies specific 
to human haemoglobin (Otto and Somogyi 1974) and Enzyme-Linked Immunosorbant 
Assays (ELISA) (Kashyap, 1989). The most recently developed identification method 
uses an immuno-chromatographic strip. Independent Forensics of Illinois (IFI) produce 
the Rapid Stain Identification (RSID™). The lateral flow test strip uses two Human 
glycophorin A (GPA) antigens.  Glycophorins are cell membrane proteins expressed in 
red blood cells (RBCs) and prevent cell aggregation.  The detection limit of these strips 
is 1 µl of human blood with no cross reactivity seen with animal blood from the species 
tested. No cross reactivity was seen with human body fluids; vaginal fluid, semen, 
saliva and urine. Menstrual blood has not been tested with this kit (Schweers et al. 
2008). 
 A major problem of interest to forensic scientists is to discriminate between 
menstrual blood and venous blood. This information could be critical in a sexual assault 
case where the female is undergoing menses. Although red in colour a more 
appropriate term to describe menstrual blood could be menstrual fluid as it is 
considered a suspension of blood and endometrium fragments within a mixture of 
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serum and cervico-vaginal fluid (Farage and Maibach 2006). The blood content of 
menstrual blood is dependent upon the degree of endometrial breakdown whereas the 
vaginal fluid portion is mainly water, electrolytes and proteins. As well as serum 
components and red and white blood cells (expected with venous blood), menstrual 
blood also contains waste tissue, endometrial proteases and vaginal fluid. Unlike 
venous blood, menstrual blood will not clot as it lacks clotting factors such as fibrinogen 
(Dockeray et al. 1987). mRNA (messenger Ribonucleic Acid) studies for the positive 
identification of menstrual blood have been shown with vaginal fluid primer sets but not 
circulatory blood primer sets (Juusola and Ballantyne 2005).  
 
1.3.2 Saliva  
  
 There are only presumptive tests available for saliva. As with blood, a UV light 
can be used to locate saliva stains which appear blue/white in colour. The high water 
content of saliva makes it harder to detect than for example, a semen stain.  
 Most detection methods rely on detecting, α-amylase activity. There are two 
isoforms of α-amylase found within the human body. Both forms are encoded by genes 
on chromosome 1; salivary amylase (AMY1) and pancreatic amylase (AMY2) (James 
and Nordby 2003). However, salivary amylase is not found exclusively within saliva and 
pancreatic amylases are not found exclusively in the pancreas. Amylase found to be 
expressed within saliva, breast milk and sweat is encoded by AMY1 (locus 1). Amylase 
found expressed within the pancreas, vaginal fluid and semen is encoded by AMY2 
(locus 2).  
 The Phadebas test is a popular test used routinely in forensic laboratories for 
detection of α-amylase activity.  The Phadebas test consists of manufactured starch 
tablets which are dissolved in water and sprayed onto a piece of filter paper for the test. 
The starch is in the form of polymer chains, homogeneously interlinked to form spheres 
of known size, known as Bio-Degradable Starch Microspheres (DSMs). As starch is 
insoluble in water so are the DSMs. A water soluble blue dye is chemically attached to 
the microspheres and, as long as the dye is bound to the DSM, it remains insoluble in 
water. In the presence of saliva, α-amylase enzymatically degrades the DSMs.  A 
positive reaction is indicated by the diffusion of liberated blue dye molecules (Figure 
1.6). 
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Figure 1.6 A schematic diagram showing the hydrolysis of starch during the Phadebas reaction.  
 
 This test, although specific for α-amylase, is not specific for saliva. As 
mentioned previously, other body fluids contain lower levels of α-amylase, and positive 
Phadebas results are shown by urine, blood and semen (Whitehead and Kipps 1975). 
The false positives shown with this test mean it is of little use for discriminating 
between saliva and semen.  
IFI have developed an immuno-chromatographic test strip for saliva using anti-
human salivary (amyA) antibodies with a detection limit of 0.5 µl saliva. No cross 
reactivity was shown with any of the animal species saliva samples tested. No cross 
reactivity was shown with human body fluids; blood, semen, urine, vaginal secretions, 
or menstrual blood. Further discussion relating to this test can be found in Chapter 3. 
 
1.3.3 Semen 
 
 Presumptive tests are available for semen.  As for saliva, semen can be 
identified using an alternative light source (eg. the Wood‟s lamp). The Wood's lamp 
emits UV light (365nm) and was primarily used for identifying fungal or bacterial 
infections on the skin or scalp. When exposed to UV light at this wavelength semen 
has been seen to fluoresce on the surface of the skin but some ointments and creams 
can give false positives (Santucci et al. 1999).  
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 The most commonly used biochemical test for the identification of semen is the 
Acid phosphatase (AP) test (Lundquist 1950). There are two steps in the reaction 
(Figure 1.7). In step one, the AP enzyme present within semen (Table 1.1 page 4) 
catalyses the hydrolysis reaction of α-naphthyl phosphate to sodium phosphate and α-
naphthol (Kobilinsky et al. 2005). In the second step, the product α-naphthol then 
reacts with the chromagen, Brentamine Fast Blue (a diazonium salt) to produce an azo 
dye with a clear to purple colour change (James and Nordby 2003).  
 
 
Stage 1 reaction 
 
 
Stage 2 reaction 
NN
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Figure 1.7 A schematic diagram showing the AP reaction in the presence of semen. Adapted 
from Shinohara and Ohkuma 1964  
 
 False positive reactions have been shown with plant matter such as cauliflower 
stems and as Table 1.1 on page 4 shows, AP has been found present within vaginal 
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fluid and female urine as well as semen (Graves et al. 1985). This could cause 
confusion if identifying samples for a suspected rape case were required,  where 
identifying body fluid samples could imply whether sexual intercourse has occurred or 
not. It has been reported that the reaction with vaginal AP is much slower than that of 
seminal AP (Saferstein 2002), so timing could be used to determine the difference 
between samples giving a positive test result although this is not ideal and should not 
be used as a confirmatory test. 
 Isoelectric Focussing (IEF)  (Toates 1979) and sodium dodecyl sulphate 
polyacrylamide gel electrophoresis (SDS-PAGE) (Stolorow et al. 1976) have been used 
to separate the two forms of AP. But these methods are not ideal for providing a quick 
identification of body fluid type prior to STR analysis. In addition to the presumptive 
tests mentioned it is common practice to confirm the presence of sperm cells within 
semen by light microscopy, staining the DNA within the sperm head to aid detection. 
Christmas tree stain, hematoxylin and eosin are commonly used. A problem could be 
encountered if there is a low sperm count (Oligozoospermia), an absence of sperm in 
the semen (Azoospermia) or if the donor had had a vasectomy. A useful identification 
method therefore should be more concerned with identifying a component of semen as 
opposed to a component of sperm cells. 
 Detection of prostate-specific antigen (PSA) by ELISA (Tsuda et al. 1984) has 
overcome this problem. It is present in seminal plasma and therefore is present in the 
semen of azoospermic males. However, PSA can be detected at low levels in other 
body fluids so a PSA test should have the detection threshold set above the low levels 
present in other body fluids so as not to cause false positive reactions.  
 IFI have developed an immuno-chromatographic test strip for semen using anti-
human semenogelin antibodies detecting up to 1µl human semen. No cross reactivity 
was seen with animal semen from the species tested or with human body fluids; blood, 
saliva, urine, vaginal secretions or menstrual blood (Pang and Cheung 2007b).  
 
1.3.4 Vaginal Fluid 
 
 In the past few years identification of vaginal epithelial cells and vaginal fluid 
have been intensively investigated as previous identification methods used have 
limitations. 
 Vaginal fluid composition varies between individuals, and as previously stated 
(Section 1.2.3) can be affected by hormone levels, and therefore changes through the 
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menstrual cycle. The Lugol‟s test detects glycogenated epithelial cells using a periodic 
acid-Schiff (PAS) reagent to stain the glycogen within the cytoplasm purple – the 
intensity of colour is proportional to the number of cells. Glycogenation is variable 
throughout the menstrual cycle and no glycogenated cells are visible in tissue from pre 
or postmenopausal women excluding two sectors of the female population. The test is 
not specific as glycogen-containing squamous epithelial cells have also been found in 
the male urethral mucosa (Alm and Colleen 1982). A large volume of sample is 
required for this test and would destroy any potential DNA evidence within the sample 
(James and Nordby 2003).  
 The oestrogen receptor has also been investigated as a potential marker for 
vaginal fluid identification using immunohistochemistry with monoclonal antibodies. 
Although positive results were shown for vaginal mucosa samples, false positives were 
also shown with male urethra samples (Hausmann et al. 1996). The false positives 
would limit interpretation of the data in any sexual assault case trying to distinguish 
between seminal and vaginal samples. 
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1.4 Limitations to Presumptive Tests 
 
All of the identification tests described yield false positives. The tests are 
therefore indicative and only indicate the nature of the fluid. They also tend to be 
destructive towards the sample being identified.  
One of the most important factors to consider when developing a method of 
identification for use within forensic science is that it is important to preserve as much 
of the sample as possible for further DNA analysis since the samples submitted for 
analysis are often limited. Another problem is that current methods for identification 
only identify one fluid at a time, so the analyst has to decide which test to use or to use 
each test in turn thus using more sample each time. An ideal test would use a number 
of different reactions in parallel.  
Although microscopic examination can confirm the presence of blood and 
sperm cells, none of the routinely used immunological tests can definitely identify the 
presence of human saliva or vaginal secretions (Juusola and Ballantyne 2005). This is 
a serious problem in sexual assault cases where it is necessary to determine if a crime 
has taken place.  
For example in an alleged rape, a defence lawyer could propose that a female 
DNA profile recovered from a penile swab originated from the victims epithelial cells 
present within her saliva during an oral sex act, but the prosecution might argue that 
the DNA present originated from the victim‟s vaginal fluid during sexual intercourse 
without consent. Without a test to discriminate between saliva and vaginal fluid 
samples, this case would rely on personal statements. Uncertainty could lead to a 
reduced charge being brought by a court for an oral sex offence rather than full 
intercourse. Another example to consider could be if a sexual assault occurred 
between two individuals living in the same house where a relative of a child for 
example, such as a stepfather, was suspected of sexually assaulting a child. The DNA 
profile of the stepfather could easily be recovered from samples taken from the child‟s 
underwear and bedding. Defence arguments for this case could suggest that the DNA 
profile originated from innocent transfer of DNA from the father‟s skin cells to the child‟s 
clothing and bedding from close contact in the house. If it could be proven that the 
source of the DNA profile was from a semen stain there would be strong evidence in 
support of a sexual assault taking place (Hanson et al. 2009). 
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1.5 New Technologies for the Identification of Body 
Fluids  
 
 This section looks into new technologies which are currently being developed 
for body fluid identification.  Most of these ideas exploit the need for a universal 
confirmatory test capable of identifying a range of different body fluids working 
alongside current DNA techniques. A common theme is the analysis of immunological 
markers.  
 
1.5.1 Immunohistochemistry 
 
A technique used often in pathology to distinguish between fluid samples is 
immunohistochemistry. The method involves incubation with antibodies to antigens 
specific to the cell types of interest. Immunohistochemistry has recently been 
successfully applied in forensics, for example in the detection of the specific sweat 
antigen, G-81 (Sagawa et al. 2003) in the eccrine sweat gland with no staining visible 
in other tissues tested including the apocrine sweat gland. Immunohistochemistry also 
successfully identified deep central nervous system tissue (Miller et al. 2002) on fabric 
from a murder case. The technique has been reported to distinguish between epithelial 
cells from different origins such as buccal and vaginal cells (Paterson et al. 2006) by 
detecting differential antigen expression.  
Epithelial cells can be distinguished by the positive antibody-antigen reaction for 
Cytokeratin (CK) intermediate filaments. In this 2006 study, vaginal fluid epithelial cells 
were exposed to antibodies specific to the oestrogen receptor and phosphodiesterase 
5 (PDE5). These antibodies were unable to uniquely identify vaginal epithelial cells 
from the other cells tested in this study; the oestrogen receptor was not detected within 
vaginal epithelial cells whereas PDE5 was discovered in buccal cells and skin cells as 
well as vaginal epithelial cells. A similar study involving the oestrogen receptor gave a 
positive reaction  with male urethral swabs (Hausmann et al. 1996). For this work to 
progress further it is necessary to characterise specific fluid antigens.  
 
1.5.2 Raman Spectroscopy 
 
 Raman Spectroscopy is a non-destructive technique and has the potential to be 
used as a confirmatory test for body fluid identification. It is already being used in 
22 
 
forensic science to differentiate between types of material fibres (Jochem and Lehnert 
2002), paints (Buzzini and Massonnet 2004) and inks (Claybourn and Ansell 2000). 
Raman spectroscopy uses the scattering of low intensity laser light on a 
sample. The advantage of this method is that a sample amount in the pictogram range 
can be analysed, leaving sufficient sample for STR analysis. There is little interference 
from water making this technique ideal for analysis of body fluids.  
 Five body fluids have been tested: semen, vaginal fluid, saliva, sweat and 
blood. The resulting spectra from each body fluid were shown to be  significantly 
different (Virkler and Lednev 2008). Canine and human semen samples were also 
distinguishable by Raman spectroscopy. The technique appears promising but needs 
further development. Further work should examine a larger number of samples as only 
two donors were used. The technique is claimed to be non destructive but it has not yet 
been demonstrated that a full DNA profile could be obtained from the body fluid sample 
after Raman spectroscopy. Samples would also have to be analysed in a laboratory 
rather than in situ at a crime scene.  
 
1.5.3 PCR of Oral Streptococci 
 
 Oral Streptococci have been investigated for bite mark analysis, by measuring 
the persistence of bacteria on the skin after a bite mark to ascertain how long the bite 
mark has been present (Brown et al. 1984); this is particularly useful in determining 
when a crime took place or in cases of child abuse. As well as isolating bacteria 
present on the skin it would be important to identify the criminal from the saliva left on 
the bite mark using DNA profiling. 
With this in mind it has recently been suggested that the same techniques could 
be applied to using bacteria as a marker for saliva (Nakanishi et al. 2009) using PCR 
(polymerase chain reaction).  This work looked at detecting and identifying the 
presence of two streptococci strains, S.salivarius and S.mutans both of which are 
known to be present within saliva. The detection rates given for S.salivarius and 
S.mutans were 100% and 90% respectively. There was no cross reactivity shown with 
other animal salivas tested or the body fluids tested (semen, urine, vaginal fluid) or skin 
surface. However when using crime scene productions such as cigarettes and fabric 
the detection success decreased to 80% for S.salivarius and 60% for S.mutans. It 
would seem that from these findings S.salivarius showed to be more reliable for 
repeated detection.  
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 Following on from this work it has been postulated that bacteria from the vagina 
could be a marker for vaginal fluid identification. The vaginal microbiology was shown 
to be unchanged after the use of oral contraceptives and the use of tampons (Morris 
and Morris 1967) and of the 291 non pregnant women, aged between 18-45 studied 
the most predominant bacteria found to be present was Lactobacilli. The normal 
bacterial flora of women differs between individuals; terminal restriction length 
polymorphism (T-RFLP) has been used to compare 5 women over a two month period 
(Coolen et al. 2005). 
Lactobacilli were shown to be the dominant vaginal bacteria (Antonio et al. 
1999) occurring in 71% of the 302 women examined. Where Lactobacilli species were 
isolated (71% of the 302 women) the variation in species was high with a total of 9 
species being isolated. There are limited tests available to differentiate between 
Lactobacillus species thus making it hard to use this as a potential vaginal fluid marker. 
Lactobacillus acidophilus is also found to be a cause of tooth decay so could cause 
confusion in fluid identity by being present in saliva.  
There is a difference between the vaginal flora of women of different ethnic 
origins (Zhou et al. 2007). A sample population of 3012 healthy menstruating women 
between the ages 13-40 years were recruited and asked to classify themselves into 
one of four racial groups: white, black, hispanic or asian. Vaginal swabs taken from 
these individuals were analysed by T-RFLP analysis of the 16S rRNA (Ribosomal 
Ribonucleic acid) gene. Analysis of the 16S rRNA gene is used for phylogenic study as 
it is highly conserved between species and contains hypervariable regions specific to 
individual bacterial species, acting as a signature to each species (Weisburg et al. 
1991).  Internal regions of the 16S RNA genes were amplified in two separate reactions 
with fluorescently labelled primer sets (set one 8fm-926r and set two 49f-926r). Primer 
8fm was labelled with VIC, 49f with NED and 926r labelled with 6-FAM. Restriction 
digests were performed with MspI and HaeIII, as these enzymes have been shown to 
provide greatest resolution for bacterial populations in vaginal samples. The restriction 
fragments were then analysed by capillary gel electrophoresis where the labelled ends 
of the amplicons were detected and the resulting electropherograms analysed by 
cluster analysis. A clone library was developed using full length 16S rRNA amplicons. 
Phylogenetically related clones with a 90% or above sequence homology were 
presumed to be members of the same genus and those with greater than 97% 
homology were assumed to be the same species.  L.salivarius, Actinobaculum sp, 
Anaerococcus sp, Mobiluncus mulieris, Mycoplasma sp, Peptococcus niger, and 
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Peptostreptococcus sp were only found in Black women and not present in Caucasian 
women within the study again hampering the identification of a universal marker (Zhou 
et al. 2007) 
 
1.5.4 mRNA 
 
A common focus for body fluid identification has been Ribonucleic Acid (RNA) 
the intermediate molecule between DNA in the nucleus and encoded proteins within 
the cell (see Figure 1.8). DNA remains within the nucleus of the cell, limiting damage to 
the molecule whilst mRNA transports a copy of the genetic code out of the nucleus to 
the cytoplasm where proteins are formed at the ribosome from tRNA (transfer 
Ribonucleic Acid).  
 
 
Figure 1.8 A schematic diagram of the Central Dogma showing the flow of information from 
DNA via RNA to protein. (adapted from Ussery, D.2000) 
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The genes expressed within the diverse range of tissues and fluids in the 
human body, are tissue specific. For example the genes expressed within the brain are 
different to those expressed in the blood giving them different structure and function 
within the body. Genes are responsible for encoding proteins, and both mRNA and 
proteins are also expressed in a tissue specific way.  
 Although gene expression is tissue specific it would be misleading to assume 
that changes in transcript levels of the mRNA indicate the same changes at a protein 
level, either in the amount expressed or the activity of the protein (Lilley et al. 2002). 
Commonly, cellular processes such as post-transcriptional splicing, translational 
regulation, and protein complex formation lead to mRNA and protein expression 
differences (Guo et al. 2008). 
The levels of mRNA expression do not give any indications of post translational 
modifications shown by the proteins themselves which could lead to discovery of the 
protein‟s function within a cell type. Unlike the genome, which is constant and identical 
in every cell of a person‟s body, the proteome, the proteins actually expressed, are 
constantly changing in response to external environmental factors, thus different 
proteins are expressed in different cell types and at different times (Fey and Larsen 
2001). 
There are a number of groups working with mRNA expression to identify body 
fluid samples (Bauer and Patzelt 2002; Juusola and Ballantyne 2003; Alvarez et al. 
2004; Fang et al. 2006; Nussbaumer et al. 2006; Zubakov et al. 2008; Haas et al. 
2009). One of the major advantages of this approach is that it can be used in parallel 
with other current techniques by using a simple organic extraction method to co-extract 
both DNA and RNA. This ensures that a limited amount of sample is used in the 
analysis. Reverse transcription-polymerase chain reaction (RT-PCR) has been used to 
identify mRNA species that are cell type specific. Genes identified by each research 
group are summarised in Table 1.5.  Ideally a method which is capable of identifying a 
number of body fluids in one application is preferred.   
One way of achieving this would be to use a multiplex PCR, a technique where 
more than one pair of primers are used in one PCR reaction. This means that multiple 
regions of DNA or cDNA (copy Deoxyribonucleic Acid) are amplified in one reaction 
thus saving time and expense.  
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Table 1.5: Expressed genes identified as being body fluid specific 
 
Body Fluid Gene ID Gene name Reference 
Blood SPTB β-spectrin Juusola and Ballantyne 2005; Haas et al. 2009 
 PBGD Porphobilinogen deaminase Juusola and Ballantyne 2005; Haas et al. 2009 
 ALAS2 Erythroid δ-aminolevulinate synthase Juusola and Ballantyne 2007 
 HBA1 Haemoglobin alpha locus 1 Nussbaumer et al. 2006 
 HBB Haemoglobin beta Haas et al. 2009 
Saliva STATH Statherin Juusola and Ballantyne 2005; Haas et al. 2009 
 HTN3 Histatin 3 Juusola and Ballantyne 2005; Haas et al. 2009 
 MUC4 Mucin 4 Nussbaumer et al. 2006 
Semen PRM1 Protamine 1 Juusola and Ballantyne 2005; Haas  et al. 2009 
 PRM2 Protamine 2 Juusola and Ballantyne 2005; Haas et al. 2009 
 KLK3 Kallikrein 3 Nussbaumer et al. 2006;  
 SEMG1 Semenogelin1 Fang et al. 2006 
 SEMG2 Semenogelin2 Fang et al. 2006 
 TGM4 Human prostate transglutaminase 
(type IV) 
Fang et al. 2006 
 MCSP Human mitochondrial capsule 
selenoprotein 
Fang et al. 2006 
 PRB4 Proline-rich protein BstNI subfamily 4 Fang et al. 2006 
Menstrual 
Blood 
MMP-7 Matrix metalloproteinase 7 Juusola and Ballantyne 2005; Haas et al. 2009 
 MMP-10 Matrix metalloproteinase 10 Juusola and Ballantyne 2007 
 MMP-11 Matrix metalloproteinase 11 Bauer and Patzelt 2002; Haas,et al. 2009 
Vaginal fluid HBD-1 Human beta-defensin 1 Juusola and Ballantyne 2005; Haas et al. 2009 
 MUC4 Mucin 4 Juusola and Ballantyne 2005; Haas et al. 2009 
 ESR1 Oestrogen receptor 1 Fang et al. 2006 
 
A multiplex assay comprising nine genes has been used to detect blood, saliva, 
semen, vaginal fluid and menstrual blood (Juusola and Ballantyne 2005). This assay 
was extended with the replacement of the blood gene porphobilinogen deaminase 
(PBGD) by erythroid δ-aminolevulinate synthase (ALAS2) and the addition of a 
menstrual blood gene, matrix metalloproteinase 10 (MMP 10) (Juusola and Ballantyne 
2007) as well as a positive control primer set for the housekeeping gene 
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH). Successful endpoint PCR 
amplification was observed with the multiplex primer set reported by Juusola and 
Ballantyne (Haas et al. 2009). 
Epigenetic events give rise to PTM (post translational modifications).  Most 
proteins within the cell have some degree of PTM that determines the localisation or 
function of the protein and these modifications would not be detected by DNA or RNA 
based methods. It is also possible to determine the number of isoforms of a protein but 
this too cannot be determined from RNA based methods. 
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An additional problem of identifying body fluids/tissues by mRNA expression is 
raised by the methodology. Haemoglobin is a known inhibitor of Taq polymerase and 
blood samples submitted to forensic laboratories are routinely washed with ultrapure 
water to remove haemoglobin prior to DNA analysis.  To remove haemoglobin 
completely is very expensive as it would involve complete protein removal 
compromising the amount of RNA/DNA available for analysis. Humus from soil is 
another well-known polymerase inhibitor and a frequent contaminant of forensic 
samples. 
Using PCR as a potential method for body fluid identification could mean that 
inhibition problems are encountered in the discovery of primer sets for blood samples.  
Because of the major problems of expense and poor reliability associated with 
performing RT-PCR, it was decided that proteomics could lead to more reliable, faster 
and cheaper methods for body fluid/tissue identification. 
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1.6. Proteomics 
 
Proteomics is the large-scale analysis of proteins (Pandey and Mann 2000) or 
the proteome. The proteome or protein complement of a cell or tissue consists of all the 
proteins that are expressed within it. It is a representation of protein expression within a 
cell or tissue sample at a particular time and under a set of particular environmental 
conditions (Fey and Larsen 2001). Proteins can be separated in one dimension (1D), 
by molecular weight, although this is a simple technique many proteins will have the 
same molecular weight hence limiting the separating power of this method. Separation 
in two dimensions (2D), firstly by isoelectric point (pI) and then by molecular weight is a 
more powerful technique that has been in use since the 1970s (O‟Farrell 1975) to 
separate proteins, each protein will reside as a single spot on a gel. The typical 
workflow employed in Proteomics is shown in Figure 1.9. 
Initially proteins are isolated from their biological source. Separation of proteins 
by gel electrophoresis (GE) is performed either in one dimension (1DGE), separated by 
molecular weight or in two dimensions (2DGE), firstly, separated by pI  and secondly 
by molecular weight. Protein spots are cut from the gel and trypsinised into peptides. 
Peptides are separated by liquid chromatography (LC) and sequenced by tandem 
mass spectroscopy (MS/MS). Once separation and sequence data has been obtained 
online databases can then be used for protein identification. 
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Figure 1.9: A schematic diagram representing each stage of a typical proteomics experiment 
using 2DGE and LC-MS/MS. Image adapted from Collins et al. 2006 and Precision combustion 
Inc. 2008. 
 
The objective of proteomics is to identify and quantify proteins within a specific 
body fluid, cell type or tissue as well as looking at expression changes between two 
states of that sample type (Bernova-Giorgianni 2003) in order to gain a greater 
understanding of protein function within that sample or its role in a particular disease.  
Proteomics has traditionally been used for a comparison of protein expression 
levels between two sample types i.e. diseased or non diseased tissue, or a sample pre 
and post treatment with a drug, to study protein-protein interactions (Pandey and Mann 
2000).  
 A disadvantage of the technology is that it is not easily automated. Unlike 
mRNA technologies, 2DGE is reliant on the operator for sample preparation and gel set 
up, whereas post electrophoresis staining and spot analysis can be automated and 
robots are routinely used for these stages of analysis. Proteomics has benefited greatly 
from the genomic and bioinformatics eras, with the development of large databases 
that are accessible over the internet. These databases contain pI, molecular weight 
and protein sequence data to facilitate the identification of protein spots.  
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Some projects such as the Human Proteome Organisation (www.hupo.org) 
specifically focus on discovery of proteomes. So far their work has looked into 
characterisation of the human plasma proteome (Anderson et al. 2004) with ongoing 
research into the human liver and brain proteomes. It has been suggested that the 
study of body fluids would generate potential biomarkers for disease. Body fluids such 
as blood plasma contain secreted proteins. If a tissue expressed or secreted a protein 
characteristic of a particular disease it might be found with body fluids that are either in 
contact with that tissue or that pass through it.   
So far there has not been any published work to date using proteomics as a 
method for forensic body fluid identification although data has been published using 
2DGE with body fluids in other scientific areas. 
 For instance the sweat specific protein, G81 has been identified and excluded 
from other body fluids tested including saliva, semen and plasma (Sagawa et al. 2003) 
by 2DGE followed by Western blotting with G-81 antibody. Western blotting is a 
technique used to detect proteins separated by electrophoresis and then transferred to 
a nitrocellulose membrane. Proteins are identified using labeled antibodies. 
Interestingly, there was no cross reactivity with samples from other sweat producing 
mammals tested such as horses, donkeys and other primates.  
 
1.6.1 Saliva 
 
Some research groups have looked at the possibility of characterising the saliva 
proteome. Three hundred proteins were identified from one human donor‟s saliva (Hu 
et al. 2005). Whereas other research groups, identified 202 spots (Huang 2004) or 600 
spots (Ghafouri et al. 2003). These differences could be accounted for by the length 
and pH range of the IPG (immobilised pH gradient) strips used for the 1st dimension 
separation along with the size of the gels the samples were run on in the second 
dimension. The longer the IPG strip the greater the separation of proteins and also the 
larger the gel the greater the separation. Some samples may contain more acid 
proteins in which case a strip with pH range 3-6 would give better separation than a 
strip with pH 5-8, which would be more suitable for a sample containing more basic 
proteins. For forensic purposes an appropriate pH range would need to be identified in 
order to resolve a maximal number of protein spots within the samples studied.  
2D proteomics could be applied to the research problem addressed within this 
thesis. In this research project, it is important to investigate proteins that are expressed 
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population wide, therefore it would not be suitable to study samples provided by one 
person as reported by Hu et al (2005).  
Many factors affect the protein profile of saliva.  Dietary influences and an 
individual‟s age have an impact on the composition and volume of saliva (Aps and 
Martens 2005), implying a wide variation between individuals. Each person may 
express a slightly different protein profile within the saliva proteome especially as we 
know that protein expression is in a state of dynamic flux – changing in response to 
external and internal stimuli. For this reason proteomics has been used to discover 
potential markers of disease. It would therefore not be suitable to base a body fluid 
identification tool upon one individual samples protein complement. A collection of 
samples would be required to be representative of the population in order to ensure 
that any proteins that are selected for use are characteristic of the human population 
and not unique to one or a group of individuals.  
Two of the major proteins in saliva are amylase with a molecular weight of 
approximately 58 kDa and a pI of 6.47 (Hu et al. 2005) and IgA, with a molecular 
weight of approximately 51 kDa and a pI 0f 7.87 (Hu et al. 2005). Amylase is currently 
being used in forensic tests for the presumptive identification of saliva. To establish a 
confirmatory test it is necessary to identify proteins specific to saliva. Statherin and 
histatin have been studied as potential salivary marker proteins using mRNA 
techniques (Juusola and Ballantyne 2005).  
 
1.6.2 Vaginal Fluid 
 
The proteomic study of vaginal fluid has been limited so far, to analysing 
samples donated by pregnant women. Research has been focussed on searching for 
biomarkers within cervical-vaginal fluid (CVF) to monitor maternal and foetal health 
during pregnancy (Dasari et al. 2007).  
The early proteomics of vaginal fluid looked at 1D SDS-PAGE. Four protein 
bands were observed at 79 kDa, 67 kDa, 58 kDa and 52 kDa which were thought to be 
transferrin, albumin, IgA and IgG respectively (Itoh and Manaka 1988). SDS-PAGE 
only separates proteins according to molecular weight so the observed bands could be 
comprised of more than one protein with the same molecular weight. Higher resolution 
methods have identified a greater number of proteins within the fluid (Klein et al. 2008, 
Di Quinzio et al. 2007 and Tang et al. 2007).  
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Shotgun proteomics using LC-MS/MS without an initial gel separation method 
has been used to identify 40 vaginal fluid proteins from women in late pregnancy (Klein 
et al. 2008). A major limitation of this study was that only seven pregnant donors were 
used so they were not representative of the general population. An initial 2DGE 
experiment was performed to show the distribution of vaginal fluid proteins but as 
vaginal fluid protein levels were low the gel images did not show much detail in the 
protein expression.  
Recent studies using 2DGE have been investigated using samples from 
pregnant women (Di Quinzio et al. 2007). 400 protein spots were detected and of these 
15 spots were identified as common to the 5 women donors. The number of donors 
used in this study did not give an accurate representation of the population. Another 
study reported on samples donated by 29 non-pregnant women (Tang et al. 2007). The 
total number of protein spots detected was not noted but 147 proteins were identified. 
No attempt was made in any of these studies to determine characteristic proteins that 
are not found in saliva 
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1.7 Mass Spectroscopy (MS) and Proteomics 
 
Mass Spectroscopy (MS) is used to accurately identify protein spots by the 
determination of the ion masses. Traditionally Matrix-Assisted Laser 
Desorption/Ionisation- Time of Flight (MALDI-TOF) mass spectroscopy has been used 
for proteomic applications. Recent developments have seen tandem Mass 
spectroscopy using an electrospray ionisation (ESI) source with a triple quadrupole 
mass analyser being used increasingly for proteomic analysis. MS consists of an ion 
source (ESI or MALDI), a mass analyser and a detector (Aebersold and Mann 2003). 
The ion mass-to-charge ratio (m/z) is measured.  
The power of MS alongside proteomics has developed in-line with the continual 
growth of gene and genome databases.   
 
1.7.1 Matrix-Assisted Laser Desorption/Ionisation - Time of 
Flight (MALDI-TOF) 
 
Until very recently MALDI-TOF was used to measure the mass of intact 
peptides. Peptide-mass fingerprinting, as it is more commonly known, identifies a 
protein by its specific peptide mass.  Proteins are identified by matching a list of 
experimental peptide masses to a list of calculated masses within an online protein 
database (Aebersold and Mann 2003). The protein sample is crystallised along with the 
matrix onto a MALDI plate. MALDI ionisation is a soft form of ionisation, and does not 
penetrate the sample itself; most of the energy is absorbed by the matrix. Desorption 
occurs at the MALDI plate causing the matrix to become ionised (Figure 1.10). Proton 
transfer from the matrix to the sample causes ionisation of the sample. Due to the 
acidic crystalline nature of the matrix the ions produced have a positive charge.  
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Figure 1.10: A schematic diagram representing matrix assisted laser desorption and ionisation 
adapted from Ashcroft, A.E. 2009. 
 
The positive sample ions are accelerated through an electric field (Figure 1.11); 
the time the ion is trapped (takes to travel to the detector) is proportional to its m/z 
ratio. Ions with a large m/z (represented by red squares in Figure 1.11)  will travel more 
slowly through the Time of Flight analyser than ions with a smaller m/z (represented by 
green triangles in Figure 1.11) (Smith and Busch 1999).  
One drawback of this method for analysis is that it is difficult to automate 
because the sample must be mixed with the MALDI matrix. The result has been 
progress toward using a liquid chromatography approach coupled to MS/MS which can 
be easily automated for high throughput proteomic analyses. 
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Figure 1.11: A schematic diagram to show how a MALDI-TOF mass spectrometry operates, 
and thus showing a representation of resultant mass spectra adapted from Nijmegen 
Proteomics Facility [online]. 
 
1.7.2 Liquid Chromatography Coupled to Tandem Mass 
Spectrometers LC-MS/MS 
 
LC MS/MS gives better discrimination than MALDI-TOF for protein identification 
both ionisation pattern and peptide sequence are identified. It can be set up for 
automatic injection enabling 24 hour use. The method uses HPLC linked to a triple 
quadrupole mass analyser in combination with an electrospray/nanospray ion source 
(Figure 1.12). The protein of interest is initially cleaved with trypsin to produce a 
mixture of peptides which are easily ionised in the mass spectrometer. These peptides 
are then separated on HPLC and injected directly into the Mass spectrometer via a fine 
needle (electrospray). In the first quadrupole (Q1) a precursor ion consisting of a single 
peptide is selected based on its m/z and transferred to the second quadrupole (Q2) 
where it is subjected to collision induced dissociation (CID). Under low energy 
conditions the peptide ions fragment in predictable patterns (Delahunty and Yates 
2005).  
The fragmented peptides are analysed by the third quadrupole (Q3) to produce 
the product ion mass spectrum. The fragmentation conditions ensure cleavage of 
peptide bonds so the product ion spectrum is a representation of each amino acid in 
the peptide chain. The spectral peak pattern can be used to give information about the 
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peptide sequence in addition to obtaining the peptide masses as with MALDI-TOF 
analysis. 
It is possible to ascertain theoretical spectra sequences within databases based 
on these predicted patterns. The spectra can then be searched with the fragmentation 
patterns produced by the mass spectrometer using computational algorithms. Protein 
identification is made using probability based matching between the experimental data 
and the theoretical data within the database. A score is given based on the significance 
of the match.   
 
 
 
Figure 1.12: A schematic diagram to show how a LC-MS/MS operates adapted from Gates.P. 
2009 [online]. 
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1.8 Confirmatory Methods for Protein Identification 
  
 When putative protein identities have been obtained from Mass spectroscopy 
data it is necessary to confirm that the MASCOT database search correctly identified 
the protein of interest. Immunological techniques are commonly used as specific 
antibodies can confirm the presence of the protein and be used to determine 
quantitatively or qualitatively its expression in a given sample. The techniques most 
commonly used for this are ELISA (Enzyme Linked Immunosorbent Assay), dot blots 
and Western blots. 
 
1.8.1 ELISA  
 
 ELISA is a technique used to quantitatively determine the presence of an 
antigen within a sample. It is usually performed in a 96 well microtitre plate alongside 
relative standards of known concentrations of the antigen of interest. The mechanism 
of the reaction (Figure 1.13) is based upon antibody-antigen interactions. An antibody 
specific to the protein of interest is immobilised onto the wells of the microtitre plate. 
When test samples are added to the microtitre plate, antigens in the sample will bind to 
the antibodies in the wells of the plate if the protein of interest is present within the 
sample. Unbound molecules are removed from the plate by washing and the plate is 
blocked to prevent further protein binding to reactive groups other than those of the 
antigen. A second antibody specific to another epitope of the sample antigen is then 
added to the plate. The second antibody is linked to an enzyme that catalyses a colour 
producing reaction, such as alkaline phosphatase or horseradish peroxidise. Both 
enzymes are capable of rapidly converting molecules of a colourless or non-fluorescent 
substrate into a coloured or fluorescent product. The amount of second antibody bound 
is directly proportional to the amount of antigen captured by the primary antibody. 
Hence by measuring the coloured or fluorescent signal with a spectrometer it is 
possible to determine quantitatively the amount of antigen in the sample. Controls 
lacking antigen are used so that cross-reactivity of antibody can be corrected for. 
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Figure 1.13: A schematic diagram to show the key steps of an ELISA reaction. 
 
1.8.2 Dot Blot 
  
 Dot blots or slot blots (depending on the shape of the blot) can be used to 
identify DNA, RNA or proteins. The dot blot and the Western blot are based upon the 
same methodology of primary and secondary antibodies (Figure 1.14). The sample to 
be analysed is loaded directly to a membrane unlike a Southern, Northern or Western 
blot where the sample is separated by electrophoresis prior to blotting. Dot blots for 
protein identification are quicker and simpler than Westerns but do not identify 
individual proteins in a mixture. Without prior electrophoretic separation it is difficult to 
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ascertain whether the staining shown on the dot blot is due to cross reaction with other 
proteins in the mixture. After membrane blocking, the sample spots are incubated with 
antibodies specific to the antigen of interest (primary antibody), washed to remove any 
unbound antibody and then incubated with a antibody specific to the primary antibody 
(secondary antibody). The secondary antibody is enzyme linked, usually with alkaline 
phosphatase or horseradish peroxidise, Once again after incubation the membrane is 
washed to remove unbound antibody. Finally the membrane is incubated with a 
substrate that produces a coloured product, catalysed by the enzyme. The coloured 
product is directly proportional to the antigen of interest present in the sample.  
 
Figure 1.14: A schematic diagram to show the key steps of a Dot Blot or Western blot 
experiment. 
40 
 
1.8.3 Western Blot 
 
 A Western blot is a technique used after electrophoretic separation of proteins 
based on size to transfer them to a nitrocellulose or nylon membrane. The blot involves 
incubation of the membrane with primary antibody as with the dot blot, and then with a 
secondary antibody specific to the primary antibody. This secondary antibody is 
enzyme linked, common enzymes used are horseradish peroxidise and alkaline 
phosphatase.  When the membrane is incubated with a substrate, a signal proportional 
to the amount of antigen present is produced. The enzyme of the secondary antibody 
catalyses a reaction, which could be result in an insoluble coloured product 
(colourmetric), or a product which emits light by excitation at a particular wavelength 
(fluorescence) or simply emits light as a result of the chemical reaction itself 
(chemiluminescence). Densitometry of the detected bands can be used for 
quantification of the antigen in the tested samples. A major advantage of Western 
blotting is that due to the separation step bands can be checked for the correct 
molecular weight. 
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1.9 Future Technological Advances for Body Fluid 
Identification. 
 
 If a protein is confirmed by MALDI-TOF or LC-MS/MS and found to be 
consistently and specifically present in a body fluid, it could be used in the 
unambiguous identification of body fluids.  The next stage would be to exploit the 
antibody-antigen reaction by either creating a specific ELISA or to immobilise specific 
antibodies onto membranes and create a test strip which could be easily transported to 
a crime scene. 
 Lateral flow immunographic strips that immobilise specific antibodies into a 
cassette form have been developed for blood, saliva, semen and urine (see chapter 3) 
over the last two years. The advantage of the strips is that they can be taken directly to 
crime scenes or used within a laboratory setting. Results are obtained in a few minutes. 
There are however, problems with the current technology. The cassettes are only 
available for a few body fluids and the signal produced by the strips is only qualitative. 
Also, one test strip only identifies one antigen and hence one body fluid thus in order to 
definitively identify a fluid, more than one test kit may be required. If more than one 
type of kit is needed the costs are increased as well as the time taken to perform the 
tests. Ideally a platform capable of testing for a range of body fluids in one strip is 
needed.  
Immunographic lateral flow test strips have been produced to test for a panel of 
six drugs using one sample of saliva (Medimpex United Inc.). This idea could be 
exploited for body fluids combining the individual test kits into one multi-body fluid test. 
The number of antibody lines that could be physically placed onto a lateral flow strip 
would limit the number of body fluids that could be identified in one hit.  An alternative 
would be a microarray with antibodies to a range of proteins. Fluorescently labelled 
antibodies are deposited onto a glass surface via an attachment layer such as agarose. 
Due to the size of the protein arrays thousands of antibodies can be spotted onto one 
chip thus more than one target antibody per body fluid could be used, increasing the 
strength of any body fluid identifications made. The use of glass slides as a platform for 
antibodies has led to standard DNA microarray equipment (including detection 
scanners) being compatible with the protein arrays. As technology improves, protein 
arrays are becoming more commonly used in diagnostic applications. This more 
sophisticated approach would provide a quantitative as well as a qualitative approach 
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which could be advantageous if a mixture of body fluids was found at a scene.  The 
method would also indicate the relative amounts of each body fluid. 
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1.10 Aims of Research  
 
 The current problems of human body fluid identification have been considered 
when addressing the aims of this study.  The work presented in this thesis aims to 
combine knowledge of forensic science and biochemistry to develop a new technology 
capable of identifying a range of body fluids without some of the current disadvantages.  
This study focuses on two body fluids, saliva and vaginal fluid, which are 
frequently encountered in sexual assault cases. Current body fluid identification 
methods are only capable of identifying saliva. There is no current method for vaginal 
fluid identification.  
Published studies have used an mRNA approach to identify body fluids using 
RT-PCR. This thesis describes the development of a proteomics based technique to 
separate proteins within human body fluids. The proteomics approach enables the 
identification of changes at the protein level clearly by ascertaining whether or not a 
protein is expressed in one body fluid sample separated on a 2D gel compared with 
another sample. As this approach has not previously been used to distinguish body 
fluid components for identification optimisation of the methodology was necessary. 
The aims of the thesis are therefore: 
 
(i) To compare and asses three of the available methods of saliva identification 
currently used in Forensic science laboratories.  
 
(ii) To develop and optimise an analytical technique for the separation and 
analysis of saliva and vaginal fluid proteins. 
 
(iii) To identify protein biomarkers of saliva and vaginal fluid by 2DGE and LC-
MS/MS. 
 
(iv) To determine individual variation in biomarker levels  
 
 
(v) To confirm protein identification by immunological methods. 
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1.10.1 Thesis Structure 
 
 The Thesis has an experimental methods section describing all the methods 
used in this study (Chapter 2). Following this Chapters 3-6 have a similar structure with 
a short introduction, results and discussion. Chapter 3 assesses the current techniques 
available for saliva identification. Chapter 4 looks at the proteomics methods used in 
this study and the steps that were taken to optimise those methods. The results of this 
study are split into two chapters, firstly looking at expression analysis of the saliva and 
vaginal fluid samples as well as identification of protein biomarkers from each fluid 
(Chapter 5) whilst the confirmation of biomarker specificity is addressed in Chapter 6.  
Finally a discussion of biomarker suitability is addressed in Chapter 7 as well as future 
work and a conclusion.  
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Chapter 2 – Materials and Methods 
All reagents were supplied by Fisher Scientific, UK unless otherwise stated 
 
2.1 Reagents and Suppliers  
 
12 cm square disposable weighing boats  
2-D SDS-PAGE protein standard    (Bio-Rad®) 
30 ml plastic sample containers 
7 cm focussing trays     (Bio-Rad®) 
7 cm reswelling trays      (Bio-Rad®) 
7 ml Bijoux tubes 
Acetone HPLC grade 
acetonitrile 
30% acrylamide/bis      (Sigma®) 
Ammonium bicarbonate  
Ammonium persulphate  
Anti-goat IgG Antibody    (Sigma®) 
Anti-Mouse IgG Antibody    (Sigma®) 
Bio-Lyte 3-10 buffer      (Bio-Rad®) 
Bovine Immunoglobulin G (IgG) 1.45 mg/ml   (Bio-Rad®) 
Bovine Serum Albumin (BSA)   1.5 mg/ml   (Bio-Rad®) 
Bromophenol blue 
CanAg SCC (Squamous cell carcinoma) EIA kit  (Fujirebio™) 
comprising:    
 Streptavidin Coated Microplate 
 SCC Calibrators 
 Biotin Anti-SCC 
Tracer, HRP Anti-SCC 
TMB HRP-Substrate 
Stop Solution 
Wash Buffer (25x) 
CHAPS  
ChemiDoc™ EQ      (Bio-Rad®) 
Cotton swabs 
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Dithothreitol    
Eppendorf tubes 
Ethanol laboratory reagent grade    
Flamingo Fluorescent Gel stain       (BioRad®)  
Formic acid  
Glacial acetic acid analytical reagent grade   
Glycerol      (ACROS Organic, Belgium) 
Glycine       (ACROS Organics, Belgium) 
Goat anti-human Cystatin SN Antibody  (R&D systems) 
Goat anti-human Lipocalin -1 Antibody  (R&D systems) 
Goat anti-human SerpinB1 Antibody   (Santa Cruz Biotechnology) 
Gold trypsin       (Promega) 
Human Serum Albumin protein   (abcam®) 
Hybond-P membrane     (GE Healthcare, UK) 
HYBRI-SLOT™     (GIBCO BRL) 
Hyudroxycinnamic acid  
Instant dried skimmed milk    (Somerfield) 
Iodoacetamide                (ACROS Organics, Belgium) 
LABOPORT® N810 FT.18 vacuum pump  (KNF Neuberger, Germany) 
MassPrep handling station     (MicroMass) 
Methanol analytical grade 
2-mercaptoethanol 
Mineral oil      (Bio-Rad®) 
Mini PROTEAN® tetra tank    (Bio-Rad®) 
Mini gyro rocker Stuart SSM3    
MRX® II microplate reader     (Dynex Technologies, Worthing) 
Mouse anti-human Cystatin SA Antibody  (R&D systems) 
Paper wicks       (Bio-Rad®) 
PharosFX™ molecular imager    (Bio-Rad®) 
Phosphate buffered saline    (Oxoid) 
Phosphoric acid       (ACROS Organics, Belgium) 
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PlusOneTM silver staining kit; comprising:   (GE Healthcare, UK) 
 EDTA-Na2.2H2O  
 Formaldehyde 
 Gluteraldehyde 
 Silver nitrate solution 
 Sodium acetate  
 Sodium carbonate 
 Sodium thiosulphate 
PowerPac® 200      (Bio-Rad®) 
Protean® IEF cell     (Bio-Rad®) 
Purified Human IgG     (R&D Systems) 
Q-Trap triple quadrupole mass spectrometer (Applied Biosystems/MDS Sciex, 
 Warrington, UK) 
Recombinant Human Cystatin SA   (R&D Systems) 
Recombinant Human Cystatin SN   (R&D Systems) 
Recombinant Human Lipocalin-1   (R&D Systems) 
Recombinant Human SerpinB1   (Abnova) 
RC DC Protein Assay; comprising:    (Bio-Rad®)  
 DC Reagent A: alkaline copper tartrate 
 DC Reagent B: dilute folin reagent 
 DC Reagent S: sodium dodecyl sulfate  
 RC reagent I (contains Universal Protein Precipitation Agent-I (UPPA-I)) 
 RC reagent II (contains Universal Protein Precipitation Agent-II (UPPA-II)) 
ReadystripTM IPG strips 7 cm pH 3-10NL   (Bio-Rad®) 
ReadystripTM IPG strips 7 cm pH 3-6   (Bio-Rad®) 
ReadystripTM IPG strips 7 cm pH 4-7   (Bio-Rad®)  
ReadystripTM IPG strips 7 cm pH 5-8   (Bio-Rad®) 
Rotary Evaporator      (Rotovap) 
SameSpots Prodigy™ software    (Nonlinear Dynamics, Newcastle, UK) 
SDS 
SDS-PAGE Molecular Weight Standards, Broad Range  (Bio-Rad®) 
Sero-wel® Microtitre plate    (Bibby Sterilin) 
SIGMAFAST™ 3,3‟-Diaminobenzidine tablets (Sigma®) 
Sodium Chloride 
Spin baskets 
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SYPRO® ruby protein gel stain    (InvitrogenTM) 
TCA        
TEMED      (National diagnostics) 
Trifluoroacetic acid  
Tris base  
TWEEN-20 
UltiMate nanoLC system     (LC Packings, Camberley, Surrey) 
Unstained precision plus protein™ standards (Bio-Rad®) 
Urea        (ACROS Organics, Belgium) 
UV/white trans-illuminator    (Vilber Lourmat) 
Vivapure®Anti-HSA kit; comprising:   (vivascience) 
 HSA-affinity resin (50% slurry) 
 Binding Buffer 
Zinc-α-2-glycoprotein ELISA kit; comprising:  (Biovendor) 
Antibody coated microtiter strips 
Conjugate Solution 
Dilution Buffer Concentrate (2x) 
Human Zinc-α-2-Glycoprotein standard 
Quality controls – High and Low 
Substrate Solution  
Stop Solution 
Wash Solution Concentrate (10x) 
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2.2 Sample Collection 
  
Saliva and vaginal fluid samples (25 of each) were donated by volunteers living 
in the Aberdeen area and attending the Golden Square sexual health clinic. Patients 
visiting the clinic elected whether to participate in the study after reading an information 
sheet provided by myself (Appendix I and II) or a clinic nurse. Informed consent was 
obtained from all donors prior to sample donation (Appendix III and IV). No further 
selection of donors was made, in order that samples were representative of the 
Aberdeen population. Donor‟s sex, age, time the sample was taken and the time since 
the donor last ate or drank were noted for all saliva samples. For vaginal fluid samples 
the donor‟s age, the stage of menstrual cycle, when the sample was taken and the 
form of contraceptive the donor was using were noted (shown in Table 2.1). Vaginal 
fluid samples were not taken from donors during menses in order to avoid potential 
contamination by menstrual blood.  Semen, menstrual blood, blood and breast milk 
samples were obtained for comparison and optimisation experiments for these reasons 
only one donor was used in each case. 
 
Table 2.1 A table to show the donor characteristics recorded for samples taken. 
 
Sample type Donor characteristics 
Saliva Sex Age Time sample 
taken 
Time since 
donor last ate 
or drank 
Vaginal fluid  Age Stage of 
menstrual 
cycle 
Donor‟s form 
of 
contraceptive 
 
 The method of sample collection was dependent upon the fluid type. Saliva 
samples were collected in 7 ml plastic Bijoux tubes with approximately 3 ml saliva per 
donor. Vaginal fluid was collected onto cotton swabs (2 swabs per donor) from source, 
no samples were discounted for analysis by visual inspection. Additional samples of 
blood, menstrual blood, semen and breast milk were collected for comparative 
purposes, using one donor for each sample type and informed consent was obtained 
as before. Blood was collected by finger puncture and deposited onto a swab head and 
as with vaginal fluid, menstrual blood was also collected onto a swab head directly from 
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source. Semen ejaculate was collected by masturbation into a 30 ml plastic container 
and breast milk was expressed into a 30 ml plastic container. After collection samples 
were stored at -20°C until required. 
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2.3 Sample Preparation 
  
2.3.1 Saliva  
 
 The preparation of the samples depended on whether they were to be used for 
optimising the methodology or for the comparative results stage of this research (see 
Figure 2.1). For optimisation each saliva sample was centrifuged at 12000 x g for 5 
minutes at room temperature, to remove debris from the sample, and 300 µl of the 
saliva supernatant was then transferred to Eppendorf tubes and precipitation 
performed (see section 2.4). For comparative results each saliva sample was 
centrifuged as above and then pooled (see section 2.3.3) prior to precipitation.  
 
2.3.2 Vaginal Fluid 
 
 The preparation of the vaginal fluid samples also differed depending on whether 
the samples were used for optimising the methodology or for the comparative results 
stage of this research (see Figure 2.1). For optimisation the swab head was transferred 
to an Eppendorf tube and the cotton part broken from the swab handle. An adapted 
phosphate buffered saline (PBS) wash was used (Martin et al. 2006). Onto the swab 
head 1 ml PBS was pipetted and vortexed briefly at room temperature to disrupt and 
detach the cells attached to the swab head. The swab was left to incubate on ice for 15 
minutes.  The tubes containing the swab heads were centrifuged at 12000 x g for 5 
minutes at room temperature, with a spin basket in order to remove as much sample as 
possible from the swab. Diluted vaginal fluid supernatant (300 µl) was transferred to 
clean Eppendorf tubes and precipitation performed (see section 2.4). For comparative 
results the swab head was transferred to an Eppendorf tube and after the cotton part 
was broken from the swab handle  the treatment was exactly as above but each 
sample extract was then pooled (see section 2.3.3) prior to precipitation ( see section 
2.4). 
 
2.3.3 Sample Pools 
 
 For comparison of body fluids, individual sample pools were made from the 
saliva samples and another sample pool made from the vaginal fluid samples. Pools 
were made after samples had been centrifuged (see section 2.3.1 and 2.3.2). A main 
pool containing 50 µl of each sample supernatant was made as well as mini pools (see 
Table 2.2), based on donor data. For each sample 200 µl of supernatant was used, or 
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for pools comprising of only two samples, 300 µl of each sample supernatant was 
used. Each pool was made up in a 15 ml centrifuge tube. The pools were vortexed at 
room temperature and 300 µl aliquots were put in Eppendorf tubes and stored at -20°C 
until precipitation was performed (see section 2.4). 
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2.3.4 Semen 
 
 1 ml of each semen sample was centrifuged (12000 x g for 5 minutes at room 
temperature) to separate liquid semen from cellular components. Analysis of the liquid 
portion of semen (supernatant) only was performed as it is likely to always be present 
at a crime scene even if the male was azoospermic. The separated semen supernatant 
(300 µl) was transferred to Eppendorf tubes and precipitation performed (see 2.4). 
 
2.3.5 Blood & Menstrual blood 
 
 Both the blood and menstrual blood samples were treated in the same manner. 
After ethanol swabbing blood was deposited onto a cotton swab head by pricking the 
donor‟s finger. Approximately a 5 mm diameter spot on the swab tip was collected. 
Menstrual blood was collected onto swab heads directly from the donor during early 
menstruation when it was most easily collectable. The swab heads were cut from the 
wooden swab handles and transferred to Eppendorf tubes. 500 µl PBS was added to 
the swab head using a pipette and the tubes vortexed briefly at room temperature. The 
tubes were pulse centrifuged at room temperature, with swab heads in spin baskets in 
order to remove as much sample as possible from the cotton swab head.  The samples 
were then passed through an albumin depletion column (see 2.3.5.1) in order to 
remove the major protein from the samples.  
 
2.3.5.1 Albumin Depletion using Vivapure®Anti-HSA Kit 
(vivascience). 
 
2.3.5.1 (i) Vivapure®Anti-HSA/IgG Kit Protocol 
 
 The Anti-HSA affinity resin (50% slurry) was resuspended according to 
manufacturer‟s recommendations with distilled water.  440 µl affinity resin was added to 
each spin column followed by 20 µl of either blood or menstrual blood supernatant. 
Each spin column was then incubated on a rotary shaker for 15 minutes at room 
temperature before centrifugation at 400 x g for 2 minutes at room temperature. The 
resulting eluate was collected in a separate tube. Binding buffer (200 µl) was added to 
the same spin column and incubated on a rotary shaker for 2 minutes at room 
temperature. The spin column was once again centrifuged as above and the eluate 
collected once more and precipitation performed (see section 2.4). 
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 2.3.6 Breast Milk 
 
 Untreated breast milk (300 µl) was transferred directly to Eppendorf tubes prior 
to precipitation (see section 2.4). 
 
A summary of preparation steps for each body fluid samples is represented in Table 
2.2. The method of sampling for each body fluid had some bearing on the preparation 
steps involved prior to precipitation. 
 
Table 2.2: A summary of body fluid sample preparation. 
 Semen Blood/Menstrual 
Blood 
Breast milk Saliva Vaginal 
fluid 
Sample 
Preparation 
Steps 
Separate 
cells from 
cellular fluid 
Deposited onto 
Swab head 
Precipitation 
 
See Figure 2.1 
 Precipitation Add 500µl PBS    
  Albumin removal    
  Precipitation    
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2.4 Protein Precipitation Methods 
 
 Body fluid samples were kept on ice throughout the precipitation procedure. 
 
2.4.1 TCA (Trichloroacetic Acid) – Acetone 
 
 The precipitation method was adapted from Chen et al. (2002). Ice cold 10% 
TCA and 0.10% DTT solution (900 µl) was added to the Eppendorf tubes containing 
300 µl sample and kept on ice. The tubes were vortexed briefly and incubated on ice 
overnight.  
 The next morning the tubes were centrifuged at 12000 x g for 10 minutes at 
room temperature. The tubes were then washed with ice cold acetone twice and the 
acetone decanted off. The protein pellets were left to air dry for ten minutes. The 
sample pellets were resuspended by pipette action using 183 µl sample reswelling 
buffer (9M urea, 4% CHAPS, 0.50% Bio-Lyte 3-10 buffer, 0.001% Bromophenol Blue) 
and 17 µl 15% (w/v) DTT per tube. 
 
2.4.2 Ethanol  
 
 An adapted version of the ethanol precipitation performed by Rajan et. al. 
(1999) was performed using Ice cold ethanol (900 µl) added to the Eppendorf tubes 
containing 300 µl sample and kept on ice. The tubes were vortexed briefly and 
incubated on ice overnight. 
 The tubes were then centrifuged at 12000 x g for 20 minutes at room 
temperature and the ethanol supernatant removed. The protein pellets were treated as 
in 2.4.1 above. 
 
2.4.3 Acetone 
 
 Acetone precipitation was adapted from Hardt et al.  (2005a). 900 µl ice cold 
acetone was added to the Eppendorf tubes containing 300 µl sample and kept on ice. 
The tubes were vortexed briefly and incubated on ice overnight. 
The tubes were then centrifuged at 12000 x g for 20 minutes at room temperature and 
the acetone supernatant removed. The protein pellets were treated as in 2.4.2 above. 
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2.5 Protein Measurement by RC DC Protein Assay (Bio-
Rad
®
)   
  
2.5.1 Assay Protocol 
 
The Bio-Rad® RC DC (reducing agent compatible detergent compatible) Protein 
assay is a colorimetric assay for determining protein quantity. The assay is a 
microplate version (Bio-Rad®) of the Lowry assay (Lowry et al. 1951) further modified to 
be compatible with reducing agents and detergents. The protein standard used for the 
determination of protein concentration varied with the major protein component of the 
body fluid being tested, e.g. bovine immunoglobulin G (IgG) for vaginal fluid, saliva, 
semen and breast milk and bovine serum albumin (BSA) for blood and menstrual 
blood. Protein standards were prepared in sample buffer (9M urea, 4% CHAPS, 0.50% 
Bio-Lyte 3-10 buffer, 0.001% Bromophenol Blue) ranging from 0.18 mg/ml to 1.45 
mg/ml for IgG and 0.20 mg/ml to 1.50 mg/ml for BSA. Five protein dilutions and a zero 
protein concentration were used for each standard curve. 
The protocol supplied with the assay was followed; 25 µl of standard or sample 
was pipetted into an Eppendorf tube and 125µl RC Reagent I (contains Universal 
Protein Precipitation Agent (UPPA) -I) was added. The tubes were incubated at room 
temperature for 1 minute then 125 µl RC Reagent II (contains UPPA-II) was added to 
each tube and centrifuged at 12000g for 5 minutes at room temperature. The 
supernatant was decanted and the pellets resuspended in 25 µl Reagent A (5 µl of DC 
Reagent S (sodium dodecyl sulfate) added to 250 µl of DC reagent A (alkaline copper 
tartrate).  Tubes were left at room temperature for 5 minutes, and the contents 
transferred to a microtitre plate with 200 µl Reagent B (dilute folin reagent) being added 
to each well and mixed by pipette action. The microtitre plate was incubated at room 
temperature for 15 minutes. 
The microtitre plate was run on a MRX® II microplate reader (Dynex 
Technologies, Worthing) at 650 nm. The absorbance was read and the protein 
concentration of the samples determined from the standard curve produced. 
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2.6 Two-Dimensional SDS-PAGE  
 
2.6.1 IPG Strip Rehydration 
 
 The Protean® isoelectric focusing cell (Bio-Rad®) was used to separate protein 
samples in the first dimension using immobilised pH gradient (IPG) 7 cm Readystrips TM 
(Bio-Rad®). The IPG strips are in dehydrated form when purchased and need to be 
rehydrated with sample overnight prior to focussing. The protein load depended on the 
sample type and was run alongside a 2-D SDS-PAGE protein standard (Bio-Rad®); 4 µl 
of standard was mixed with the sample and sample reswelling buffer (9M urea, 4% 
CHAPS, 0.50% Bio-Lyte 3-10 buffer, 0.001% Bromophenol Blue)  to a final volume of 
125 µl. The 125 µl buffer/protein mixture was pipetted into the middle of an unused well 
of a 7 cm plastic 12 well IPG reswelling tray (Bio-Rad®). The plastic protective strip was 
removed from the IPG strip using forceps (see Figure 2.2) and the IPG strip was gently 
bent into a U shape, gel side down, into the well of the reswelling tray on top of the 
buffer/protein mixture.  
 
 
 
 
 
 
 
 
 
    a)                b) 
Figure 2.2 Photographs showing a) the plastic backing being removed from a dehydrated IPG 
strip prior to sample rehydration and b) sample loading into a focussing tray (ReadyStrip IPG 
strip instruction manual). 
 
 The strip was left for an hour to allow the liquid to distribute throughout the 
whole strip and then 1.50 ml of mineral oil (Bio-Rad®) was added on top of the strip and 
it was left to rehydrate overnight. 
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2.6.2 Isoelectric Focussing 
 
 Paper wicks (Bio-Rad®) were placed over each electrode of the 7 cm focussing 
tray (Bio-Rad®). Water (10 µl) was added to each wick to dampen it and thus maintain 
a good contact with the electrode. The IPG strip was removed from the reswelling tray 
and gently blotted onto tissue paper in order to remove any excess liquid. The strip was 
placed gel side down into the focussing tray with the positive end of the strip orientated 
towards the positive end of the focussing tray (see Figure 2.3).  
 
 
Figure 2.3: A Photograph to show an IPG strip being lowered into the focussing tray prior to 
being positioned into the IEF cell (ReadyStrip IPG strip instruction manual). 
. 
 
 The strip was covered with 1.50 ml of mineral oil. The lid was placed on top of 
the tray and the tray was positioned onto the peltier platform of the Protean® IEF cell 
(see Figure 2.4) ensuring that there was sufficient contact with the electrodes. 
Isoelectric focussing was performed overnight using a programme with the following 
settings: 
   
Rapid ramping to 200 V for 15 minutes 
  Rapid ramping to a maximum of 4000 V for 2 hours 
  Rapid ramping to a maximum of 4000 V for 20000 Vhr 
  Held at 500 V for a minimum of 30 minutes. 
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Figure 2.4: A Photograph to show the Protean
®
 IEF cell (BioRad
®
) (photograph taken in 
house). 
 
 The IPG strips were either kept at 500 V or the focussing tray was removed 
from the platform, wrapped in cling film and stored at -80°C depending on whether the 
second dimension stage was to be performed immediately following focussing or up to 
a week later. 
 
2.6.3 Separation in the Second Dimension – SDS PAGE 
 
     Table 2.3: A table to show the composition of 2D – SDS PAGE gels  
Solution 15% acrylamide 
gel 
12% acrylamide 
gel 
10% acrylamide 
gel 
30% acrylamide/bis  5 ml 4 ml 3.30 ml 
MilliQ water 2.30 ml 3.30 ml 4 ml 
1.5 M tris-HCL pH 8.8 2.50 ml 2.50 ml 2.50 ml 
10% (w/v) SDS 0.10 ml 0.10 ml 0.10 ml 
    
10% (w/v) Ammonium 
persulphate (APS) 
100 µl 100 µl 100 µl 
TEMED  4 µl 4 µl 4 µl 
 
The second dimension was performed using the mini-PROTEAN® tetra cell 
(Bio-Rad®). The casting stand was set up with 1 mm glass plates according to the Bio-
Rad® instruction manual (see Figure 2.5) and the appropriate gel mix made (see Table 
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2.3) in a conical flask. The APS (ammonium Persulphate) and TEMED 
(Tetramethylethylenediamine) were added finally before the gel was poured.  
 
 
Figure 2.5: A Photograph to show the SDS-PAGE gel (7 cm wide) set up (photograph taken in 
house) 
 
The gel mixture was swirled gently to initiate polymerisation. The gel was 
poured between the two glass plates of the casting stand using a disposable Pasteur 
pipette, to approximately 0.50 cm from the top of the shortest glass plate. Water was 
gently placed on the top of the gel using a pipette, to create a straight line when the gel 
sets, in order for the IPG strip to sit evenly on top of the gel. The gel was left to 
polymerise for 45 minutes. This time changed depending upon the temperature in the 
laboratory at the time. If the focussing tray had been stored at -80°C for up to a week, 
the focussing tray was removed from the freezer for a maximum of 15 minutes to allow 
the IPG strips to defrost sufficiently to be removed with ease from the tray. If the 
focussing tray was still positioned on the focussing platform, the program was paused 
and the IPG strips were removed from the focussing tray. Once removed from the 
focussing tray the IPG strips were blotted with tissue paper in order to remove excess 
liquid. Each IPG strip was placed gel side up in a fresh well of a reswelling tray 
specifically used for the equilibrium stage of the procedure. Firstly 2 ml of DTT 
(Dithiothreitol) equilibrium buffer (50 mg DTT in 2.5 ml equilibrium base buffer stock (6 
M Urea, 2% SDS, 50 mM Tris-HCl pH 8.8, 20% glycerol)) was added to each strip and 
the lid placed onto the tray. The tray was placed onto an orbital shaker at low speed for 
10 minutes. DTT is incorporated into the first step for the reduction of the disulphide 
bonds and complete unfolding of proteins (Gorg et al. 2000). The DTT buffer was 
decanted from each well of the reswelling tray and 2 ml of Iodoacetamide buffer (62.50 
mg Iodoacetamide in 2.50 ml equilibrium base buffer stock (6 M Urea, 2% SDS, 50 mM 
Tris-HCl pH 8.8, 20% glycerol)) was added to each strip. Iodoacetamide is added to the 
second buffer stage to remove excess DTT which would cause streaking in the 2D 
image (Gorg et al. 2000). Once more the lid was returned to the tray and the tray 
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placed onto the orbital shaker at low speed again for 10 minutes. After 10 minutes the 
Iodacetamide buffer was decanted from the reswelling tray and the strips were left in 1 
x Laemmli running buffer (Laemmli 1970) diluted from 10 x Laemmli running buffer 
stock (0.25 M Tris base, 1.92 M Glycine,1% (w/v) SDS) until the second dimension 
gels were ready to run. 
 Once the gels had set, the water was poured off and any residue absorbed by 
tissue paper. The glass plates were removed from the casting stand and positioned at 
an angle allowing for the IPG strip to be pushed down with the plastic coating facing 
the front of the glass plates and the + end of the strip to the left hand side of the gel. 
The strip was pushed into place using a small spatula until it made contact with the gel. 
Unstained precision plus protein™ standards (Bio-Rad®) were run alongside the gel, to 
give a representation of molecular weight in the second dimension. A paper wick (Bio-
Rad®) was cut in half using scissors and 5 µl of precision plus protein™ standard was 
added to it and stored at -20°C until required. One of these standards was lowered 
onto the right hand edge of each gel. Overlay agarose (Bio-Rad) was melted using a 
hot water bath and 1 ml was poured on top of the IPG strip to keep it in place and to 
monitor the electrophoresis run. Once the agarose had set the glass plates were 
assembled into the mini-PROTEAN® tetra electrophoresis cell (see Figure 2.6). The cell 
was filled with 1L of 1x running buffer and connected to a PowerPac™ 300 (Bio-Rad®) 
and gels were run at 200 V for 40-45 minutes. 
 
 
   
    a)      b) 
Figure 2.6: A Photograph to show a) the casket assembly and b) the electrophoresis set up for 
two 7 cm wide gels (photograph taken in house). 
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2.7 1D SDS- PAGE 
 
      Table 2.4: A table to show the composition of 1D – SDS PAGE gels  
Solution 4% Stacking gel 10% Separating gel 
30% acrylamide/bis  0.51 ml 3.30 ml 
MilliQ water 2.04 ml 4 ml 
1.50 M tris-HCl pH 8.8 - 2.50 ml 
0.50 M tris-HCl pH 6.8 0.375 ml - 
10% (w/v) SDS 30 µl 0.10ml  
10% (w/v) (APS) 30 µl  100 µl 
TEMED  3 µl  4 µl 
Total 3 ml 10ml 
 
 The SDS-PAGE separating gel setup was performed in the manner described 
for the second dimension (section 2.6.3) using the mini-PROTEAN® tetra cell (Bio-
Rad®). The separating gel mixture was made using the volumes described above 
(Table 2.4) and poured between the glass plates to approximately 1.5 cm from the top 
of the shortest glass plate. Water was gently overlaid as before to create a straight 
edge to the gel and the gel left to set. After approximately 40 minutes, when the 
separating gel had set, the water was poured off and a stacking gel was mixed (Table 
2.3), poured on top of the separating gel and a 10 well comb was placed in between 
the glass plates. Once the gel had set, the plates were removed from the casting stand 
and placed into the gel tank. The tank was filled with 1 x Laemmli running buffer diluted 
from 10 x Laemmli running buffer stock (0.25 M Tris base, 1.92 M Glycine,1% (w/v) 
SDS) and the combs removed from the glass plates. Each sample was prepared by 
transferring the desired load into an Eppendorf tube and adding 3 µl of 3 x dissociation 
buffer (0.50 M Tris-HCL pH 6.8, 25% (w/v) SDS, 21% (v/v) 2-mercaptoethanol, 27% 
glycerol, 0.01% Bromophenol blue) to it in a fume hood. An unstained standard was 
prepared also using 5 µl stock SDS-PAGE Standards (Bio-Rad®) and adding 3 µl of 3 x 
dissociation buffer (0.50 M Tris-HCL pH 6.8, 25% (w/v) SDS, 21% (v/v) 2-
mercaptoethanol, 27% glycerol, 0.01% Bromophenol blue)  to it in a fume hood. The 
sample tubes were placed into a heating block at 95°C for 5 minutes. Samples were 
pulse centrifuged and then the whole volume loaded into the gel wells using a pipette. 
The mini PROTEAN® tetra tank was plugged into a PowerPac® 300 (Bio-Rad®) and 
gels were run at 200 V for 40-45 minutes. 
 
 
 
 
65 
 
2.8 Post Electrophoretic Staining 
 
 Once electrophoresis had been completed the gels encased in glass plates 
were removed from the gel tank and separated using a small plastic separator. The 
gels were placed into individual 12 cm square disposable plastic weighing boats for 
staining. 
   
2.8.1 Staining with Colloidal Coomassie Blue G-250 
 
 All steps were performed with gentle agitation on a 3D orbital shaker. Firstly the 
gels were placed in 30 ml fixing solution (50% (v/v) ethanol, 25% (v/v) phosphoric acid) 
in a disposable weighing boat and left overnight. The gel was transferred to a clean 
weighing boat and washed in distilled water three times each for 30 minutes. The gel 
was then transferred to another weighing boat and put in equilibrium buffer (17% (w/v) 
ammonium sulphate, 34% (v/v) methanol, 2% (v/v) Phosphoric acid) for one hour. A 
small spatula (approx 10 mg) of Coomassie Brilliant Blue (CBB) G-250 powder was 
added to the equilibrium buffer avoiding direct contact with the gel and left to stain for 
up to three days. 
 The gel was rinsed with distilled water to remove any unbound CBB stain until 
the background staining was minimal. 
 
2.8.2 Detection of Proteins by Silver Staining (using PlusOneTM 
Silver Staining Kit GE Healthcare, UK) 
 
 The staining protocol was performed according to the manufacturer‟s 
recommendations and all steps were performed with gentle agitation on a 3D orbital 
shaker.  
 Initially the gel was placed in fixing solution (40% (v/v) Ethanol, 10% (v/v) 
glacial acetic acid) overnight and the following morning the gel was transferred to 
sensitizing solution (30% (v/v) Ethanol, 0.50%(v/v) Gluteraldehyde, 4% (v/v) Sodium 
thiosulphate, 6.8% (w/v) sodium acetate) for 30 minutes. The gel was then washed in 
distilled water (5 minutes x 3) and then in silver solution (10% (v/v) silver nitrate 
solution, 0.04% (v/v) formaldehyde) for twenty minutes. After this the gel was washed 
in distilled water twice for 1 minute each time. 
 The gel was placed in developing solution (2.50% (w/v) sodium carbonate, 
0.02% (w/v) formaldehyde) for 2½ minutes and then transferred to stop solution (1.50% 
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(w/v) EDTA-Na2.2H2O) for 10 minutes to prevent over developing of the gel. The gel 
was finally washed in distilled water three times for 5 minutes each time.  
 
2.8.3 Detection of Proteins using SYPRO® Ruby (Invitrogen™) 
Fluorescent Gel Stain. 
 
 The staining protocol was performed according to the manufacturer‟s 
recommendations and all steps were performed with gentle agitation on a 3D orbital 
shaker.  
 Initially the gel was placed in 30 ml fixing solution (40% (v/v) methanol, 10% 
(v/v) glacial acetic acid) for one hour. The gel was then transferred to a clean weighing 
boat and 30ml SYPRO® Ruby (Invitrogen™)  protein gel stain added to it, and covered 
in aluminium foil as SYPRO® Ruby (Invitrogen™) is a photosensitive stain. 
 The following morning the gel was transferred to a clean weighing boat and 30 
ml wash solution (10% (v/v) methanol analytical grade, 7% (v/v) glacial acetic acid) was 
added for 1 hour.  
 
2.8.4 Detection of Proteins using Flamingo™ Fluorescent Gel 
Stain (Bio-Rad®). . 
 
 The staining protocol was performed according to the manufacturer‟s 
reccommendations. All steps were performed with gentle agitation on a 3D orbital 
shaker.  Firstly the gel was fixed in 30 ml of fix solution (40% (v/v) methanol, 10% (v/v) 
glacial acetic acid) for 2 hours. The gel was then transferred to 30 ml of 1 x working 
staining solution (stock solution diluted 1:10 with MilliQ water) for 3 hours and the gel 
covered with aluminium foil to protect the photosensitive stain from light.  
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2.9 Image Analysis of Protein Gels. 
 
 Initially images were obtained using a ChemiDoc™ EQ (Bio-Rad®) Gel 
documentary system using either the epi white setting with a white conversion plate for 
CBB and PlusOne™ Silver stained gels, or  trans UV setting for fluorescently stained 
gels – SYPRO® and Flamingo™. The digital images produced using this method were 
8 bit resolution which provided images with insufficient grey tones for software analysis. 
An alternative imaging system was required. A PharosFX™ molecular imager (Bio-
Rad®) was used to obtain images with 16 bit resolution providing a greater number of 
grey tones per pixel more suitable for analysis using SameSpots Prodigy™ software 
(Nonlinear Dynamics, Newcastle, UK). Images were analysed to determine acceptable 
expression fold differences between identical spots on duplicate gels of the same 
sample. These were then used to identify expression changes between sub groups of 
samples and determine spots suitable for identification. The SameSpots Prodigy 
software guides the user through each stage of 2D gel analysis, by firstly ensuring 
images are of sufficient quality for analysis and matching the gel images to a master 
gel image through 21 matched expression vectors (identical spot matches) between 
each gel and the master gel image. These manually assigned vectors are used to align 
each gel positioning each gel relative to one another and hence allowing comparison 
between them to be performed. Once aligned, gel images are sorted for spot analysis 
and spots of interest are selected and a report formed containing expression data for 
each spot of interest on each gel analysed. 
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2.10 Spot Excision 
  
  Proteins fixed in two-dimensional gels were located with a UV/white trans-
illuminator (Vilber Lourmat). Protein spots were excised from the two dimensional gel 
using a pasteur pipette. The tip of the pipette was used to cover the spot and by 
pushing down on the gel the spot was cut from the gel. Each gel plug was then 
transferred to an Eppendorf tube.  To ensure sufficient protein was present within each 
tube a duplicate spot was cut for each sample. The spot samples were stored in 100 µl 
distilled water at 4°C until further analysis. 
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2.11 LC-MS/ MS  
 
 Gel plugs were trypsinised using the MassPrep (see Figure 2.7) automated 
handling station (MicroMass). The gel plugs were destained (50% acetonitrile, 0.05M 
ammonium bicarbonate), reduced (1.54 mg/ml dithiothreitol) and alkylated (10.20 
mg/ml iodoacetamide). Each stage took 30 minutes. The protein plugs were trypsin 
digested for 5 hours (Promega Gold trypsin in 0.1 M ammonium bicarbonate). Tryptic 
peptides were extracted from the gel plugs (40% acetonitrile, 0.10% formic acid) for 1 
hour.  All operations were performed at 37°C and the peptides were evaporated to 
dryness using a Rotovap.  
 
 
Figure 2.7: A Photograph to show the Mass prep automated liquid handling system (Rowett 
Institute of Nutrition and Health) 
 
The samples were prepared using 20 µl 0.10% formic acid, sonicated for 30 
minutes and transferred to sample vials for injection into the HPLC. An UltiMate nano 
LC system (LC Packings, Camberley, Surrey) was used with a C18 PepMap 100 
nanocolumn (see Figure 2.8), 15 cm x 75 µm id, 3 µm, 100 Ǻ (LC Packings). The 
system was operated with a column flow rate of 0.30 µl / min, a Famos autosampler set 
to an injection volume of 10 µl and a switchos microcolumn switching device set at a 
flow rate 0.03 ml / min using 0.10% formic acid. Two HPLC grade solvents were used 
in a gradient system (see Table 2.5); solvent A: 2% ACN (acetonitrile) and 0.10% 
formic acid and solvent B: 80% ACN and 0.08% formic acid. The gradient started at 5% 
B 95% A, moving to 50% of B and A over 30 minutes ramping to 80% B 20% A. The 
system was equilibrated at 95% A for 9 minutes prior to injection of the next sample. 
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The samples were held in the trap column for 7 minutes before entering the Mass 
spectrometer. 
 
 
Figure 2.8: A Photograph to show the UltiMate nanoLC system and Q trap Quadrupole MS 
(photograph taken in house). 
 
      Table 2.5: The HPLC solvent ramping sequence.   
Time (min) Flow Rate (µL/min) % Solvent A % Solvent B 
0.00 0.30 95 5 
30.00 0.30 50 50 
32.00 0.30 20 80 
42.00 0.30 20 80 
51.00 0.30 95 5 
60.00 0.30 95 5 
 
The Mass Spectrometry was performed using a Q-Trap (Applied 
Biosystems/MDS Sciex, Warrington, UK) triple quadrupole mass spectrometer fitted 
with a nanospray ion source, where Quadrupole 3 (Q3) operated as a linear Ion trap. 
The nanospray needle was set at 2800V. Oxygen free nitrogen (OFN) was used as the 
curtain gas and the collision gas. The mass range in Quadrupole 1 (Q1) was set to m/z 
400-1200 with a scan rate of 4000 amu/s. The criteria for selection of ions for the 
fragmentation (Quadrupole 2 (Q2)) were ions of 105 cps (counts per second) or above. 
The trap fill time (Quadrupole 3 (Q3)) was 250ms and the scan rate was 1000 amu/s 
(Atomic Mass Unit/second).  
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2.12 Database Searching  
 
Obtaining protein identification is not a simple process of data entry into a 
database resulting in an identification being produced. The experimental data produced 
by an LC-MS/MS experiment consists of the mass of the intact peptide, the peptide 
fragments and the retention time. Data output is in the form of a TIC (total ion count) 
spectra which displays a molecular ion scan of the retention times (in the LC capillary) 
of the molecular ions within the peptide mixture (Figure 2.9). This spectra alone does 
not provide any information regarding the protein identification.  
The TIC spectra were highlighted between 10 min and 55 min (which is where 
most of the peptides are detected and shown in the spectra). Following LC separation 
CID fragmentation of the molecular ion into daughter ions allows structural 
determination to be ascertained from the mass intervals of the daughter ions. 
BioAnalyst™ deconvolution software transforms the TIC spectra obtained from LC-
MS/MS into an electronic format compatible with the MASCOT database to identify the 
protein of interest. The area outlined in red would be highlighted by the analyst and the 
data transferred to the MASCOT MS/MS Ion search database (Matrix science). 
 
 
Figure 2.9: Total Ion Count spectra of sample control 1C. 
TIC: from Sample 1 (08-34342 2c) of 08-34342 2c.wiff (Nanospray) Max. 2.5e9 cps.
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The following search parameters  were used: the MSDB database, species homo 
sapien; allowance of zero or one missed cleavage; peptide mass tolerance at ± 1.50 
Da; digestion enzyme trypsin; carbamidomethyl modification of cysteine; partial 
modification methione oxidation and charged state of MH+ (see Figure 2.10). 
 
 
Figure 2.10: An example of the MASCOT MS/MS Ions search screen with desired search 
parameters set. 
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2.13 ELISA 
 
Saliva, breast milk, urine and semen were dispensed into 500 µl aliquots. The 
second vaginal fluid swab taken from each donor was used for the ELISA tests. Swabs 
were removed from their holders and the swab heads removed from their wooden 
sticks using scissors and placed into Eppendorf tubes. 300 µl PBS was added to each 
swab head and were vortexed for approximately 1 minute. The swab head was placed 
into a spin basket and pulse centrifuged to ensure the entire sample was recovered 
from the swab. Blood swabs were treated as in section 2.3.5 without removal of 
albumin.  
 
 2.13.1 CanAg SCC EIA ELISA kit (FUJIREBIO™) 
 
 The manufacturer‟s protocol was followed as below. Assay solutions were 
made prior to commencing the ELISA protocol. Each SCC Calibrator (Cal A-E) was 
reconstituted with 0.75 ml water, mixed gently by inversion and left to stand for 15 
minutes. Wash solution was diluted from the 25x stock solution to a 1x working 
solution. Antibody solution was prepared by adding the vial of Tracer, HRP Anti-SCC to 
the bottle of Biotin Anti-SCC. 
 Each strip of the 96 well plate was washed once with wash solution. The SCC 
calibrators (A-E) and samples (diluted 1:50) were pipetted (25 µl) into the wells of the 
96 well ELISA plate according to the template (Figure 2.11). Antibody solution (100 µl) 
was added to each well and the plate was incubated for 1 hour at room temperature on 
a microplate shaker. Each well was washed six times using 200 µl wash solution. TMB 
HRP-substrate was added to each well (100 µl) and the plate covered in aluminium foil 
and incubated for 30 minutes at room temperature on a microplate shaker. Stop 
solution (100 µl), was added to each well and the plate shaken briefly on a microplate 
shaker to mix. The absorbance was read using a MRX® II microplate reader (Dynex 
Technologies, Worthing) at 405nm within 15 minutes of the stop solution addition. The 
results of this ELISA were expressed as bar graphs. 
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2.13.2 Human Zinc-α-2-Glycoprotein (ZA2G) ELISA Kit 
(BioVendor). 
 
 The manufacturer‟s protocol recommends a 1:5000 dilution of serum samples 
with kit dilution buffer, but the test samples were diluted 1:2 as it was thought that the 
antigen would be expressed in lower amounts in the samples being studied compared 
with the human serum samples that the kit was designed for. 
 Dilution buffer was diluted 2 fold to produce a 1 x working buffer. Human Zinc-α-
2-Glycoprotein standard was reconstituted by adding 1.4 ml of 1 x dilution buffer to the 
vial making a stock solution of 100 ng/ml. Both the High and Low quality controls were 
also reconstituted using 1x dilution buffer (1 ml to each vial). Wash solution was diluted 
ten-fold in distilled water to produce a 1x working solution. 
 Standards were prepared by diluting Human Zinc-α-2-Glycoprotein master 
standard stock with dilution buffer (see Table 2.6). 
 
Table 2.6 A table to show the composition of ZA2G standards. 
Concentration Volume of standard Standard diluent 
100 ng/ml Stock - 
50 ng/ml 300 µl of stock 300 µl 
25 ng/ml 300 µl of 50 ng/ml 300 µl 
12 ng/ml 300 µl of 25 ng/ml 325 µl 
6 ng/ml 300 µl of 12 ng/ml 300 µl 
3 ng/ml 300 µl of 6 ng/ml 300 µl 
 
Diluted standards (Std), quality controls (QC), blank (dilution buffer) and samples (1:2 
dilution) were pipetted (100 µl) into the wells of the 96 well ELISA plate according to the 
template (Figure 2.12).  
 The plate was incubated for 1 hour at room temperature on a microplate 
shaker. The plate wells were washed 3 times (200 µl) with wash solution. After the final 
wash the plate was inverted onto paper towel and tapped to remove the remaining  
wash solution trapped in the wells. Conjugate solution was added to each well (100 µl) 
and the plate incubated for 1 hour at room temperature on a microplate shaker. The 
plate wells were washed 3 times (200 µl) with wash solution. After the final wash the 
plate was inverted onto paper towel and tapped to remove the remaining wash solution 
trapped in the wells. Substrate solution was added to each well (100 µl), the plate 
covered with aluminium foil and incubated for 10 minutes at room temperature without 
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shaking. Colour development was stopped by adding stop solution (100 µl) to each 
well. The absorbance was read using a MRX® II microplate reader (Dynex 
Technologies, Worthing) at 450nm within 5 minutes of the stop solution being added to 
the wells. Results expressed as bar graphs. 
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2.14 Dot Blot 
 
 Dot blots were performed according to an adapted version of a dot blot protocol 
reccommended by R&D Systems (R&D Systems 2009. Dot Blot Protocol. [online]).  
Initially Antibody sensitivity was tested using recombinant proteins to act as 
positive controls for the primary antibody reactions. Commercial recombinant proteins 
were sourced from R&D Systems (Cystatin SA, Cystatin SN and Lipocalin-1) and 
Abnova (Serpin B1). The method below was used throughout. 
A piece of Hybond-P (GE Healthcare) PVDF (Polyvinylidene Fluoride) 
membrane was cut to an appropriate size for the dot blot apparatus and the number of 
samples being blotted. 5 µl of loading buffer (0.12M Tris-HCl, pH 6.8, 6% (w/v) SDS, 
12% (v/v) Glycerol, 6mM DTT, 0.03% (w/v) Bromophenol blue) was added to each 
sample and they were incubated at 95°C for 5 minutes. The membrane was washed in 
methanol in a large plastic weighing boat and then washed in TBST (50 mM Tris base, 
0.5 M NaCl, 0.05% TWEEN-20, pH 7.4). The membrane was placed between the 
plastic blocks of the blotting manifold (GIBCO) and the screws tightened to keep the 
membrane in place. The Laboport vacuum pump was switched on (KNF Neuberger, 
Germany) and the samples loaded to the slot wells. The vacuum was kept on until the 
samples had fully penetrated the membrane; this took approximately 30 minutes. The 
vacuum was switched off and the membrane removed from the manifold and placed in 
block solution (8% dry skimmed milk in TBST) for 1 hour at room temperature. The 
membrane was incubated with primary antibody (diluted in block solution) for 1 hour at 
room temperature. Working antibody concentrations are listed in Table 2.7. The 
membrane was washed 3 times (10 minutes TBST, room temperature) then incubated 
with secondary antibody (diluted in TBST) for 1 hour at room temperature. Working 
antibody concentrations are listed in Table 2.7. The resultant blots appeared more like 
a line in shape rather than a dot due to the shape of the apertures of the blot 
equipment used. 
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Table 2.7: Working Primary and Secondary antibody concentrations. 
Antibody name Concentration Dilution Working 
concentration 
Anti-human Cystatin SN  0.10 mg/ml 1:1000 0.10 µg/ml 
Anti-human Cystatin SA 500 µg/ml 1:500 1.00 µg/ml 
Anti-human Lipocalin-1 0.10 mg/ml 1:1000 0.10 µg/ml 
Anti-human SerpinB1 200 µg/ml 1:200 1.00 µg/ml 
Anti-Goat IgG 7.90 mg/ml 1:8000 1.00 µg/ml 
Anti-Mouse IgG 0.80 mg/ml 1:4000 0.20 µg/ml 
  
The membrane was once again washed in TBST 3 times (10 minutes each 
time). Two SIGMAFAST™ DAB with cobalt chloride tablets (SIGMA) two urea 
hydrogen peroxide tablets were removed from the freezer and allowed to reach room 
temperature. 10 ml of MilliQ water was added to a 15ml centrifuge tube and the tablets 
added and vortexed until they had dissolved. The membrane was transferred to a clean 
plastic weighing boat and the DAB solution was poured over the top. Colour 
development took approximately 5-10 minutes. The membrane was washed in MilliQ 
water to stop colour development progressing once the desired intensity had been 
reached. 
The reaction mechanism for DAB colour development is shown below in Figure 
2.13. The Cobalt Chloride enhances the blue black colour produced in the DAB 
reaction. 
 
Peroxidase            +                    2H2O2                                         O2             +            2H2O 
(Secondary antibody)     (Urea Hydrogen Peroxide)                                            (pH 7.6) 
 
The oxygen liberated above reacts with DAB to produce a colour change 
 
O2      +     DAB/cobalt chloride                      blue/black ppt 
 
 
Figure 2.13 A schematic diagram showing the reaction of DAB with peroxidase labelled 
antibodies 
 
 
In the technical information provided from the antibody suppliers Anti-human 
Cystatin SA antibody (R&D systems) stated 100% cross reactivity with human Cystatin 
SN. Anti-human Lipocalin-1 antibody (R&D systems) stated 5% cross reactivity with 
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Lipocalin-2.  Anti-human Cystatin SN antibody (R&D systems) stated 30% cross 
reactivity with Cystatin SA, 15% cross reactivity with Cystatin S and 5% cross reactivity 
with Cystatin C. Anti-human SERPINB1 (Santa Cruz) antibody did not state any 
information on cross reactivity. No information was provided regarding the specificity of 
the secondary antibodies.  
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Chapter 3 
Identification of saliva: A 
comparison of three detection 
methods 
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Chapter 3 - Identification of saliva: A comparison 
of three detection methods. 
 
3.1 Introduction 
 
Historically saliva stain identification has been based on the detection of the 
most abundant and resilient enzyme to be found within saliva, amylase (Kirk 1963). 
Amylase is an enzyme that exists in two forms, α-amylase is found in animals whereas 
β-amylase is found in bacteria and plants. In humans there are two isoforms of the α-
amylase enzyme produced in saliva glands and in the pancreas and secreted into the 
digestive system, as a consequence of this small amounts diffuse into blood and are 
removed in sweat and urine (Barni et al. 2006) thus being detected in low levels in a 
number of other body fluids. Amylase has been shown to be present in perspiration, 
tears, breast milk, vaginal secretions, urine and seminal fluid (Merritt et al. 1973). From 
these findings it is important when considering using amylase as a detection enzyme 
for saliva, especially in sexual assault cases, to ensure that the kit is capable of 
distinguishing between the two isoforms of α-amylase. Failing that, positive results 
could be given for vaginal secretions and seminal fluid thus causing confusion in case 
circumstances.  
This chapter looks to compare two currently marketed identification methods 
(RSID-Saliva from Independent forensics, a chromatographic membrane strip test, and 
SALIgAE® tube test) with the more traditional Phadebas® (Magle Life Sciences) paper 
method currently employed in forensic laboratories throughout the UK. The work 
described in this chapter investigates test sensitivity with human saliva and cross 
reactivity with different mammalian species and other human body fluids. In order to 
determine whether the tests are compatible with routine forensic DNA extraction 
methods, saliva detection was tested with a range of alternative extraction buffers to 
those provided with the kits.  
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3.1.1 Phadebas® Paper Test 
 
Willott first reported the use of the Phadebas test in 1974, testing for amylase 
activity within a number of biological stains. The method used involved cutting out the 
stain, mixing with water and dissolving Phadebas tablets in the sample mixture and 
measuring the colorimetric change of the sample. This method confirmed the presence 
of amylase at low levels in other fluids as well as saliva. This method was further 
adapted into a touch test by dissolving Phadebas tablets in water and spraying the 
resultant mixture onto filter paper. This non destructive method is the method used 
more commonly today as the sample itself is not destroyed in any way and a DNA 
profile can be extracted from the exhibit after the test. In the Phadebas test amylase 
activity is tested with a blue dye crossed-linked to starch microspheres. These 
microspheres are immobilised onto filter paper and in the presence of amylase, the 
starch is hydrolysed, releasing the water soluble blue dye which stains the paper. 
 
3.1.2 RSID-Saliva Test 
 
The RSID-Saliva kit is a recently marketed kit which claims to use antibodies 
specific to human salivary α-amylase for detection. The manufacturers claim that it is 
the most sensitive test for human saliva with no animal saliva cross reactivity 
(Independent Forensics 2009). The test uses two mouse monoclonal antibodies 
specific to human salivary α-amylase, and detects the presence of salivary amylase 
rather than the activity of the enzyme.  It does this in a lateral flow strip format.  
One of the antibodies is conjugated to a colloidal gold dye to generate a signal 
and is deposited underneath the sample window. A capture antibody is at the test line 
of the strip. Anti-mouse IgG antibody is used as a positive control on each strip. The 
sample is loaded at position S (Figure 3.1); the sample moves through the membrane 
by capillary action and when it comes into contact with antibodies at the test line (T) an 
antigen-antibody complex is formed and a red line becomes visible if the sample 
contains amylase. At the control line (C) a similar reaction occurs between anti-mouse 
IgG and the mouse antibodies flowing past the test line, ensuring the sample fluid was 
transported through the strip effectively (Figure 3.1).  
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Figure 3.1:  A schematic diagram to show the positive antibody-antigen reaction which occurs 
when a saliva sample has been added to an RSID immunochromatographic test strip (image 
adapted from Wide University 2001) alongside a test strip displaying both a positive control 
band (T) and a band representing a positive result for saliva (C). Sample added at site S. 
 
3.1.3 SALIgAE Test 
 
The SALIgAE® test is based upon the presence of salivary amylase within a 
sample and consists of a transparent solution in a small glass vial. In the presence of a 
saliva sample a colour change from colourless to yellow is visible. The manufacturers 
have not released any information regarding the mode of action for this test yet.  
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3.3 Methods 
 
3.3.1 Samples 
 
3.3.1.1 Body Fluids 
 
 Human saliva, urine, blood, menstrual blood vaginal fluid, semen, sweat and 
breast milk samples were obtained with informed consent (Appendix V) from volunteer 
donors. Samples of vaginal fluid and menstrual blood were collected onto cotton 
swabs. For ease of comparison, the other samples were also applied to cotton swabs 
by dipping the swab head into the fluid sample. All samples were air dried at room 
temperature for 15 minutes, then stored at -20°C until required.  
 
3.3.1.2 Saliva from Animals 
  
 Three saliva samples were taken from each of cow, domestic cat and dog by 
collection onto swabs.  The swabs were dried for 15 min at room temperature and 
stored at -20oC for use in this study. 
 
3.3.1.3 Commercial Amylases 
 
 Two commercial α-amylases were tested for cross reactivity in all the tests. α-
amylase from porcine pancreas (A3176, sigma) and α-amylase from Bacillus 
licheniformis (A3403, sigma) were diluted with deionised water to    6.25 units/µl and 
26.10 units/µl respectively before use. 
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3.3.2 RSID-Saliva 
 
 Dried saliva on cotton swabs was the source material for analysis. One quarter 
of each cotton swab was cut off and placed into a labelled Eppendorf tube. PBS (1 x 
250 µl) was added to each tube and left to extract for two hours at room temperature. 
After a brief vortex, 20 µl sample was mixed with 80 µl of TBS in a clean labelled 
Eppendorf tube and the contents deposited into the sample window of the kit (marked 
S in Figure 3.2).  Almost immediately a pink control line appeared. The reaction state 
was recorded after 10 minutes in accordance with manufacturer‟s instructions, this 
allowed the background of the strip to fade. A positive test result was shown by 
red/pink lines appearing in the T and C regions of the cassette.  A negative result was 
shown by a line appearing in the C region of the cassette only (Figure 3.2). 
 
 
Figure 3.2:  RSID strip tests showing from left to right negative and positive test results 
respectively (photo taken in house). 
 
3.3.3 SALIgAE® 
 
The manufacturer‟s instructions were followed with a minor variation. The 
recommended volume of extraction buffer for the swab was 50 µl. In this work, the 
volume was increased to 500 µl, as when 50 µl was added to the swab for extraction it 
was completely absorbed by the swab making recovery of the liquid very difficult. 
 In accordance with the instructions, half a swab was used for extraction in 500 
µl distilled water at room temperature for 30 minutes. The test vials were equilibrated to 
room temperature before saliva samples were added. Sample (8 µl) was added to the 
test vial and the reaction timed for 10 minutes. A clear to yellow colour change was 
S S 
T 
C 
T 
C 
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shown if the test was positive and no colour change shown in the negative reactions 
(Figure 3.3) 
 
Figure 3.3: SALIgAE vial tests showing from left to right, positive and negative test results 
respectively (photo taken in house) 
 
3.3.4 Phadebas Test 
 
Phadebas paper was produced according to the manufacturer‟s guidelines. A 
positive reaction was observed when saliva was spat directly onto a piece of Phadebas 
paper, resulting in a blue colour being formed characteristic of the presence of amylase 
(Figure 3.4). 
Body fluid stains on white cotton fabric were tested. One Phadebas tablet was 
dissolved in 10 ml deionised water and transferred to filter paper using a fine aerosol 
spray and left to dry for approximately 15 minutes until touch dry. The paper was then 
placed sprayed side down onto the fabric, the back of the paper lightly sprayed with 
water and covered with a piece of plastic , A weight was applied to ensure a good 
contact was made and the reaction left for approximately 40 minutes or when the blue 
dye could be seen through the back of the paper. 
 
Figure 3.4: A piece of phadebas paper showing a positive reaction for the presence of saliva 
(photo taken in house). 
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3.3.5 Determination of Test Sensitivity 
 
In order to determine the limits of each test five saliva dilutions were made to a 
final volume of 50 µl (Tables 3.1, 3.2 and 3.3) with the extraction buffer of each kit. 
Water was used to dilute samples used in the Phadebas test.   
The methods used for this were described in sections 3.3.2 and 3.3.3 except 
that 50 µl was loaded to each swab head and for RSID the whole swab head was 
extracted in 1 ml of 1x PBS for 2 hours, whereas for the SALIgAE test the method was 
not changed. For the Phadebas test, saliva dilutions were prepared in Eppendorf tubes 
to a final volume of 50 µl and then the whole volume of saliva was deposited onto 
cotton fabric 
 
Table 3.1: Serial dilution of saliva used for RSID test sensitivity. 
 
Sample 
identification 
Dilution of saliva 
loaded to swab 
Final saliva 
Dilution 
 
Equivalent saliva in 
final test volume 
RSID 
(µl) 
A undiluted 1:1,000 1.00 
B 1:1 1:2,000 0.50 
C 1:4 1:5,000 0.20 
D 1:9 1:10,000 0.10 
E 1:49 1:50,000 0.02 
F 1:100 1:100,000 0.01 
N.B Equivalent saliva in final test volume stated to compare with RSID validation study 
published by Independent Forensics (Old et al. 2009). 
 
 
 
 
 
Table 3.2: Serial dilution of saliva used for SALIgAE test sensitivity. 
 
Sample 
identification 
Dilution of saliva 
loaded to swab 
Final saliva 
Dilution 
SALIgAE 
A undiluted 1:500 
B 1:1 1:1,000 
C 1:4 1:2,500 
D 1:9 1:5,000 
E 1:49 1:25,000 
F 1:100 1:50,000 
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Table 3.3: Serial dilution of saliva used for Phadebas test sensitivity. 
 
Sample 
identification 
Dilution of saliva 
loaded onto fabric 
for Phadebas 
A undiluted 
B 1:1 
C 1:4 
D 1:9 
E 1:49 
F 1:100 
 
3.3.6 Determination of Specificity 
 
3.3.6.1 Body Fluids 
 
All body fluids listed were used to determine the specificity of all three tests by 
extracting the samples as described in section 3.3.2 and 3.3.3. For the Phadebas test 
the samples were either deposited directly onto cotton fabric or the swab head 
moistened with distilled water and rubbed against the fabric (depending upon the 
sample type) and left to air dry before the test protocol was performed. 
 
3.3.6.2. Species Specificity 
 
 All animal body fluids listed were used to determine the specificity of each test, 
again the swab heads were extracted according to the RSID and SALIgAE protocols 
(sections 3.3.2. and 3.3.3) and for the phadebas test the swabs were moistened using 
distilled water and rubbed onto cotton fabric and left to dry before the test was 
performed 
 
3.3.6.3. Commercial Specificity 
 
 In order to maintain the same conditions across each test and between samples 
the number of units of amylase loaded onto each swab for each test was kept the 
same. Swabs were extracted as described for the RSID and SALIgAE tests (section 
3.3.2 and 3.3.3.) and deposited onto cotton fabric for the Phadebas test.  
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3.3.7 Compatibility of Tests with Alternative Extraction Buffers. 
 
 Saliva was collected into a bijoux tube and swabs were dipped into the saliva. 
Each swab head was cut from the stick and transferred to Eppendorf tubes labelled 
with the extraction buffer to be used in each case. Extraction buffers used were Lysis 
buffer, TE (Tris-EDTA) buffer, PBS buffer, water and the kit extraction buffer for RSID. 
Both tests were run as before (section 3.3.2 and 3.3.3); 1 ml of test extraction buffer 
was added to the corresponding labelled tubes for that test and vortexed briefly. The 
samples were left to extract for 1.5 hours and the appropriate amount of sample tested. 
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3.4. Results and Discussion 
 
 In this chapter the results and discussion will be combined together due to the 
integral part this initial study plays in the method development of the work presented in 
this thesis. 
 
3.4.1 Sensitivity 
 
 A summary of the results for kit sensitivity when tested with human saliva is 
shown in Table 3.4. Human saliva was diluted to determine the sensitivity of each test. 
The RSID-Saliva test performed best and could detect a 1:50,000 dilution of neat saliva 
applied to the test cassette. The SALIgAE could detect saliva at a 1:2500 dilution.  
RSID-Saliva instructions state that the reaction is not linear, which agreed with 
findings from this experiment. A standard curve was drawn using densitometry 
readings for the test strip band intensities using the GelDoc in association with 
QuantityOne software (Bio-Rad) (Figure 3.5).  On the graph drawn the intensity of 
bands seemed to level off with higher volumes of saliva being tested. No positive 
results were obtained for the Phadebas test used with the same saliva dilutions; this 
could be due to insufficient saliva being deposited onto the fabric.  
 
 
Figure 3.5:  A calibration curve to show the density of the test band of the RSID kits used in the 
saliva sensitivity test. 
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Table 3.4: The sensitivity of three different saliva detection methods. 
 
Sample 
identification 
Dilution 
of saliva 
SALIgAE-
Saliva test 
RSID-Saliva 
test 
Dilution of saliva 
loaded to fabric for 
Phadebas 
Phadebas-
Saliva test 
A 1:500 +++ +++ undiluted - 
B 1:1000 +++ +++ 1:1 - 
C 1:2500 +++ ++ 1:4 - 
D 1:5000 - + 1:9 - 
E 1:25000 - + 1:49 - 
F 1:50000 - - 1:100 - 
 
+++ strong signal, ++ medium signal, + barely detectable signal, – no signal. 
 
 These detection limits fall within reported values. Independent Forensics 
(manufacturers of the RSID – Saliva test) claim that the kit can detect as little as 1 µl of 
saliva (Old et al. 2009). However a higher detection limit was seen by (Pang and 
Cheung 2008) of 1:10000 saliva dilution which would be the equivalent of 0.1 µl saliva.  
Abacus SALIgAE (Miller and Hodges 2005) showed a positive result for a 
1:1000 saliva dilution but not 1:10000. In this work SALIgAE gave a positive result with 
a 1:2500 dilution of saliva. The findings from this experiment are consistent with work 
carried out by Lim.  Si-Keun et al. (2008).  
In contrast, the results using Phadebas paper did not confirm reported values. 
Previous work has shown Phadebas to successfully detect saliva at 1:100 (Pang and 
Cheung 2008) and 1:200 (Myers and Adkins 2008) using the Phadebas tube test. 
Using Phadebas paper the lowest detection dilution has been reported as 1:5 (Lim.  Si-
Keun et al. 2008). In this work saliva was dropped directly onto the Phadebas paper. 
The volumes used in this experiment did not detect saliva even when undiluted. The 
low detection limit for Phadebas detection is reported as 2000U/L (Magle Life 
Sciences). Human saliva has an average amylase concentration of 263000-376000 
U/L (Whitehead and Kipps 1975). From this it was expected that at least the undiluted 
saliva would have shown a positive result with the Phadebas paper. Therefore this 
experiment proves that the antibody identification methods detecting the actual 
presence of the enzyme are more sensitive than the Phadebas method detecting the 
activity of the enzyme or that the amylase tested was not active. 
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3.4.2. Body Fluids 
  
Previous validation experiments have tested a limited range of body fluids. The 
manufacturer of RSID-Saliva states that the test is specific for human salivary amylase 
as there was no cross reactivity observed with blood, semen, urine, vaginal secretions, 
or menstrual blood (Old et al. 2009).  This claim was investigated and sweat and breast 
milk were also tested (Table 3.5).  
The results from this experiment showed a weak positive reaction produced 
from the sweat and breast milk samples. The reaction time was set at 10 minutes as 
recommended by the manufacturer, outside this time-frame a weak signal was 
produced for the semen test cassette. It should be noted that this result was clearly not 
as strong a reaction as the saliva sample. Previous work has shown positive reactions 
with fecal swabs, breast milk and urine (Pang and Cheung 2008) but the authors gave 
no indication as to the strength of the signal produced from these fluids. There was no 
other cross reactivity with any of the other body fluids tested. It was also noted that the 
timing of this test was a very important factor in interpreting results.  
 It seems likely that the SALIgAE saliva test is based upon the presence of 
salivary amylase. Miller and Hodges (2005) reached a similar conclusion. In an 
independent validation of this test there was no cross reactivity with human semen, 
vaginal secretions, sweat or blood. In addition to these body fluids menstrual blood, 
breast milk and urine were also tested using the SALIgAE kit (Table 3.5). In this 
experiment, positive test results were shown with breast milk and urine as well as 
saliva. These experimental findings confirm those of Pang and Cheung (2008).  The 
recommended test time is 10 minutes. Positive results have been shown for nasal 
secretions within this time-frame (Lim.  Si-Keun et al. 2008). Other positive results have 
been detected after longer incubations with sweat, urine, vaginal fluid and semen 
emphasising the importance of time when identifying potential saliva samples. Unlike 
the RSID false positives the colour changes for SALIgAE were seen to be as strong as 
those for saliva. 
The Phadebas test is specific for amylase but not necessarily specific for saliva, 
as amylase is found within other body fluids at lower levels than in saliva. A positive 
result was seen with the breast milk sample as well as the saliva sample when saliva 
was spat upon the Phadebas paper. The presence of salivary amylase in body fluids 
other than saliva can be justified. Salivary amylase was shown to be detected in all 
volunteers of a study looking at whether salivary amylase is destroyed during digestion 
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(Fried et al. 1987). Salivary amylase has also been detected in breast milk (Lindberg 
and Skude 1982) and in semen samples (Auvdel 1986). 
 
Table 3.5: Testing three different saliva detection methods with various body fluids. 
  
Body fluid SALIgAE- 
Saliva test 
RSID- Saliva test Phadebas – Saliva 
test 
Blood - - - 
Breast milk ++ + ++ 
Menstrual blood - - - 
Saliva +++ +++ +++ 
Semen - - - 
Sweat - + - 
Urine +++ - - 
Vaginal fluid - - - 
 
+++ strong signal, ++ medium signal, + barely detectable signal, – no signal. 
 
3.4.3 Species Specificity 
 
No cross-reactivity was found in any of the tests with cat, cow or dog saliva 
(Table 3.6). The manufacturer of RSID-Saliva state that their test is specific for human 
salivary amylase and that in their validation study there was no cross reactivity 
observed with other animal saliva samples. The SALIgAE test had also previously 
given negative results with animal saliva samples. This result shown here, confirmed 
the trend also (Table 3.6). Others have reported similar results with cat and dog saliva 
(Pang and Cheung 2008). The same authors however reported positive test results for 
RSID with rat saliva only and positive results for pig, rat, mouse, rabbit, guinea pig and 
hamster were seen for both the SALIgAE and Phadebas tests; further samples were 
not tested in this experiment due to lack of accessibility of samples. 
 
Table 3.6: Testing three different saliva detection methods with animal saliva. 
 
Sample SALIgAE- 
Saliva test 
RSID- Saliva test Phadebas – Saliva 
test 
Cat - - - 
Cow 
Dog 
- 
- 
- 
- 
- 
- 
 
+++ strong signal, ++ medium signal, + barely detectable signal, – no signal. 
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3.4.4 Commercial α-amylases 
 
 Due to difficulties obtaining a human pancreatic amylase sample a commercial 
porcine pancreatic α-amylase sample was tested along with a commercial bacterial α-
amylase. The RSID test gave negative results for each of the two samples (Table 3.7). 
The SALIgAE test gave a negative result for the bacterial α-amylase but a positive 
result for the porcine pancreatic α-amylase. Positive results were observed with both 
samples when the Phadebas paper was used. 
 
Table 3.7:  Testing three different saliva detection methods with commercial α-amylases. 
Sample SALIgAE- 
Saliva test 
RSID - 
Saliva test 
Phadebas – 
Saliva test 
Porcine pancreatic α-amylase +++ - +++ 
Bacillus α-amylase  - - ++ 
 
+++ strong signal, ++ medium signal, + barely detectable signal, – no signal. 
 
These results are in agreement with previous work (Pang and Cheung 2008) showing 
the same trends as seen in this experiment for the same samples and tests. 
 
3.4.5 Compatibility of Tests with Alternative Extraction Buffers. 
 
It is important when using a saliva detection kit to know if the test is compatible 
with techniques used currently within forensic laboratories. A major difference lies in 
the different buffers used for extracting forensic samples. Therefore it was of interest to 
determine whether the kits tested could be used in different buffers such as those 
commonly encountered for DNA extraction. A compatible buffer would enable a 
potential forensic submission to be utilised for both body fluid identification and DNA 
profiling without having to extract two separate samples. For the RSID test the test 
buffer was used along with PBS, Water, Lysis buffer and TE buffers for the 
comparison. For the SALIgAE test, as water is used for the test extraction buffer, PBS, 
Lysis buffer and TE buffer were used for the comparison. From the results produced 
from this experiment (Table 3.8) it can be seen that the type of extraction buffer used 
does not seem to affect either set of test results. 
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Table 3.8 : Testing RSID – Saliva and SALgAE  kits with different extraction buffers 
Buffer SALIgAE- 
Saliva test 
RSID - 
Saliva test 
PBS +++ +++ 
Water  +++ +++ 
Lysis buffer +++ ++ 
TE buffer +++ +++ 
 
+++ strong signal, ++ medium signal, + barely detectable signal, – no signal. 
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3.5 Chapter Summary 
  
This chapter has compared current methods for saliva identification with 
different methodologies. RSID proved to be the most sensitive followed by SALIgAE 
and lastly Phadebas was the least sensitive method of those tested. The Phadebas 
test took longest whereas the other two tests were relatively quick. RSID - Saliva was 
most specific and showed the least cross reactivity with other body fluids.  Positive 
results were seen for breast milk with both the Phadebas and the SALIgAE tests. Urine 
also showed a positive result with the SALIgAE. None of the animal saliva samples 
gave positive test results with any of the kits tested. Porcine pancreatic amylase gave a 
positive reaction with both the SALIgAE and the Phadebas tests. The Phadebas test 
gave a positive reaction with the bacterial amylase also. No cross reactivity was seen 
with the RSID kits with the commercial amylases. Concluding from these findings the 
RSID saliva test is the most accurate method currently on the market for saliva 
identification. It should also be noted that due to time constraints the findings were only 
tested once. 
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Chapter 4. Optimisation of Proteomic Conditions 
for the Analysis of Body Fluids  
 
4.1 Introduction 
 
2DGE is a method that is capable of delivering high resolution images with the 
ability to simultaneously separate hundreds to thousands of proteins (Herbert et al. 
2001). It has been a powerful tool for both the analysis and the detection of proteins 
since the 1970‟s (O'Farrell 1975).  The methods used between laboratories tend to 
differ greatly as there is not a set of standard running conditions for 2DGE which 
makes comparison of results among laboratories a challenge. Definitive comparison 
can only be made once a protein has been successfully identified by MS (mass 
spectroscopy). In order to obtain the best results from 2DGE, sample treatment and 
efficient protein extraction are important considerations (Herbert et al. 2001). Due to 
the complexity of a sample proteome it cannot be completely represented by a single 
extraction method and separation step. 2DGE captures a static image of the proteome 
at a particular point in time and under certain conditions.  
This chapter describes various steps taken to optimise the stages associated 
with proteomic methodology as depicted in Figure 4.1, firstly giving an introduction to 
the techniques used (section 4.1) and then describing (section 4.2)  and discussing 
(section 4.3) the results obtained during each stage of the proteomic process.   
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Figure 4.1: Flow chart showing each stage of the methodology optimised to study the 
proteomics of body fluids. 
 
4.1.1 Sample Preparation 
  
Sample preparation is an important step prior to 2DGE. Ideally samples should 
have a high protein concentration and be free of components which could interfere with 
electrophoresis such as salts, nucleic acids and lipids (Jiang et al. 2004). Sample 
preparation methods depend on the individual sample to be analysed and what portion 
of that sample is of interest. In the work described in this chapter no prior extraction 
method is employed as the proteins are precipitated directly from the fluid source.   
There are several methods that can be applied to ensure the removal of 
interference components and these include dialysis, desalting and precipitating of the 
protein. Unlike desalting or dialysis to remove mineral salts, protein precipitation acts 
as a concentrating step; this is particularly useful when a dilute source of protein is 
being used as for example, when studying body fluids. 
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 4.1.1.1 Precipitation Methods used in the Isolation of Proteins  
 
Body fluids and tissues contain many substances which if left in the sample 
would interfere with the electrophoresis process causing insufficient focussing of 
protein spots, streaking or smearing on the gel, all of which would make interpretation 
and consequent identification of protein spots extremely difficult.  
Protein precipitation is a method used to concentrate protein within a given 
sample and to separate the protein from the unwanted components of the sample. 
Once proteins have been precipitated from the body fluid sample they are mixed with 
an IEF compatible sample buffer to ensure that the sample itself does not interfere with 
the focussing step of electrophoresis.  
Saliva samples can be easily collected in liquid form within a tube, but a cotton 
swab is used in vaginal fluid collection. In order to recover proteins from the swab, the 
swab head must be immersed into a suitable liquid. In forensic laboratories it is 
common to wash both vaginal cells and spermatozoa from swab heads using water 
followed by agitation. This technique is used both for visualisation on microscope slides 
and also for extraction of DNA for profiling. It is known that a hypotonic solution such as 
water, will give low cell recovery, due to cells bursting open during the washing stage. 
For this reason isotonic PBS is used as an alternative to water (Martin et al. 2006) as a 
wash solution. It is important when precipitating protein from a sample that as much 
protein as possible is recovered without the removal of portions of the proteome. 
 
4.1.1.2 Depletion of Abundant Proteins 
 
 Proteomic studies have shown that body fluid samples can contain up to 1,000 
proteins (Shen et al. 2004). Each individual protein may have a number of associated 
isoforms or post translational modifications that are separated on a 2D gel. The 
dynamic range of protein expression remains a challenge when trying to identify 
potential biomarkers, in this instance for fluid type. It is important to determine whether 
target proteins are highly expressed and therefore clearly shown on a protein gel, or 
expressed at lower levels which could mean that they are masked by the presence of 
more abundant proteins. High abundance proteins such as immunoglobulins in saliva 
or albumin in blood can be removed from samples enhancing the resolution of proteins 
in lower abundance. This can be performed using affinity columns to bind the high 
abundant proteins. An example of this is depicted in Figure 4.2 where a serum sample 
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is shown on a 2D gel before and after treatment with an albumin affinity column 
showing the removal of a large albumin spot revealing smaller spots otherwise hidden.  
 
   
Figure 4.2: A 2D gel image showing a human serum sample before and after treatment with 
Vivapure
® 
Anti HSA/IgG kit removing Albumin. (source: Sartoriuns Stedim Biotech). 
  
4.1.2 Determination of Protein Concentration  
 
It is important to determine the concentration of protein in the sample after 
precipitating protein from solution and prior to performing electrophoresis (1D or 2D). 
This enables accurate determination of the protein load whether loading to an IPG strip 
or depositing into a well of a SDS-PAGE gel.  It is important that the method chosen is 
quick, sensitive and reproducible. The most common methods to determine protein 
concentration are the Bradford assay and the Lowry assay. The Lowry assay uses 
Folin phenol reagent in a two step reaction a) with copper in alkali, and b) reduction of 
phosphomolybdic-phoshotungstic reagent by the copper treated protein (Lowry et al. 
1951) when in the presence of protein in a sample. Disadvantages of this method 
include a variability in colour development with different protein mixtures and the colour 
development being shown not to be completely proportional to protein concentration 
(Lowry et al. 1951). Interference has also been seen with Tris, EDTA, and magnesium 
and potassium ions (Bradford 1976). The Bradford assay involves CBB G-250 dye 
binding to protein which causes a shift in absorbance from 465nm to 595nm. The test 
is rapid and reproducible with colour stability for up to 1 hour. Drawbacks to this test 
show that detergents such as SDS can interfere with the test results.  
Both these methods have disadvantages with interference and sensitivity. A 
new RCDC protein assay has been developed by Bio-Rad based on the Lowry assay. 
This protein assay is particularly useful as the IEF sample buffer recommended by Bio-
Rad contains DTT CHAPS and UREA, and for 1DGE compatible with -
mercaptoethanol. The assay is linear between 0.2 mg/ml and 1.5 mg/ml, it is quick and 
simple to use and can be adapted for a microplate version rather than the cuvette form 
(Bio-Rad RCDC protein assay guide) and for this reason was used in this study.   
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4.1.3 First Dimension Optimisation  
 
The post genomic era has seen the proteomics field rapidly advance in two-
dimensional technology. One of the first new technologies introduced was IPG strips 
for the first dimension (Bjellquist et al.1982) as an alternative to rod gels using carrier 
ampholytes. The pH gradients of rod gels were considerably variable (Ong and Pandey 
2001) thus making reproducibility difficult.  
The IPG strips require reswelling with sample and sample buffer to rehydrate 
the gel attached to the strip prior to isoelectric focussing. In comparison to the 
previously used rod gels they are quick and easy to prepare. They have demonstrated 
improved reproducibility both within the same research group and inter-laboratory, 
higher loading capacity and increased resolution (Gorg et al. 1988).  
After the IPG strips have been focussed they must be equilibrated prior to 
2DGE.  It is important that all proteins are loaded to the second dimension gel with 
SDS for improved transfer from first to second dimension. Proteins bind more strongly 
to the IPG strips than to rod gels, used previously. Strips are therefore washed twice 
with equilibrium buffer; firstly with the addition of DTT to reduce disulphide bonds and 
enhance protein unfolding, and secondly with iodoacetamide to remove excess DTT 
and to alkylate proteins. This second process prevents reoxidation of sulphydral groups 
during the second dimension (Gorg et al. 2000). 
4.1.3.1 IPG Strip Load Determination 
 
Protein dynamic range poses a problem with 2DGE. It is important when 
obtaining a 2D image that as much of the proteome is represented as possible. This 
plays an important role when ascertaining the appropriate sample load for an optimal 
2D gel image. The less abundant proteins should be stained so that they are visible 
without over-staining the more abundant proteins. For example, in a body fluid such as 
blood, serum albumin is present at a concentration of approximately 40 mg/ml whereas 
cytokines are expressed at a picogram level showing a dynamic range variation  of 109 
(Rabilloud 2002). If too much protein is loaded on an IPG strip the gel image produced 
will be impaired. Horizontal streaking can be caused by protein aggregation and 
precipitation at a particular protein‟s isoelectric point, preventing complete separation in 
the first dimension.  The load capacity of narrow-range IPG strips is substantially higher 
than that of broad-range IPG strips enabling the visualisation and identification of 
proteins that would not be seen on the broad range strips. 
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Protein load is dependent upon the type of staining used for gel visualisation. 
For example, there could be intense staining of high abundance proteins if the protein 
load is too high or the proteins would hardly be visible if not enough protein was loaded 
to the strip.  
The amount of protein that can be loaded onto an IPG strip depends upon the 
strip length. The recommended range for protein loading onto a Readystrip™ 7cm IPG 
strip (Bio-Rad®) is between 5-100 µg of protein dependent upon the chosen staining 
method and the sample type (Bio-Rad® Readystrip™ IPG strip instruction manual). For 
Silver/SYPRO® Ruby (Invitrogen™) staining the recommended amount of protein to 
load is 5-20 µg, and for CBB it is 50-100 µg. The maximum load for a 7cm strip is 500 
µg (Bio-Rad® Readystrip™ IPG strip instruction manual).  
Different sample types show variability in the amount of protein that can be 
loaded to IPG strips. Lopez et al. (2000) used 50 µg protein standards run on mini gels 
with silver and SYPRO® Ruby stains, which is over twice the maximum recommended 
load stated by the manufacturer. Previous work looking at saliva proteins used 300 µg 
protein with 13 cm IPG strips and stained with CBB (Huang 2004). 
 
4.1.3.2 IPG Strip Range Determination. 
 
Each protein has a pH represented by a position on the IPG strip where it has a 
charge of zero; this is known as the pI of the protein. Proteins are separated in the first 
dimension based upon their pI. IPG strips can cover a wide range of pHs such as a 
broad range strip with a pH of 3-10 or can be limited to a much smaller range such as a 
zoom strip with a pH of 3.9-5.1. Initially when dealing with a new sample type it is 
common practice to use a broad range strip such as pH3-10 (Ong and Pandey 2001) to 
give an overview of the proteins present within the sample and to determine whether 
the sample contains mainly basic or acidic proteins and then focus in on that specific 
area of interest. IPG strips can also be used as an alternative to separating more 
complex samples into acidic and basic fractions prior to analysis using ion exchange 
chromatography. Overlapping narrow range IPG strips in the first dimension of a two-
dimensional gel can be used to show protein separation across a range of pHs thus 
avoiding aggregation of multiple proteins at a single spot (Gorg et al. 2000). 
 When separating in 2D using a broad range pH range strip, only a small 
proportion of the whole proteome is shown. This is due to insufficient spatial resolution 
and the difficulty of seeing low copy number proteins in the presence of abundant 
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proteins (Gorg et al. 2000). Resolution and the separation power are lower using broad 
range strips compared to the narrow range strips but the representation of the sample 
as a whole is greater. By using a narrow range strip the proteins shown to be one spot 
on a broad range strip could in fact be a number of smaller spots that had not resolved 
completely. Thus a strip with a smaller pH range could display a larger number of 
protein spots with better resolution than a strip with a wider pH range.  
 
4.1.4 Second Dimension Optimisation  
 
4.1.4.1 The Determination of Gel Acrylamide Percentage  
 
 When separating proteins in the second dimension it is important to consider 
the range of molecular weight proteins to be analysed within the sample. The ease at 
which proteins move through the gel matrix is determined by the pore size of the gel 
and the size and shape of the protein. Pore size is inversely proportional to the amount 
of acrylamide added to the gel mixture.  Gels with a higher acrylamide percentage have 
a smaller pore size and thus have a greater ability to separate smaller molecules. Gels 
with a lower acrylamide percentage have larger pore sizes, separating larger molecules 
more easily.  Although the separation of larger molecular weight proteins would be 
seen with a lower acrylamide percentage gel, smaller proteins could move too quickly 
through the gel matrix and be lost off the end of the gel. For these reasons the proteins 
within the sample should be used as a guide to determine the gel percentage suitable 
for use.  
 
4.1.4.2 Protein Detection using Post Electrophoretic Stains 
 
When looking at a staining method for use with two-dimensional electrophoresis 
it is important to consider the sensitivity of the stain, the reproducibility of the staining, 
and its compatibility with downstream techniques associated with protein 
characterisation. For expression analysis a stain must provide a linear measure of 
protein abundance (Smales et al. 2003) in order to determine accurately the expression 
changes in protein spots between gel images. 
In the past, the most commonly used staining methods for 2D gels have been 
CBB and silver staining. These stains have not been ideal due to poor sensitivity (CBB) 
and poor compatibility (silver) with MS applications downstream (Lopez et al. 2000). 
Within the last few years the introduction of fluorescent dyes such as SYPRO® Ruby 
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(Invitrogen™) and Flamingo™ protein stain (Bio-Rad®) have added further possibilities 
in staining techniques.  
 
4.1.4.2 (i) Protein Detection using Colloidal CBB G-250 
 
CBB has been a popular method for protein staining  since the early 1960s 
(Williams 2001) as it is easy to use, relatively cheap and is compatible with 
downstream techniques (it does not alter the protein configuration in any way).   
CBB staining has low sensitivity and limited detection of proteins, so an adapted 
colloidal CBB method has been developed (Neuhoff et al. 1988) using progressive 
staining until reaching an endpoint. Equilibrium is set up between colloidal particles and 
free dye in solution. The low concentration of free dye penetrates the gel matrix, 
staining the proteins. The colloidal particle is excluded from the gel preventing 
background staining, overcoming detection limitations by increasing the stain‟s 
sensitivity. By using CBB as a colloidal stain the sensitivity of the method is increased 
from detection of 30-100 ng of protein down to 8-10 ng of protein (Patton 2002). The 
dye has been seen to have a linear dynamic range over a 10-30 fold range (Patton 
2002) although a disadvantage of this method is the increase in staining time (up to 
three days). 
 
4.1.4.2 (ii) Protein Detection using Silver Staining (PlusOne™ 
Silver Staining Kit, Amersham Biosciences) 
 
Silver staining is based on the origins of photography development and was first 
introduced for protein staining post electrophoresis in 1970s (Kerenyi and Gallyas 
1972). Although silver staining has been the stain of choice for its sensitivity, it is 
destructive for MS applications, so the benefits of resolving 1,000 protein spots is offset 
by the inability to identify them. Additionally silver acts as a strong oxidising agent that 
can lead to chemical modification or destruction of proteins. Furthermore the presence 
of sensitising agents such as gluteraldehyde can cross-link to the proteins causing 
covalent modifications and preventing efficient digestion by trypsin prior to MS analysis 
(Shevchenko et al. 1996; Scheler et al. 1998). To resolve these problems an adapted 
silver staining method has been used by Shevchenko  and colleagues (1996) 
permitting further proteomic analysis using mass spectroscopy by the omission of 
gluteraldehyde. Silver staining is a multistep procedure with four main steps common to 
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most protocols; (i) fixation, (ii) sensitisation, (iii) silver impregnation and (iv) image 
development. Unlike CBB, it is not an end point stain. The staining intensity of spots 
can vary from gel to gel making reproducibility increasingly difficult to achieve. This 
may also cause problems if using software to analyse silver stained gels when 
determining whether spot intensity variation is due to an expression change or simply a 
difference in the staining between gels. 
Silver staining is achieved by saturating the gels with silver ions, washing the 
molecules that are less tightly bound from the gel matrix, and then reducing the bound 
metal ions to form metallic silver. Silver staining does not act by specific binding to the 
protein, rather it interacts with lysine residues (Lopez et al. 2000). The sensitivity of 
PlusOne™ Silver staining kit (Amersham biosciences) is 0.20-0.60 ng protein 
(PlusOne™ Silver staining kit Protein instructions) whereas the linear dynamic range is 
limited (10-fold) (Patton 2002). This has made it difficult to determine subtle differences 
in protein quantities (Lopez et al. 2000). 
 
4.1.4.2 (iii) Protein Detection using SYPRO® Ruby Fluorescent 
Stain (Invitrogen™). 
 
SYPRO® Ruby (Invitrogen™) is a relatively new stain introduced to proteomics 
that contains Ruthenium which is chelated into a fluorophore (White et al. 2004).  This 
stain does not require the use of any protein modifying agents and is therefore 
compatible with downstream spectrometric techniques. It binds non covalently to basic 
amino acids; lysine, arginine and histidine residues (Lopez et al. 2000) via an 
electrostatic interaction similar to CBB (Miller et al. 2006). SYPRO® Ruby (Invitrogen™) 
staining has a sensitivity that is similar to silver. It is described as an endpoint stain 
therefore over-staining cannot cause visibility problems when viewing the gels. It is also 
is a simple method with only three staining steps in comparison with silver staining 
which has many more steps involved. Protein detection between 4-8 ng is possible with 
this staining method giving an alternative in sensitivity to silver staining and a quicker, 
easier staining method to use. The linear dynamic range of the dye extends over three 
orders of magnitude; greater than that of both silver and colloidal CBB stains (Patton 
2002).  
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4.1.4.2 (iv) Detection of Proteins using Flamingo™ Fluorescent 
Stain (Bio-Rad®) 
 
 Flamingo™ fluorescent gel stain (Bio-Rad®) is reported to be a more sensitive 
alternative to SYPRO® Ruby gel stain (Invitrogen™). The dye in this stain only 
fluoresces when bound to denatured protein (Bio-Rad Literature Bulletin 5346). It has 
the advantage of a short and simple protocol which can be completed within five hours 
and has only two steps (lower than any other stain used in this experiment). Like 
SYPRO® Ruby (Invitrogen™), Flamingo™ (BioRad®) stain is compatible with 
downstream techniques such as mass spectrometry and enzymatic digestion. It has 
been reportedly shown to display sensitivity of 0.50-2 ng using a UV transilluminator 
and is therefore the most sensitive of all the stains tested.  
 
4.1.5 Optimisation of Image Analysis – Gel Repeat Expression 
Comparison. 
 
 Image capture is critical for the successful analysis of 2D gels. Image dynamic 
range is described as the range of grey tones within a digital image whereas „bit depth‟ 
refers to the number of bits used to define each pixel and hence the number of grey 
tones generated. The larger the bit depth, the larger the range of grey tones per pixel. 
For example, an 8 bit image file produced by a Charged Coupled Device (CCD) 
camera (ChemiDoc™ EQ) has 256 (28) shades of grey per pixel. This compares to 16 
bit image files with 65536 (216) shades of grey per pixel obtained when the laser 
scanner (PharosFX™ molecular imager) was used for image capture for the same 2D 
gels. A higher number of shades of grey per pixel (16 bit images) enables the software 
to differentiate between low abundance spots and the background of the gel thus 
increasing the number of spots detected and analysed (Miller et al. 2006). 
.  
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4.2 Results 
All SDS-PAGE gels run in duplicate in parallel throughout this study and the gel 
images displayed in this results section are representative of the two duplicates unless 
otherwise stated.  
 
4.2.1 Sample Preparation 
 
4.2.1.1 Precipitation Methods used in the Isolation of Saliva 
Proteins. 
 
Three of the most widely used precipitation methods were studied; TCA-
acetone, ethanol, and acetone precipitations. The most effective precipitation method 
was selected and applied for 2D gel electrophoresis experiments conducted in this 
research. 
An independent experiment was performed three times using 300µl of one 
donor‟s saliva in duplicate to compare the three precipitation methods (see sections 2.3 
and 2.4). Figure 4.3 shows the average results for each saliva precipitation. The total 
protein precipitated was measured using the RCDC™ protein assay (Bio-Rad®)(see 
section 2.5).  
 
 
Figure 4.3: Comparison of TCA-acetone (TCA), Ethanol and Acetone precipitation methods 
with unprecipitated saliva protein. Showing total saliva protein recovered by each method. 
Average total protein of three replicate experiments was plotted ±1SD from the three averages, 
each average based on two duplicates. 
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The results for saliva precipitation (Figure 4.3) show that using acetone to 
precipitate protein from a 300 µl saliva sample afforded the highest average total 
protein (332 µg). Both Ethanol and Acetone gave the greatest recovery, and ability to 
concentrate protein from the original saliva sample with little difference between them. 
TCA-acetone produced the lowest total protein (270 µg) among all three methods 
tested.  Although absolute differences in means were found, variation on the three 
replicates shows overlapping results. 
From these results the method that yielded the highest level of total protein and 
the lowest total protein were compared to determine whether differences could be seen 
in a 2D gel image depending upon the precipitation method used (see Figure 4.4).  
Acetone and TCA-acetone precipitated saliva samples were run in the first dimension 
using 3-10NL Readystrip™ IPG strips (see section 2.6) and in the second dimension 
(see section 2.6) using 12% polyacrylamide gels, stained with SYPRO® Ruby gel stain 
(see section 2.8.3). 
 
                          
        a) Acetone precipitation    b)TCA – Acetone precipitation 
 
Figure 4.4: Saliva protein (50 µg) precipitated with a) acetone and b) TCA- Acetone using  3-
10NL Readystrip™ IPG strips and 12% polyacrylamide gels, stained with SYPRO
®
 Ruby 
fluorescent gel stain. 
 
Distinct differences can be seen in the gel images produced by each 
precipitation method. Although the main protein groups seem to be present within each 
image (those highlighted in red), a greater number of spots are visible in a) when 
compared with b). The spots in the TCA-acetone sample image are less resolved than 
those in the acetone sample. It is therefore very important to keep the precipitation 
method constant throughout a study when comparisons of gel images are involved. 
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4.2.1.2 Protein Extraction from Cotton Swab Heads 
 
An experiment was performed to determine the total protein recovered from a 
swab head when immersed in either water or PBS (see section 2.3.2), followed by an 
acetone precipitation (see section 2.4.3). The total protein within each sample was 
measured using an RCDC™ protein assay (BioRad®)(see section 2.5). This experiment 
was repeated three times and the results are presented in Figure 4.5.  
 
 
Figure 4.5: A comparison of protein extraction from a single swab head using PBS or water. 
Average total protein plotted as a result of three swab heads tested independently with 
duplicate readings from each swab head ±1SD.  
 
The comparison of PBS and water to elute protein from a vaginal swab head 
showed little difference between the different wash buffers used. The total protein 
recovered using PBS was slightly higher (126 µg) than the total protein recovered using 
water (118 µg). Due to compatibility with different DNA extraction methods used in 
forensic laboratories either method could be used prior to precipitation. For this study 
PBS was chosen to avoid potential osmotic imbalances within the cells. 
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4.2.1.3 Precipitation Methods used in the Isolation of Vaginal 
Fluid Proteins 
 
  The same three precipitation methods were tested once again using 
one donor‟s samples but by looking at vaginal fluid instead of saliva. The 
average results from this experiment are displayed in Figure 4.6.  
 
 
Figure 4.6: Comparison of TCA-acetone (TCA), Ethanol and Acetone precipitation methods 
showing total vaginal fluid protein recovered by each method. Average total protein plotted 
±1SD (n=3). 
  
The total protein measurement of unprecipitated vaginal fluid was low (73 µg) in 
comparison with unprecipitated saliva (244 µg). This was likely in part due to a dilution 
of vaginal fluid samples in 1 ml PBS prior to precipitation, in order to recover protein 
from the swab head. These results demonstrate different findings to those of the saliva 
experiment. TCA-acetone and ethanol recovered a higher average total protein (237 µg 
and 231 µg respectively) than acetone precipitation (186 µg) but the high standard 
deviation shown for the TCA-acetone method means a high level of variability in the 
average total protein recovered using this method. In this study it is important to 
consider a method that is shown to yield a consistently high concentration of protein 
with a simple method as more steps give a greater chance for loss of protein. To 
enable comparison between samples, the acetone precipitation method was chosen 
and applied for each body fluid used in this study. 
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4.2.1.4 Depletion of Abundant Proteins 
 
In order to efficiently remove abundant proteins from samples, columns 
containing antibodies raised against the abundant human proteins IgG and HSA were 
used. The samples to be analysed were passed through the column and the high 
abundance proteins removed by binding to the antibodies. In this research, all blood 
samples were treated with the Vivapure® anti HSA/IgG columns (Sartorius) prior to 
being applied to 2D gels. The samples were also run on 1D gels to show the eluted 
fractions from the columns. Blood and menstrual blood sample swabs from one donor 
were used to avoid person to person differences having an effect on the data 
produced. Both samples were run through anti HSA/IgG columns (Vivapure®) and the 
eluted fractions collected in separate tubes (see section 2.3.5). The samples were 
quantified using RCDC protein assay (Bio-Rad®). 1D gels were poured (see section 
2.7) and run in duplicate for each sample type. An aliquot of sample that had not been 
treated with the column was run alongside each column eluate and a protein molecular 
weight standard (see Figure 4.7). Each well was loaded with 10 µg protein sample and 
after electrophoresis, the gels were stained with colloidal CBB stain (see section 2.8.1).  
 
 
 
 
                     
a) Blood          b) Menstrual blood 
 
Figure 4.7: Two 1D gel images of a) blood and b) menstrual blood samples. Lane 1 – before 
treatment, lanes 2, 3 and 4 show successive eluted fractions after treatment with an anti HSA/IgG 
column (Vivapure) and lane 5 contains the SDS-PAGE protein standard (Bio-Rad).  
 
 
The successive column elutes displayed a reduction in the albumin band visible 
at approx 66 kDa and also showed a reduction in the total protein visible on the 1D gel.  
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Lane 1 (loaded with sample not passed through the column) did not show distortion in 
the albumin band as would be expected with blood samples. From this it was possible 
to infer that the level of albumin present within both the blood swab and the menstrual 
blood swab was much lower than from clinical blood samples. In respect of the blood 
swab this could be explained by the small volume of blood being deposited onto the 
swab. Although the menstrual blood sample was taken when menses was heaviest, the 
proportion of blood present in the sample could be lower than expected due to being a 
mixture of blood, endometrium and vaginal fluid. Sample dilution with PBS during 
extraction from the swab led to a lower proportion of blood within the sample and thus 
less entering the column. The general use of anti HSA/IgG columns is for whole blood 
samples collected direct from the vein of a donor which would tend to have a higher 
concentration of albumin present than forensic samples deposited onto a swab head or 
exposed to air for a period of time.  
 2D gels were used to assess the composition of both blood samples in more 
detail (see Figure 4.8).  
 
                
          a) Blood without treatment          b) Blood passed through column 
Figure 4.8: 2D gel images of blood protein (acetone precipitation, 50 µg protein load, pH 5-8 
Readystrip™ IPG strips, 12% polyacrylamide gels, SYPRO
®
 Ruby stained (Invitrogen™)). Panel 
a) sample not passed through the column and panel b) sample having been treated with the anti 
HSA/IgG column (vivascience
®
).  
 
The molecular weight standards run on these gels have been removed from the 
images (Figures 4.8 and 4.9) for aesthetic purposes. There is little difference between 
the 2D images produced by blood protein (Figure 4.8) but a higher load of protein may 
provide a better comparison. From these images it is clear that the sample that had not 
been passed through the column does not show albumin masking spots at 66 kDa 
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where expected, and hence a column may not be necessary for this application. 
Menstrual blood samples were also compared by 2DGE (Figure 4.9).  
 
             
a) Menstrual blood without treatment             b) Menstrual blood passed through column  
Figure 4.9: 2D gel images of menstrual blood protein (acetone precipitation, 50 µg protein load, 
pH 5-8 Readystrip™ IPG strips, 12% polyacrylamide gels, SYPRO
®
 Ruby stained 
(Invitrogen™). Panel a) sample not passed through the column and panel b) sample having 
been treated with the anti HSA/IgG column (vivascience
®
).  
  
 The results from the menstrual blood sample show more protein spots are 
visible in both gel images when compared with the images for the blood sample. There 
does not appear to be a strong band visible at 66 kDa that would be indicative of 
albumin being in high abundance within menstrual blood and these results are 
consistent with those from the blood sample. Panel b) shows the major effect of the 
anti HSA/IgG column is to eliminate a variety of some protein spots which could be 
characteristic of menstrual blood. Published reports of using columns has shown that 
as well as albumin and immunoglobulin, other proteins may be lost in the process (Joo 
et al. 2003). For this reason it was decided not to use the columns in any future 
experiments.  
 
4.2.2 Determination of Protein Concentration – A Comparison 
of Two Protein Assays 
 
Two protein assays were compared in order to determine whether IPG strip 
reswelling buffer had an effect on the accuracy of the standard curve. Hence the 
Bradford protein assay (Bradford 1976) and the RCDC protein assay (Bio-Rad®) were 
compared in one experiment. The RCDC assay is known to be compatible with a 
number of different buffers, reducing agents and detergents that may be present in a 
sample as a result of the extraction methods. Both assays were tested using IgG 
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protein standards in the range of 0.10 mg/ml – 1mg/ml. The standards were diluted 
using the reswelling buffer (as the samples would be) in order to ascertain whether or 
not the buffer had an effect on the quality of the standard curve produced. Thus 
inaccurate protein concentrations for samples associated with that particular assay 
would be avoided if this was the case. Figure 4.10 shows the standard curve produced 
using the Bradford assay and in comparison Figure 4.11 shows the standard curve 
produced using the RCDC protein assay. From these standard curves, the R2 value for 
the Bradford assay was 0.75 and for the RCDC assay was 0.97. Therefore the 
reswelling buffer appears to affect the standard curve accuracy in the Bradford assay 
but not in the RCDC assay. The closer the R2 value is to 1, the more linear the 
relationship between the optical density of the sample and its concentration for the 
range of standards used in the experiment, indicating that more reliable protein 
concentrations can be determined from the curve. On the basis of these results, the 
RCDC assay was selected for this work. 
 
 
Figure 4.10: A Bradford assay using IgG standards with reswelling buffer, values taken as an 
average of two optical density readings. 
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Figure 4.11:  A RCDC protein assay using IgG standards with reswelling buffer, values taken 
as an average of two optical density readings. 
  
 
4.2.3 First Dimension Optimisation 
 
4.2.3.1 A Comparison of IPG Strip Load Variation using Saliva 
Protein 
 
An experiment was conducted to determine the optimal protein load for each 
body fluid (Figure 4.12). Initially, for saliva and vaginal fluid, three load quantities were 
chosen; 25 µg, 50 µg and 75 µg. This was limited in later experiments to a narrower 
range based upon the findings of this experiment. Gels were run in duplicate using 7cm 
pH 5-8 IPG and in the second dimension run on 12% polyacrylamide gels (see section 
2.6) and stained with SYPRO® Ruby (Invitrogen™) gel stain (see section 2.8.3). 
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   a) 25 µg load                                         b) 50 µg load 
 
 
   c) 75µg load 
 
Figure 4.12: 2D gel images of a) 25 µg, b) 50 µg and c) 75 µg saliva protein (acetone 
precipitation, pH 5-8 Readystrip™ IPG strips, 12% polyacrylamide gels and SYPRO
®
 Ruby 
(Invitrogen™) stain.  
 
Results from this experiment (see Figure 4.12) showed that the lowest load (25 
µg) of saliva protein displays only four major protein groups. The results also 
demonstrated that medium load (50 µg) generally displayed more detail within the gel. 
A greater number of smaller protein spots were also visible as well as emphasising the 
major protein groups. The highest load (75 µg) showed the greatest detail overall but 
the major protein spots seemed over stained resulting in low resolution and the more 
abundant protein spots were distorted on the gel. From these findings a 50 µg protein 
load was determined to be suitable for subsequent experiments using saliva samples. 
 
4.2.3.2 Determination of IPG Strip Loading for Vaginal Fluid 
Protein 
 
A similar experiment to that described in section 4.2.3.1 was performed to 
determine the optimal protein load from vaginal fluid. Gels were run in duplicate using 
7cm pH 5-8 IPG and in the second dimension on 12% polyacrylamide gels (see section 
2.6). Both were stained with SYPRO® Ruby (Invitrogen™) gel stain (see section 2.8.3). 
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a) 25 µg load         b) 50 µg load 
 
 
    c) 75 µg load 
Figure 4.13: 2D gel images of a) 25 µg, b) 50 µg and c) 75 µg vaginal fluid protein (acetone 
precipitation, pH 5-8 Readystrip™ IPG strips, 12% polyacrylamide gels and SYPRO
®
 Ruby 
(Invitrogen™) stain).  
 
Figure 4.13 shows the images produced with different vaginal fluid protein 
loads. A similar trend to that noted in respect of saliva protein is demonstrated and 
there are fewer protein spots visible with the lowest load (25 µg). A larger number of 
spots were visible with the medium load (50 µg), with good separation and resolution. 
However the gel with the highest load (75 µg) showed distortion and masking of some 
of the areas by abundant proteins, which appeared overloaded (shown by very bright 
staining in the top left corner of the gel). On the basis of these results a 50 µg load was 
chosen as a suitable load for vaginal fluid. 
 
4.2.3.3 IPG Strip Range Determination. 
 
Experiments were performed to identify the optimal strip pH range in order to 
achieve the best protein separation. Four strip ranges were chosen; pH 3-10, pH 3-6, 
pH 4-7, and pH 5-8. Each strip was run in the second dimension using 12% 
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polyacrylamide gels. For each body fluid type the protein load remained constant; 50 
µg of protein was loaded onto each strip so that accurate comparisons could be 
performed.  Alongside the samples, 2D SDS PAGE protein standards were run (Figure 
4.14) in order to determine the pI and molecular weight of proteins within the gel.  
Table 4.1 describes the pI of the protein standards represented in Figure 4.14 
(numbers shown below the spot of interest). A molecular weight standard was also run 
on the right hand side of each gel. This also enabled the confirmation of protein 
identification from MASCOT search data to be ascertained based on the cut spots 
position within the 2D gel.  
 
 
Figure 4.14: A 2D gel image to show 2D SDS-PAGE standards (Bio-Rad) run using pH 3-10 
strips run on a 12% gel stained with SYPRO Ruby gel stain (Bio-Rad). 
 
The proteins displayed in Figure 4.14 have their name, pI and molecular weight 
listed in table 4.1.  
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Table 4.1: 2D SDS-PAGE standard protein data (ref: Bio-Rad 2D SDS-PAGE standards 
instruction manual).  
 
Protein Molecular weight pI 
1. Hen egg white conalbumin 1 76,000 6.0, 6.3, 6.6 
2. Bovine serum albumin 66,200 5.4, 5.6 
3. Bovine muscle actin 43,000 5.0, 5.1 
4. Rabbit muscle GAPDH 36,000 8.3, 8.5 
5. Bovine carbonic anhydrase 31,000 5.9, 6.0 
6. Soybean trypsin inhibitor 21,500 4.5 
7. Equine myoglobin 17,500 7.0 
N.B Standards with more than one isoform separate showing more than one spot on a 2D gel 
and hence have more than one pI value. 
 
 
4.2.3.4 A Comparison of IPG Strips pH Range using Saliva 
Protein 
 
It is evident from the separation shown by each strip (Figures 4.15 and 4.16) 
that although the broad range strip (pH 3-10) gives a good overview of the proteins 
expressed within the saliva sample,  the resolution and the number of spots visible 
increased when narrower pH range strips were used. The gel image of strip pH 4-7 
displayed blurred (unfocussed) spots towards the acidic end of the strip range but 
showed an increase in spot numbers at the neutral end. The pH 3-6 strip gave better 
separation than the broad range strip for the same pH range and the proportion of 
spots visible was greatly increased. The pH 5-8 strip displayed the greatest number of 
spots with the highest resolution of the strips tested thus making it the most suitable 
strip for further analysis. Choosing only one pH range would limit any biomarkers 
identified to this range hence dismissing any potential biomarkers outside this range. 
Ideally the whole range would be covered however the benefit this could provide could 
be limited by the extra gels run and the time taken to do so. 
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Figure 4.15: Saliva protein 2D gel images (12% polyacrylamide) IPG strips of range a) pH 4-7, 
b) pH 3-10  and c) pH 5-8. Stained with SYPRO
®
 Ruby (Invitrogen™).  
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Figure 4.16:  Saliva protein 2D gel images (12% polyacrylamide) IPG strips of range a) pH 3-
10, and b) pH 3-6, stained with SYPRO
®
 Ruby (Invitrogen™). 
 
A further increase in resolution and separation of protein spots could be made 
by extending the separating distances using strips of different lengths. This was not 
possible for this study as there were no tanks available for running longer length gels. 
Total protein extracted from body fluid samples was shown to contain proteins with 
isoelectric points ranging from pH3 - pH12. When these samples were loaded to IPG 
strips with a narrow pH range (such as a pH 5-8 strip - Figure 4.17) many proteins were 
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found to lie outside the range of the strip. As a result, many of the proteins migrate 
towards the ends of the IPG strip and precipitate in concentrated lines. 
 
Figure 4.17: A 2D gel image of 50µg saliva protein (acetone precipitation, pH 5-8 Readystrip™ 
IPG strips, 12% polyacrylamide gels, and  SYPRO
®
 Ruby (Invitrogen™) stain.  
 
4.2.3.5 A Comparison of IPG Strips pH Range using Vaginal 
Fluid Protein. 
 
A similar trend to that described in section 4.2.3.4 was seen when the 
experiment was repeated using vaginal fluid (Figures 4.18 and 4.19). The broad range 
strip pH 3-10 showed an overview of protein expression for the sample showing that 
the majority of protein expression was in the middle of the gel. Once again, separation 
was improved when narrower range strips were used. The gel images demonstrate that 
pH strip 5-8 gave the greatest number of resolved spots and whereas the pH 3-6 strip 
displayed the least spots for this sample.  IPG strip 4-7 showed a reasonable number 
of clearly focussed spots but not as many as the 5-8 strip. Therefore, in order to make 
accurate comparisons between samples pH 5-8 strips were used in this project.  
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Figure 4.18: Vaginal fluid protein 2D gel images (12% polyacrylamide) IPG strips of range a) 
pH 4-7, b) pH 3-10 and c) pH 5-8, stained with SYPRO
®
 Ruby (Invitrogen™).   
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Figure 4.19: Vaginal fluid protein 2D gel images (12% polyacrylamide) IPG strips of range a) pH 
3-10 and b) pH 3-6, stained with SYPRO
®
 Ruby (Invitrogen™).  
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4.2.4 Second Dimension Optimisation  
 
4.2.4.1 A Comparison of Gel Acrylamide Percentage using 
Saliva Protein 
 
In this experiment three different acrylamide percentage gels were run with 50 
µg saliva protein loaded using pH 3-10NL (non linear) IPG readystrips. 
Each set of gels was run in duplicate and all gels were stained with SYPRO® 
Ruby gel stain (Invitrogen™). Figure 4.20 showed that when using a 15% acrylamide 
gel the high abundance proteins did not move through the gel far enough thus leaving 
a large space at the bottom of the gel. The 12% gel showed that all the proteins were 
well distributed throughout the gel providing a better separation of the high abundance 
proteins. Finally, the 10% gel showed that the low molecular weight proteins at the 
bottom right of the gel have run off the end. From these results the 12% gel was 
selected for use throughout this research as this was considered to give the best 
protein separation. 
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                 a)         b) 
 
 
 
               c) 
Figure 4.20: 2D gel images showing the separation of saliva protein using IPG strips of range 
pH 3-10 with a) 15% acrylamide, b) 12% acrylamide and c) 10% acrylamide gels stained with 
SYPRO
®
 Ruby (Invitrogen™).  
 
4.2.4.2 Protein Detection using Post Electrophoretic Stains 
 
In order to determine the most effective staining method for use within this 
study, a comparison study of four protein stains was undertaken. Two of the older 
commonly used stains; Colloidal CBB and silver staining (PlusOne silver stain kit) were 
compared with two newer fluorescent stains; SYPRO Ruby and Flamingo. Three 
independent experiments were performed in order to examine the sensitivity, linearity 
and reproducibility of each stain.   
To determine the sensitivity of each stain by visual comparison, 50 µg of saliva 
protein was loaded onto four 7cm IPG strips with pH range of 5-8. The second 
dimension was run using 12% polyacrylamide gels and then each gel was stained 
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using a different method. The experiment was run in duplicate (see Figure 4.21). The 
gel images showed that PlusOne™ silver staining (Amersham Biosciences) and 
SYPRO® Ruby (Invitrogen™) were the most sensitive methods of staining displaying 
the greatest number of resolved protein spots (panels a) and c) respectively). Colloidal 
CBB G-250 (panel b) showed that the most abundant proteins were clearly visible. 
However, Flamingo™ (BioRad®) showed very poor staining with some of the abundant 
proteins visible (panel d) although not as clear as could be seen with Colloidal CBB G-
250 stain which was the most economical staining technique used. 
 
 
 
     
a)           b) 
 
 
 
   
c)           d) 
Figure 4.21: 2D gel images of saliva protein using pH 5-8 7cm IPG strip stained with a) 
PlusOne™ silver stain kit (Amersham Biosciences) b) Colloidal CBB G-250 c) SYPRO
®
 Ruby 
(Invitrogen™) and d) Flamingo™ gel stain(BioRad
®
).  
 
As well as determining sensitivity by eye, looking at the number of protein spots 
present on the 2D gels (Figure 4.21) an experiment was also performed measuring the 
PlusOne Silver Stain Colloidal CBB 
Sypro Ruby Flamingo 
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sensitivity and linearity quantitatively. Four 1D gels were loaded with broad range 
Precision Plus Protein™ standards in serial dilution. The serial dilution was based upon 
the amount of protein present within the 50 kDa protein band of the broad range 
standard.  The instruction manual stated this as 750 ng in the total 1 ml provided. The 
range of protein tested wthin the 50 kDa band was 20 ng – 0.50 ng. The experiment 
would enable the limits of the dye to be detected and would thus facilitate comparisons 
with published data. The linearity of each stain was determined by measuring the 
density of each 50kDa band and plotting this against the protein load within that band.  
Finally, reproducibility was analysed by running 1D gels loaded with a serial 
dilution of saliva protein. The densitometry of the highest molecular weight protein 
bands (approx 66 kDa) was determined using the ChemiDoc (BioRad) for densitometry 
analysis once again (Figure 4.22). The U1- U7 displayed on Figure 4.22 is the area 
used to calculate density with the ChemiDoc. Each area is the same size and 
measures the density within the rectangle drawn by the Quantity One software. This 
was repeated three times in order to determine whether the results obtained each time 
were reproducible. 
 
 
 
 
Figure 4.22: A 1D gel image of saliva protein in a serial dilution stained with SYPRO ruby. 
Density measurements recorded of U1-U7 (n=3). 
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4.2.4.2 (i) Protein Detection using Colloidal CBB G-250 
 
Colloidal CBB G-250 staining (Figure 4.23) demonstrated that the lowest 50 
kDa band visible was 0.75 ng protein. Clear bands were detectable from 20 ng to 3.25 
ng although beyond this, the level of detection was faint. Staining with Colloidal CBB 
was shown to be linear (Figure 4.24) with an R2 value of 0.96. It seemed likely that 
characteristic marker proteins for body fluids may not necessarily be the most 
abundant proteins in the sample. Thus due to the low detection limits of Colloidal CBB 
it would not be the most suitable stain for this project as it may not be sensitive enough 
to stain low abundance proteins. Reproducibility of Colloidal CBB staining was 
demonstrated (Figure 4.25). The serial dilution of saliva proteins follows a negative 
trend as expected (the less protein loaded to a well, the lower the density/mm2 in that 
band). There is some variation in the density values between the repeats which is 
surprising when using an endpoint stain as the staining would be expected to reach a 
maximum and maintain this level. Colloidal CBB G-250 staining method demonstrated 
the least variability among the four methods, thus confirming the rationale for its 
historical use in the Bradford protein assay for protein quantification. 
 
 
 
 
 
 
 
 
. 
 
 
 
 
 
 
 
Figure 4.23: A 1D gel showing Precision Plus Protein™standards (BioRad
®
) in serial dilution stained 
with Colloidal CBB G-250 staining.  The values used to determine the sensitivity of the stain within the 
50 kDa band are highlighted by the red box. 
 
 
 
 
132 
 
 
Figure 4.24: The linearity of colloidal CBB G-250 staining by measurement the protein in the 50kD 
band. 
 
 
Figure 4.25:  The average density of saliva protein bands for reproducibility of colloidal CBB G-
250 staining (n=3). 
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4.2.4.2 (ii) Protein Detection using Silver Staining (PlusOne™ 
Silver Staining Kit, Amersham Biosciences) 
 
One concern when using the silver staining method is that silver acts as a 
strong oxidising agent which can lead to chemical modification or destruction of the 
protein. The use of sensitizing agents such as gluteraldehyde can also result in 
covalent modifications to proteins and resulting in low sequence coverage 
(Shevchenko, Wilm et al. 1996; Scheler, Lamer et al. 1998) 
An adapted silver staining method has been used (Shevchenko, Wilm et al. 
1996) permitting further proteomic analysis using mass spectroscopy by the omission 
of gluteraldehyde which can cause covalent modifications of proteins. 
Silver staining is achieved by saturating the gels with silver ions, washing the 
molecules that are less tightly bound from the gel matrix, and then reducing the bound 
metal ions to form metallic silver. Silver staining does not act by specific binding to the 
protein. Silver nitrate stain interacts with lysine residues while SYPRO® Ruby stain 
detects lysine, arginine and histadine residues (Chou1990). The sensitivity of 
PlusOne™ Silver staining kit (Amersham biosciences) is 0.2-0.6 ng protein (PlusOne™ 
Silver staining kit Protein instructions). PlusOne™ silver staining showed a visible 50 
kD band at 0.5 ng protein (Figure 4.26) this is consistent with the published data given 
above.  
 
Figure 4.26: A 1D gel showing Precision Plus Protein™ standards (BioRad
®
) in serial dilution 
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stained with PlusOne™ silver staining kit (Amersham Biosciences). The values used to 
determine the sensitivity of the stain within the 50 kDa band are highlighted by the red box. 
Silver staining also showed linearity in the range tested (Figure 4.27) this is unusual as 
silver staining is not known to be linear. Silver staining has a detection range of 1-10 ng 
of protein (Rabilloud, Brodard et al. 1992).  
 
 
Figure 4.27: The linearity of PlusOne™ silver staining (Amersham Biosciences). 
 
Unlike Coomassie and SYPRO® Ruby stains silver stain is not an endpoint 
stain, it needs to be stopped at an arbitrary point this can limit the reproducibility of the 
staining method unless an automated staining method is used. Silver staining is a multi 
step procedure that is quite time consuming and can display run to run variability in 
staining. The multiple staining steps produced a problem when trying to test the 
reproducibility of the staining method. In order to test this accurately each step was 
timed using a stopwatch in order to maintain the same conditions each time the 
staining was performed. A way to overcome this would be to use an automated staining 
vessel which would maintain the same staining times each time it was used. The 
results for this showed that in order to obtain suitable staining of the gel the density of 
staining was similar for many of the dilutions (Figure 4.28) which did not show 
discrimination in the amount of protein loaded to each well. Although a decrease in 
density/mm2 was shown for the serial dilution it was minimal.  
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Figure 4.28: The average density of saliva protein bands for repeatability of PlusOne™ silver 
staining (Amersham Biosciences) (n=3). 
 
 
Negative staining was shown in the silver stained images (Figure 4.29), this can 
occur where high abundant proteins are over stained, this could be a limitation with this 
method in order to achieve a suitable staining intensity for some of the smaller proteins 
within a gel image the high abundant protein may become negatively stained. 
 
 
 
 
 
Figure 4.29: A 1D gel showing Saliva protein in serial dilution stained with PlusOne™ silver 
staining kit (Amersham Biosciences) showing an example of negative silver staining highlighted 
at approximately 55 kDa. 
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4.2.4.2 (iii) Protein Detection using SYPRO® Ruby Fluorescent 
Stain (Invitrogen™) 
 
Decreasing density/mm2 was demonstrated (Figure 4.30) as for the other 
endpoint stains tested, although unlike colloidal CBB G-250, SYPRO® Ruby showed an 
increase in variability between the repeats. SYPRO® Ruby (Invitrogen™) stained a 50 
kD band at 0.50 ng (Figure 4.30) similar to that seen with PlusOne™ silver stain. This 
result was expected as SYPRO® Ruby is reported to have sensitivity similar to silver 
staining. SYPRO® Ruby (Invitrogen™) was as linear (Figure 4.31) as colloidal CBB G-
250 and silver staining over the range tested, with little increase in signal seen at 
higher (20 ng) protein amounts.  
 
 
  
0.5ng 
 
 
 
 
 
 
 
 
 
Figure 4.30: A 1D gel showing Precision Plus Protein™ standards (BioRad
®
) in serial dilution 
stained SYPRO
®
 Ruby gel stain (Invitrogen™). The values used to determine the sensitivity of 
the stain within the 50 kD band are highlighted by the red box. 
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Figure 4.31: The linearity of SYPRO
®
 Ruby gel stain (Invitrogen™). 
 
Figure 4.32: The average density of saliva protein bands for repeatability of SYPRO
®
 Ruby 
staining (n=3). 
 
4.2.4.2 (iv) Detection of Proteins using Flamingo™ Fluorescent 
Stain (Bio-Rad®) 
 
Flamingo stain is less sensitive than SYPRO® Ruby (Invitrogen™), detecting a 
50 kDa band at 7.5 ng as compared to 0.5 ng (Figure 4.33). The linearity of flamingo™ 
(BioRad®) (Figure 4.34) was less than that of all the other stains tested, especially at 
the higher protein concentrations. Reproducibility studies demonstrated (Figure 4.35) 
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that the staining method was unable to detect the two smallest serial dilutions of saliva 
unlike the other stains. Therefore the results were more variable than the other 
methods used. The first serial dilution displayed a greater density/mm2 than that of the 
previous well with a greater protein load. The results from this comparison showed that 
as well as having a low sensitivity Flamingo staining was also variable between 
repeated gels. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.33:  A 1D gel showing Precision Plus Protein™ standards (BioRad
®
) in serial dilution 
stained Flamingo™ fluorescent gel stain (BioRad
®
). The values used to determine the sensitivity 
 of the stain within the 50 kDa band are highlighted by the red box. 
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Figure 4.34: The linearity of Flamingo™ fluorescent gel stain (BioRad
®
). 
 
Figure 4.35: The average density of saliva protein bands for repeatability of Flamingo staining 
(n=3). 
 
A summary of the staining methods compared (Table 4.1) is shown below. 
 
 
Table 4.2: Summary of the four staining methods compared showing limits of Sensitivity, 
Linearity and Reproducibility of each method. 
Stain Colloidal CBB PlusOne 
Silver Stain 
SYPRO Ruby Flamingo 
Sensitivity 0.75 ng 0.5 ng 0.5 ng 7.5 ng 
Linearity (R2) 0.9554 0.9727 0.9573 0.8469 
Reproducibility *** * ** * 
y = 0.2717x + 1.9508
R2 = 0.8439
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4.2.5 Optimisation of Image Analysis – Gel Repeat Expression 
Comparison 
 
Images were grouped according to sample pools using the Prodigy same spots 
software. For example, the gels from vaginal pools 4 and 4a were placed in one group 
to allow direct comparison between them and the gels from saliva pools 4 and 4a were 
placed in a separate group to allow comparisons to be made between them.  
A pair of gel repeats were chosen for each sample type based on their similarity 
and lack of any gel distortion. Gels PV4 and PV4a were selected for vaginal fluid 
sample comparison (Figure 4.36) and gels PS12a and PS12b (Figure 4.37) were 
selected for saliva sample comparison. These pairs were selected as they showed the 
least visual variation between them. The highest fold difference shown between 
matching spots for the vaginal fluid gels was 1.6 (see Figure 4.38) and for saliva gels 
1.9 (see Figure 4.39).  
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Figure 4.36: Duplicate 2D gel images (vaginal pool 4 and 4a respectively) used for comparison 
of spot expression fold differences. 
 
 
 
   
Figure 4.37: Duplicate gel images (saliva pool 12 and 12a respectively) used for comparison of 
spot expression fold differences. 
 
 
From the values displayed in Figures 4.38 and 4.39 it was determined that the 
lower limits for spot selection would be 2.5 for vaginal samples and 3 for saliva 
samples. This would allow for expression changes to be deemed acceptable between 
factor sub groups such as age and time of cycle. 
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                    a)    b) 
Figure 4.38: Images to show pair analysis of gels a) PV4 and b) PV4a showing the highest fold 
difference of 1.6 between matching spots on duplicated gels. 
 
 
 
      
           a)    b) 
Figure 4.39: Images to show pair analysis of gels a) PS12 and b) PS12a showing the highest 
fold difference of 1.9 between matching spots on duplicated gels. 
 
The lowest fold differences demonstrated for vaginal fluid gels was 1.2 (Figure 
4.40) and for saliva was 1.0 (Figure 4.41). Spots with a fold difference of 1 show the 
same intensity in the gel images. Spots with a fold difference between these values 
and the lower limit set above were used for comparison of spots between samples 
when identifying potential markers for uniform expression across all sample gels. 
“Speckling” can be observed on gel images (Figure 4.39) as the SYPRO Ruby stain is 
susceptible to crystallising on the gel during the staining process. It is important to 
recognise this speckle by eye when analysing gel images so as not to confuse these 
with true protein spots that appear with a less sharp outline. 
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         a)    b) 
Figure 4.40: Images to show pair analysis of gels a) PV4 and b) PV4a showing the lowest fold 
difference of 1.2 between matching spots on duplicated gels. 
      
 
       
                   a)    b) 
Figure 4.41: Images to show pair analysis of gels a) PS12 and b) PS12a showing the lowest 
fold difference of 1.0 between matching spots on duplicated gels. 
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4.3 Discussion  
 
4.3.1 Optimisation of Body Fluid Proteomics 
 
 It is important when comparing samples by 2DGE that the sample preparation 
and running conditions are kept constant to allow accurate comparisons to be made 
between gels showing relative protein expression changes (Ong and Pandey 2001). It 
is also important to remember that 2DGE is known for run to run variability and inter 
laboratory variability. Therefore gel images cannot be compared easily without suitable 
software capable of compensating for slight gel to gel differences. 
 Unlike the genome which is identical in every somatic cell of the body the 
proteome is in a state of dynamic flux (Fey and Larsen 2001). A 2D gel is a 
representation of the sample, saliva or vaginal fluid at a particular moment in time 
under a particular set of environmental conditions (Fey and Larsen 2001; Ong and 
Pandey 2001). As with all other proteins, salivary proteins are transcribed from mRNA 
and translated into proteins with post translational modifications occurring prior to 
secretion into the oral cavity. Further salivary protein modifications occur in the oral 
cavity where both host and bacterial enzymes cleave proteins secreted from the 
salivary glands, thus the proteins detected in saliva have undergone significant 
changes from the initial mRNA transcripts in the salivary glands (Helmerhorst and 
Oppenheim 2007). It is for these reasons that proteomics was the chosen method over 
mRNA analysis as it is more representative of the biology of human body fluids (Fey 
and Larsen 2001) for this study. 
 
4.3.1.1 Sample Preparation Prior to Proteomic Analysis  
 
 Sample preparation is an important step in obtaining reliable results in any 
proteomics study. Protein samples commonly contain substances capable of interfering 
with downstream proteomic methods. Sample preparation should look to remove salts 
and detergents and any other factors that could interfere with 2DGE (Jiang, He et al. 
2004). 
 
4.3.1.1(i) Precipitation 
 
 Precipitation of protein followed by pellet uptake in IEF sample buffer is the 
most common method used to concentrate and purify proteins (Jiang, He et al. 2004) 
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precipitation is particularly useful for body fluid proteomics analysis as it minimises 
protein depletion in the sample (Martins de Souza, Oliveira et al. 2008). For saliva and 
vaginal fluid the precipitation method affording the highest total protein differed, ie. 
Acetone and TCA-acetone respectively (Figure 4.3 and 4.6). When the two methods 
were compared, however, and a 2D gel was run, clear distinctions were seen between 
the two protein profiles produced by the same saliva sample (Figure 4.4). Acetone 
precipitation produced a more resolved image with a greater number of spots visible on 
the gel and for this reason, was the precipitation method chosen. TCA-acetone 
precipitation has been used by others for both saliva and vaginal fluid proteomics 
studies (Giusti, Baldini et al. 2007; Tang, De Seta et al. 2007) whereas acetone has 
only been used for saliva (Hardt, Thomas et al. 2005). Ethanol precipitation has been 
applied to precipitate proteins from vaginal fluid (Rajan, Cao et al. 1999) and so was 
therefore used for comparison. When  the precipitation is performed the proteins within 
the sample are concentrated and resuspended in a smaller volume of IEF sample 
buffer, thus protein assay values for the average total protein in precipitated samples 
would be expected to be higher compared with non precipitated samples, this was the 
case with vaginal fluid samples (Figure 4.5 and 4.6). 
 
4.3.1.1 (ii) Protein Extraction 
 
 Unlike saliva, where proteins are readily obtained in solution, a problem was 
encountered with vaginal fluid collected by swab. A suitable buffer was required to 
wash the vaginal fluid from the swab without substantial protein loss in the process. A 
comparison of PBS and water (Figure 4.5) showed that more protein was afforded with 
PBS than with water.  Both samples were assayed prior to precipitation hence the 
average total protein in the sample was lower than the values obtained in the 
precipitated samples (Figure 4.6) due to a dilute sample being assayed. A buffer 
compatible with downstream techniques such as in 2DGE used in this study and DNA 
typing in a forensic laboratory would also be advantageous. No adverse effect was 
observed with PBS when vaginal cells was washed from swabs for DNA profiling or 
Haematoxylin and Eosin staining (Martin, Pirie et al. 2006).  
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4.3.1.1 (iii) Depletion of Abundant Proteins 
 
 Biomarker discovery in blood samples is often hampered by the high proportion 
of albumin and IgG present within the sample (Echan, Tang et al. 2005). Although in 
this study blood and menstrual blood samples were not studied in depth for biomarker 
discovery, sample optimisation was carried out with the depletion of abundant proteins 
using Vivapure® anti HSA/IgG columns (Sartorius).  1DGE showed a pronounced 
reduction of protein (Figure 4.7) in both blood and menstrual blood samples. When 
comparisons were made with 2DGE significant protein loss was shown in the gels 
where the blood (Figure 4.8) and menstrual blood (Figure 4.9) had been passed 
through an anti HSA/IgG column.  Albumin has been previously shown to interact with 
low molecular weight proteins, acting as a carrier by binding to cytokines and 
hormones resulting in their removal from the samples (Veenstra, Conrads et al. 2005). 
More defined protein spots were observed in the gels with samples that had not been 
passed through the anti HSA/IgG column.  Therefore it was decided that for further 
work with either blood or menstrual blood, the anti HSA/IgG column would not be used. 
Menstrual blood is composed of a mixture of blood and cervical and vaginal secretions 
(Fraser, McCarron et al. 1985). It was thought that the level of blood protein present 
was much lower than in traditional plasma or serum samples. The volume of blood that 
was deposited onto a swab head by finger prick was small and hence could account for 
the low levels of protein in the sample.  
 
4.3.1.1.4 Protein Assay Comparison 
 
 Traditional assays used for protein measurement are the Bradford (Bradford 
1976) and the Lowry assays (Lowry, Rosebrough et al. 1951).  After protein 
precipitation, the pellets were reconstituted in the IEF sample buffer containing urea, 
CHAPS and DTT (compatible with the RC DC assay). Comparison of the RC DC 
protein assay with an adapted microplate version of the Bradford assay showed that 
the IEF sample buffer reduced the linearity of the standard curve given by IgG. The 
standard curve produced with the Bradford assay gave an R2 value of 0.7489 (Figure 
4.10) in comparison with the standard curve from the RC DC assay giving an R2 value 
of 0.9717 (Figure 4.11). The linearity of the Bradford assay was clearly compromised in 
the presence of IEF sample buffer hence the RC DC assay was used for protein 
quantification when IEF sample buffer was used. Other researchers have shown a 
preference for the RC DC protein assay (Giusti, Baldini et al. 2007). 
 
 
 
 
147 
 
4.3.2 First Dimension Optimisation 
 
4.3.2.1 IPG Strip Load 
 
The dynamic range of serum proteins is greater than 10 orders of magnitude 
which poses a problem. The six most abundant proteins constitute approximately 85% 
of the total protein content (Martins de Souza, Oliveira et al. 2008), when resolving both 
high and low abundance proteins. Increasing the protein load may also increase the 
intensity of the low abundance proteins but in turn this could cause overloading of the 
IPG strip causing poor resolution of proteins on the gel (Ong and Pandey 2001). For 
both saliva (Figure 4.12) and vaginal fluid (Figure 4.13) 50 µg was determined to be the 
optimal protein load when tested with SYPRO Ruby as the detection stain. At this 
protein load high abundant proteins were clearly resolved and the smaller low 
abundant protein spots were visible on the gel without distortion of the high abundant 
proteins or any lost of details from the disappearance of less abundant proteins.  
 
4.3.2.2 IPG Strip Range 
 
 It is common practice when analysing a new sample type to use a broad range 
IPG strip in order to determine the range of protein pIs (Ong and Pandey 2001). One 
limitation of the broad range strips is that some of the spots that appear to be a single 
defined spot can be a mixture of two or more proteins migrating together (Ong and 
Pandey 2001). This was seen when a pH 3-6 IPG was used with saliva, where what 
appeared to be a large single protein in the pH 3-10 gel (Figure 4.16) was separated 
into three large proteins in the pH 3-6 gel.  The use of narrow range IPG strips gives 
greater resolution and more separation on the gel. A disadvantage of using more than 
one narrow range strip to create a wider picture of protein expression within the sample 
means running a larger number of gels and more labour. The number of spots from 
both saliva and vaginal fluid gels was increased with narrower range IPG strips pH 4-7 
and pH 5-8 (Figure 4.15 and 4.18 respectively). For both saliva and vaginal fluid the gel 
run with IPG strip of pH 3-6  gave fewer protein spots in that range than with other gels. 
Those that were expressed had increased resolution and separation (Figure 4.16 and 
4.19 respectively).  
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4.3.3 Second Dimension Gel Optimisation 
 
4.3.3.1 Gel Percentage 
 
 The percentage of acrylamide used in the second dimension can determine the 
distribution of proteins on the gel. In this work 10%, 12% and 15% acrylamide were 
studied (Figure 4.20). Of these percentages, 12% acrylamide showed the most even 
protein distribution while ensuring lower molecular weight proteins were not lost off at 
the end of the gel while the higher molecular weight proteins had moved a sufficient 
amount through the gel avoiding aggregation at the top of the gel.  Giusti et al. (2007) 
used this acrylamide gel percentage to successfully separate whole saliva and these 
results were confirmed in this study. 
.  
4.3.3.2 Staining 
 
A comparison of several protein gel stains showed that silver staining and 
SYPRO were the most sensitive with the greatest number of visible gel spots. High 
abundant proteins were observed on the gel stained with SYPRO whereas hardly any 
spots were visible with Flamingo staining. A summary of the staining methods 
compared (Table 4.2) showed comparisons each method more simply. Quantitative 
analysis for the limit of detection of each stain showed that with Colloidal CBB G-250 
staining (Figure 4.23) showed that the lowest visible 50 kD band was at 0.75ng protein. 
This value was much lower than the 8-10 ng limit reported by Neuhoff et al. (1998). 
This could be due to a greater sensitivity of the silver staining kit used in this study. A 
similar experiment conducted by Kang et al. (2002) showed that the limit of detection 
with colloidal CBB staining was 1ng protein/band which is consistent with that seen in 
this experiment. Staining with Colloidal CBB was shown to be linear (Figure 4.24) with 
an R2 value of 0.9554. This is consistent with Colloidal CBB being used to quantify 
proteins in the Bradford assay (Kang. D, Y et al. 2002). Linearity of staining has been 
reported up to 3 orders of magnitude (Patton 2002). In this study less than two orders 
of magnitude were studied.  
PlusOne™ silver staining gave a visible 50 kD band at 0.5 ng protein (Figure 
4.26). Silver staining also showed linearity in the range 0.5 ng-20 ng protein tested 
(Figure 4.27). This was unexpected as silver staining is not known to give linear 
calibration curve (White, Pickford et al. 2004). Silver staining had previously shown to 
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have  a detection range of 1-10 ng of protein (Rabilloud, Brodard et al. 1992) which is 
higher than that seen in this study. 
Negative staining, (Figure 4.29) has been a common problem with silver 
staining(Miller, Crawford et al. 2006). In order to achieve a suitable staining intensity for 
some of the smaller proteins within a 2D gel image the high abundant proteins may 
become negatively stained. Unlike colloidal CBB G-250 stain, silver stain is not an 
endpoint stain, since it needs to be stopped at an arbitrary point. As a result this can 
limit the reproducibility of the staining method unless an automated staining method is 
used. The negative staining seen with this method when using 1D gels shows that the 
stain is more suitable for 2D gels where proteins are distributed throughout the gel 
rather than being confined to bands in the 1D gels. If a large area of high abundant 
protein was present in a 2D gel, for example amylase in saliva or albumin in blood 
negative staining may be experienced. 
Silver staining is a multi step procedure and is relatively time consuming and 
can result in staining variability between runs. When testing the reproducibility of the 
staining method, problems were encountered with the multiple staining steps. In order 
to test this accurately each step was timed using a stopwatch to ensure the same 
conditions each time the staining was performed. This could be overcome by using an 
automated staining vessel which would maintain the same staining times each time it 
was used.  
SYPRO® Ruby (Invitrogen™) displayed a 50 kD band at 0.5 ng (Figure 4.30) 
thus showing a similar sensitivity to silver staining.  This was lower than the previously 
reported detection limit for SYPRO Ruby of 1ng (SYPRO Ruby data sheet, SIGMA). 
Although being an endpoint stain like colloidal CBB G-250, SYPRO® Ruby showed an 
increase in variability between the repeats as shown by larger standard deviations 
(Figure 4.32). SYPRO® Ruby (Invitrogen™) showed a similar linearity to both colloidal 
CBB G-250 and silver staining (Figure 4.31) over the range tested, although a linear 
response has been seen over three orders of magnitude (Berggren, Schulenberg et al. 
2002). The intensity of Flamingo staining was much lower than that of SYPRO® Ruby 
(Invitrogen™). A 50 kD band was detected at 7.5 ng (Figure 4.33). The linearity of 
flamingo™ (BioRad®) (Figure 4.34) is less than that of the other stains tested. 
Flamingo™ (BioRad®), like SYPRO® Ruby (Invitrogen™), is an endpoint stain although 
in this study it has the disadvantage of having a lower sensitivity.  
The primary fluorescence excitation maximum of Flamingo fluorescent gel stain is at 
512 nm. There is a minor excitation maximum at 271 nm (Flamingo stain user guide). 
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The stain was stated to be compatible with a UV transilluminator with a 300 nm bulb 
but in our hands the images obtained using this method were poor. A more 
sophisticated imager may be necessary for this stain such as a laser scanner rather 
than a CCD camera. Sensitivity has been stated at 0.5 ng of protein using a UV 
transilluminator with a wavelength of 300nm and a sensitivity of 0.25ng using a laser 
scanner with a wavelength of 532nm. The filter used in the ChemiDoc was 302nm 
inferring that the fluorescence exhibited by the Flamingo stain should have been in the 
sensitivity of that stated by the manufacturer. Increasing the length of time the gel 
spent in fix could have increased the sensitivity, as residual SDS on the gel may 
hamper imaging at 300nm, this was not performed but could be considered if a more 
economic alternative to SYPRO was considered. Reproducibility studies demonstrated 
(Figure 4.35) that the staining method was unable to detect the two smallest serial 
dilutions (1 µg and 2 µg) unlike the other stains described above. Therefore the results 
with Flamingo staining were more variable than the other methods used. The well 
containing 15 µg saliva protein displayed a greater density/mm2 than that of the 
previous well with 20 µg saliva protein but the standard deviations show variability 
between repeats hence this could be an anomaly in the results and not a significant 
decrease in the protein level in this band. The results from this comparison showed that 
as well as having a low sensitivity, Flamingo staining was also variable between 
repeated gels.  
Variability in the staining method chosen by laboratories still defines how many 
protein spots are identified within a 2D gel. Although the introduction of fluorescent 
stains has been seen to increase the sensitivity of the proteomics system, some 
laboratories still prefer to stain with colloidal CBB. This has been the case for the 
identification of potential spots likely to yield successful spectroscopy results (personal 
communication). 
 
4.3.3.3 2DGE Image Analysis 
 
Gels were scanned to generate 16 bit images for analysis. Bit depth is a term 
given to describe the number of bits defining each pixel of a digital image (Miller, 
Crawford et al. 2006). This determines how many levels of grey that can be generated. 
The greater the bit depth, the greater the range of grey tones represented by a pixel. 
The image analysis software is able to distinguish between these different levels of 
grey. Thus the more levels of grey represented in an image the better the ability of the 
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analysis software to differentiate low abundance spots from background  and hence the 
greater the accuracy of the software analysis (Miller, Crawford et al. 2006).  
Ideally all replicate gel images of a sample would contain the same number of 
spots with the same staining intensity (individual spot volumes), with each spot 
migrating to exactly the same gel position. However this is not the case with 2DGE and 
there will always be process variability factors due to different conditions in a 2D gel 
run. This variation can arise at any stage during the 2D process and as a result of this 
in order to identify any significant protein expression changes accurately, the error in 
the system must be identified (Smales, Birch et al. 2003). Matching spot pairs could be 
examined between the samples, thus showing the highest and lowest fold difference 
(expression change) seen by  matching spots between gel repeats of the same pool.  
The highest fold difference shown between matching spots for the vaginal fluid 
gels was 1.6 (see Figure 4.38) and for saliva gels 1.9 (see Figure 4.39). The lowest fold 
differences exhibited by vaginal fluid gels was 1.2 (Figure 4.40) and by saliva was 1.0 
(Figure 4.41).  
These two values were used to indicate the level of  
fold difference seen between gel repeats and hence determine whether a fold 
difference could be considered as a true change due to biological factors or to gel to 
gel run differences between the duplicates.  
These figures were used to determine inclusion and exclusion criteria when 
selecting potential spots for further analysis. For example there should be a limit for 
fold difference to determine whether a spot should be selected for further analysis. 
Traditionally when looking to identify expression differences between samples this limit 
should be above the highest fold difference seen between duplicate gels used for the 
pair analysis. In matching spots within duplicate gels an expected fold difference would 
be of 1, although this is rarely seen due to inter-gel variability throughout the 2D 
process.  In this project if the fold difference of the same spot was shown to be a 
similar level across different sample pools within the same sample type, it could be 
determined that the protein spot may be of interest as a marker for that fluid type as 
expression seemed constant in each of the pools tested. 
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4.4 Chapter Summary 
 
 The work described in this chapter has determined the optimum conditions for 
2DGE of body fluids under investigation.  
In future work the samples will be used either directly from source or extracted into 
PBS before protein concentration measurement by the RCDC protein assay. After 
acetone precipitation electrophoresis will be run using 7cm pH 5-8 strips in the first 
dimension and 12% polyacrylamide gels in the second dimension. Post electrophoretic 
staining will be performed using SYPRO Ruby fluorescent gel stain (Invitrogen). Image 
analysis will be performed by Prodigy samespots software.  
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CHAPTER 5 – Protein Expression Analysis of 
Saliva and Vaginal Samples  
 
5.1 Introduction 
 
 The aim of work described in this chapter was to identify proteins with 
expression specific to one fluid type, i.e. only expressed within either saliva or vaginal 
fluid.  
 
5.1.1 Factors Effecting Protein Expression in Saliva 
 
Proteomic analysis of saliva can be complicated by gland specific effects of circadian 
rhythm (Hardt et al. 2005). Daily oscillations in the secretion of saliva can be affected 
by physical factors such as exposure to light and changing time zones and biological 
factors including age, sex, emotions and stress. For these reasons gender, age and 
collection time were selected as factors which may show proteomic variability. 
 
5.1.1.1The Effect of Gender on Protein Expression in Saliva 
 
 Previous workers have reported that unstimulated whole saliva flow rate is 
greater in males than in females (Percival et al. 1994). To date proteomic studies 
investigating whether gender has an effect on changes in protein expression have 
been limited. It has been shown that there are no differences between men‟s and 
women‟s α-amylase levels (Nater et al. 2007). A mouse study stated that mRNA 
expression is higher for many genes in salivary glands of males than females (Treister 
et al. 2005a).  
 
5.1.1.2 The Effect of Age on Protein Expression in Saliva 
 
 Previous studies have focussed on saliva flow rate rather than protein 
expression changes with age. Un-stimulated whole saliva flow rate has been shown to 
decrease with age (Percival et al. 1994; Yeh et al. 1998). Age has no effect on the level 
of α-amylase within saliva (Nater et al. 2007), but the concentration of mucins in saliva 
decreases with age (Vissink et al. 1996). IgA concentrations increase with age; this is 
thought to occur in response to alterations in the oral microbiota (Ambatipudi et al. 
2009) comparing two saliva pools from donors aged  20-30 and 55-65 years old. 
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5.1.1.3 The Effect of Sample Donation Time on Protein 
Expression in Saliva    
 
 Salivary flow rate and saliva salt concentrations have been shown to vary over 
a 24 hour period (Dawes 1974). Day time variations in saliva protein expression have 
been studied with particular interest being paid to α-amylase. The autonomic nervous 
system controls both the flow (parasympathetic stimulation) and composition of saliva 
(sympathetic stimulation). Salivary α-amylase is regulated by the sympathetic nervous 
system and measurement of salivary α-amylase levels are proposed to reflect changes 
in the nervous system especially under stress conditions (van Stegeren et al. 2008). 
Levels of α-amylase change throughout the day as shown by Ferguson et al. (1973) 
where low levels were seen in the morning and high levels in the afternoon (Ferguson 
et al. 1973).  
 
5.1.1.4 The Effect of Food Consumption on Protein Expression 
in Saliva 
 
 Previous research has inferred that a carbohydrate rich diet can increase the 
level of α-amylase within saliva (Squires 1953). During eating the proportion of parotid 
saliva increases, participating in the bolus formation and digestion by α-amylase 
(Neyraud et al. 2009). It is thought that α-amylase levels increase after food 
consumption whereas eating or drinking was found to have no effect on α-amylase 
expression (Nater et al. 2007). The literature on this subject remains limited.  
 
5.1.2 Factors Affecting Protein Expression in Vaginal Fluid 
  
5.1.2.1 The Effect of Age on Protein Expression in Vaginal Fluid  
 
 For the age range studied changes in the vagina are mostly linked to the 
reproductive cycle and its termination (Farage and Maibach 2006). Menopause is 
defined by the World Health Organization as the permanent cessation of menstruation 
due to the loss of ovarian follicular activity. The term perimenopause is used to 
describe the period ending 12 months after the final menstrual period (Burger 1996). 
There is a decrease in vaginal secretions after this time. There does not appear to be 
substantial literature relating to proteomic changes in vaginal fluid at the time of writing.  
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5.1.2.2 The Effect of Contraception on Protein Expression in 
Vaginal Fluid  
 
 The protein lactoferrin within vaginal secretions differs according to oral 
contraceptive use. In women not taking oral contraceptives the level of lactoferrin is at 
its lowest in the luteal phase and at its highest in the follicular phase immediately after 
menses. In comparison women taking oral contraceptives have lower levels of 
lactoferrin which remains unchanged throughout the cycle (Wilson 2005).  
   
5.1.2.3 The effect of the Menstrual Cycle on Protein Expression 
in Vaginal Fluid 
   
 The vaginal mucosa is sensitive to ovarian hormone cycling (Farage and 
Maibach 2006). Oestrogen causes the thickness and glycogen content of the 
epithelium to peak at mid cycle during the ovulatory phase. The most abundant 
immunoglobulin in vaginal fluid is IgG (Wilson 2005). The level of this protein has been 
seen to peak before ovulation and decline in the luteal phase (Usala et al. 1989). Other 
anti-microbial proteins in the vaginal fluid have also shown fluctuations during the 
menstrual cycle. Human β-defensin (HBD) 5 has been shown to increase throughout 
the menstrual cycle reaching a maximum during the luteal phase (Wilson 2005).   
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5.2 Methodology 
 
5.2.1 Sample Selection 
 
Samples (25 for each saliva and vaginal fluid) were obtained from volunteer donors as 
described in Section 2.2.  The samples were categorised according to predefined 
variables. Saliva samples were taken;  
a) at different times of the day  
b) at different times after food or drink  
c) from males and females  
d) from people of different ages.  
Vaginal fluid samples were taken from women; 
a) of different ages, 
b) at different stages of the menstrual cycle (not menses) 
c) using different forms of contraception. 
The information used for characterisation was obtained from the consent form filled in 
by each donor (Appendices III & IV). Each variable had 25 samples associated with it 
spread across the sample pools (Figure 5.1 and 5.2) for that variable.  
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Table 5.1: Composition of pools for saliva samples. 
Saliva pool 
identification 
number 
Saliva pool description Total 
number 
Sample composition of pool* 
PS1 All saliva samples pooled 25 1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19, 20, 
21,22,23,24,25 
PS2 Sex: - Male samples 8 2,9,12,13,14,15,20,21 
PS3 Sex: - Female samples 17 1,3,4,5,6,7,8,10,11,16,17,18,19,22,23,24,25 
PS4 Age < 23 14 2,3,4,5,7,8,11,18,19,21,22,23,24,25 
PS5 Age 24 - 27 7 9,10,13,14,15,17,20 
PS6 Age 28 - 31 4 1,6,12,16 
PS7 Samples donated in the morning 
between 9am - 12pm 
6 20,21,22,23,24,25 
PS8 Samples donated at lunchtime 
between 12pm - 2pm 
10 1,2,3,6,7,8,9,10,11,19 
PS9 Samples donated in the 
afternoon between 2pm - 5pm 
7 4,5,13,14,16,17,18 
PS10 Samples donated in the evening 
after 6pm 
2 12,15 
PS11 Time since eating < 15 minutes 7 1,7,9,10,15,16,18 
PS12 Time since eating < 60 minutes 13 2,3,4,5,6,14,17,19,20,21,22,24,25 
PS13 Time since eating > 60 minutes 5 8,11,12,13,23 
*Each pool was composed of samples relevant to that pool type for examples all male samples 
in the male pool. For anonymity reasons samples were allocated a number. 
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Table 5.2: Composition of pools for vaginal fluid samples. 
Vaginal fluid pool 
identification number 
Vaginal fluid pool 
description 
total Sample composition of pool* 
PV1 All samples pooled 25 1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20, 
21,22,23,24,25 
PV2 Age – teens 3 2,6,19 
PV3 Age – 20s 9 1,5,7,9,15,17,20,23,24 
PV4 Age – 30s 9 3,8,10,12,13,14,16,21,25 
PV5 Age – 40s 2 4,11 
PV6 Age – 50s 2 18,22 
PV7 Combined pill 7 1,3,5,8,15,16,17 
PV8 Pill 5 2,7,21,22,23 
PV9 None 6 4,10,11,13,18,25 
PV10 Implanon implant 2 6,12 
PV11 Depo-Provera 
injection 
2 9,24 
PV12 Condoms  3 14,19,20 
PV13 Not menstruating 4 9,18,20,24 
PV14 Cycle stage - 
Follicular 
8 1,2,4,6,8,17,21,25 
PV15 Cycle stage - 
Ovulatory 
5 5,7,12,16,23 
PV16 Cycle stage - Luteal 8 3,10,11,13,14,15,19,22 
*Each pool was composed of samples relevant to that pool type for examples all samples from 
donors in their 30s in the age 30s pool. For anonymity reasons samples were allocated a 
number. 
 
5.2.2 2DGE  
 
All pooled samples were analysed by 2DGE. Each gel was run in duplicate in 
parallel using pH 5-8 IPG strips (section 2.6.2, 2.6.3) and stained with SYPRO Ruby 
(section 2.8.3). The gels were scanned using a PharosFX™ molecular imager and 
analysed with SameSpots Prodigy™ software (section 2.9). The gel running conditions 
were identical for each fluid type in order that gel images were comparable.  
 In order to identify potential biomarkers for each fluid type it was important to 
ascertain whether a particular protein was consistently present or absent within each of 
the pools. If protein expression remained constant across all pools of a fluid the protein 
was considered a potential biomarker for that fluid. If expression of a protein was 
affected by different biological variables it would be unreliable as a marker and was 
therefore rejected. 268 spots were observed in the saliva samples (see appendix VI) 
and 193 spots were observed in the vaginal fluid samples (see appendix VI) 
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Each protein spot was expressed in terms of its individual volume in the gel. 
Protein spots on each gel were measured using normalised spot volumes. Spots were 
normalised as a percentage of the total volume of all spots present in a gel. This was 
performed automatically by the SameSpots analysis software ensuring any run 
differences between gels did not have an effect on the expression data of proteins 
between gels.  
Spots chosen for LC-MS/MS analysis were those observed to be uniquely and 
consistently expressed in each fluid type. Spots were cut from the polyacrylamide gels 
and then submitted to the ROWETT Research Institute for LC-MS/MS analysis. 
Proteins were identified from their ion fragmentation pattern and peptide mass 
fingerprint data through a MASCOT search (see sections 2.11 and 2.12).  
Positive protein identifications were made from MASCOT output data by considering 
the following criteria;  
 
(i) the probability MOWSE (Molecular Weight Search) score calculated by the 
MASCOT software should be >40 indicating identity or extensive homology (p<0.05);  
 
(ii) the expected and observed molecular weights and pIs of protein hits should match 
the protein spots from the gel  
 
(iii) the protein hit should be consistent with the source tissue.  When these criteria 
were met, the protein determined, was considered a good hit. On the other hand if only 
one of the criteria was satisfied, the protein hit was described as poor.  
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5.3 Results - LC-MS/MS Analysis of Proteins 
 
5.3.1 Using IgG Standards as an Internal Control for LC-MS/MS 
Output 
 
An internal control standard IgG protein (Bio-Rad) was run on a 12% 2D gel using pH 
3-10 IPG strips (see section 2.6.2. and 2.6.3). Two spots (1C and 2C) were cut from 
that gel and submitted for blind analysis as positive controls (see Figure 5.1). Two 
spots with different degrees of staining intensity were chosen to determine whether this 
factor may affect excised protein spot identification.  
 
 
 
Figure 5.1: A 2DGE image showing IgG protein standard (Bio-Rad) run with pH 3-10 strips on a 
12% polyacrylamide gel. Labels 1C and 2C represent the control spots submitted for LC-MS/MS 
analysis.  
 
Blind LC-MS/MS analysis on the two control spots gave different results; control 2C 
gave a positive hit for Immunoglobulin λ chain variable region with a MOWSE score of 
45 and 2 peptide hits. Interestingly another protein hit (MOWSE score 35) gave a 
positive identification of HSV-I stimulating-related protein with 1 protein hit was also 
seen. These two hits are shown as small bars in Figure 5.2, the taller the bar the more 
peptide hits associated with the MOWSE score.  However control 1C did not identify 
IgG as the matched protein after MASCOT search. The distribution of hits was skewed 
with the majority having a MOWSE score under 40 (see Figure 5.3) and hence did not 
meet the predefined criteria (section 5.2.2).  
 
1C 
2C 
mW 
(kDa) 
75 
50 
 
37 
 
 
pI        3                                              6                                         10 
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Figure 5.2: Distribution of protein hits and their associated MOWSE scores for blind control 
sample 2C. 
 
 
Figure 5.3: Distribution of protein hits and their associated MOWSE scores for blind control 
sample 1C. 
 
The details of the MASCOT hits with MOWSE scores > 40 are summarised in table 5.3. 
The identification hits for sample 1C are poor, i.e. Putative anti-CNG α 1 cation channel 
translation product and centrosomal protein 2. Although the MOWSE score is high, the 
theoretical pI / mass differs from the observed pI / mass. For sample 2C a good 
identification hit for Immunoglobulin λ chain variable region was seen.  The MOWSE 
score was >40 and the theoretical and observed pI / mass match. The blind samples 
confirmed the validity of the hit criteria on page 158. 
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Table 5.3: A summary of MASCOT output data for the two IgG control spots submitted for 
analysis. 
Sample 
ID 
 
MASCOT protein hit 
name 
 
MOWSE 
score 
 
Theoretical 
pI / Mass 
 
Observed pI 
/ Mass 
 
Peptides 
matched 
 
1C 
 
Putative anti-CNG α 1 
cation channel 
translation product  
Bottom of Form 
50 
 
11.39 / 9081 
 
6 / 78000 
 
2 
 
 Centrosomal protein 2 
 
47 
 
5.21 /19393 
 
6 / 78000 
 
3 
 
2C 
 
Immunoglobulin λ chain 
variable region 
(Fragment) 
 
45 
 
6.19 / 35000 
 
6 / 38000 
 
2 
 
5.3.2 Protein Expression Analysis of Saliva Samples 
 
 Spots were selected for excision if they were consistently expressed within all 
saliva sample pools (see Table 5.4 and Figure 5.4). The fold difference threshold of 
1.00 (see section 4.2.5) was adhered to for comparison of samples for this experiment. 
Table 5.4 shows the fold difference determined by comparison of the highest 
normalised volume pool against the pool of lowest normalised volume for each 
individual spot. Spots were automatically ranked according to fold change by the 
Prodigy same spots software and thus allocated the spot numbers listed in Table 5.4. 
Nineteen spots were excised for saliva with the fold differences between spots ranging 
from 1.60 to 8.20. 
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Table 5.4: Saliva spot identification number and expression fold difference for spots analysed 
by LC-MS/MS.  
Spot Identification Number Fold Difference 
6 8.20 
34 7.80 
13 7.40 
66 5.80 
27 5.60 
33 4.60 
83 3.80 
47 3.80 
41 3.40 
46 3.20 
81 2.80 
79 2.80 
76 2.70 
70 2.50 
43 2.30 
89 2.20 
72 1.90 
59 1.90 
85 1.60 
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Figure 5.4: A 2D gel image of the master comparison gel (pool 1) to show spot identification 
numbers and gel position of saliva spots chosen for analysis.  
 
A summary of MS/MS ion MASCOT search data is described in Table 5.5, 
showing good protein identification hits for spots excised from saliva sample gels.  
Nine protein spots were successfully identified using LC-MS/MS data using a MASCOT 
search. 
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Total ion count spectra for each spot can be found in Appendix VIII. The 
MOWSE scores for these proteins ranged from 43 – 166 with the number of 
matching peptides for ranging from 1 – 4. As well as the above scores, the 
theoretical data for molecular mass and pI also appeared to be approximately the 
same as the protein spot gel position. The error in these two values ranged between 
500 and 6000 kDa for molecular weight with 0.07 and 0.80 for pI. Hit distribution 
graphs for the saliva spots identified can be seen in Appendix VII.  
Salivary proteins identified were; Lipocalin-1, Zinc- α-2 glycoprotein (ZA2G), 
two Cystatin proteins; Cystatin SA and Cystatin SN, Actin and immunoglobin.  
It has been hypothesised that Lipocalin-1 or Von Ebners gland (VEGh) protein has a 
role in bitter taste perception (Holzfeind et al. 1996). The tertiary structure of the 
protein contains a hydrophobic pocket providing a binding site for small lipophilic 
molecules. In the mouth (a hydrophilic environment) this function allows the 
transportation of lipophilic bitter compounds to the taste buds (Holzfeind et al. 1996; 
van't Hof et al. 1997).  
ZA2G is a multifunctional protein which is expressed within a number of body 
fluids (Hassan et al. 2008),  and is thought to be related to urinary glucocorticoids 
(Airoldi et al 2009).  
Cystatins are extracellular secreted proteins found in relatively high 
concentrations in body fluids (Turk et al. 2008). They function as competitive, 
reversible inhibitors of cysteine proteases responsible for protein metabolism or to 
protect tissues from attack by bacteria or viruses (Isemura et al. 1991). Cystatins 
were segregated into three types by Barrett et al (1986) based upon their molecular 
structure.  Salivary Cystatins fall into the type 2 Cystatin superfamily which are 
localised mostly within body fluids (Isemura et al. 1987). Type 2 cystatins have two 
disulfide bonds and a molecular mass of approximately 14 kDa (Hiltke et al. 1999). 
Table 5.5 showed that the theoretical mass and the observed mass (Figure 5.4) were 
higher than the weight stated by (Hiltke et al. 1999). Cystatin SN (spot 81) and 
Cystatin SA (spot 66) each had theoretical masses of approximately 16 kDa and 
observed masses of 17 kDa and 20 kDa respectively. 
The final two proteins, actin and immunoglobulin-α (IgA) were not 
investigated further as they are almost ubiquitous. Actin is a globular protein which 
forms filaments for a support role within the cell cytoskeleton (Hennessey et al. 1993) 
and therefore localisation is not confined to saliva alone.   
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IgA is the predominant immunoglobulin in saliva of normal individuals 
(Norhagen et al. 1989). Secreted into the oral cavity from the salivary gland epithelial 
cells and plays a role in defence of the mucosal surface against infection. 
Localisation of immunoglobulin alpha is also not expressed solely in saliva but is 
found within all body secretions. 
LC-MS/MS data also provided nine protein identifications rated poor (see 
Table 5.6). MOWSE scores for these proteins ranged from 30-50 and the number of 
matching peptides to make these identifications was either 1 or 2. Insufficient data 
was available to successfully identify spot 34 by LC-MS/MS. The poor protein 
identifications (Table 5.6) were rejected based either upon their MOWSE score or a 
comparison between theoretical and actual protein data. They were not used in 
further analysis.  
Expression bar graphs of the nine proteins positively identified by LC-MS/MS 
were drawn for each saliva sample pool.  The graphs compare protein expression by 
measurement of normalised spot volume for each pool. Each Gel duplicate 
(duplicate gels were run at the same time) is shown as a separate bar on the graph. 
Comparisons were made between each pool subset which are; sex (Figure 5.5), age 
(Figure 5.6), time of sample collection (Figure 5.7) and time since eating (Figure 5.8). 
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5.3.2.1 Protein Expression Analysis of Saliva Samples – 
Gender Comparison 
 
 
   a)                 b)  
 
Figure 5.5: Bar graphs illustrating protein expression measured using normalised spot 
volume between a) male and b) female pools, with two gel repeats. Gel repeat 1 represented 
by black bars and gel repeat 2 represented by grey bars. 
 
Protein expression between the gel duplicates for both male (represented in 
panel a) and female samples (represented in panel b) was shown to be low for the 
majority of spots (<1400) with consistent expression between gel repeats 
represented by a similarity in bar height between gel duplicates (Figure 5.5). 
Normalised volumes ranged between 573 (spot 41 – actin-γ) and 1362 (spot 70 – 
zinc-α-2 glycoprotein) for male samples and 570 (spot 79 immunoglobulin α) and 
1280 (spot 59 – Lipocalin-1) for female sample pools. However, protein spot 66 
(Cystatin SA) and 81 (Cystatin SN) were high in both male (Figure 5.5 a) and female 
(Figure 5.5 b) duplicates. For gel one, expression of protein spot 66 (Cystatin SA) in 
male samples (Figure 5.5 a) was 5337 whereas for gel duplicate two, the expression 
of Cystatin SA was greatly reduced to 855. The differences in spot intensity can be 
seen in figures 5.6 a and b. A smaller difference was seen in the female samples 
(Figure 5.5 b). Duplicate one showed a normalised volume of 1717 whereas 
duplicate two showed almost double that of 3424. This expression difference is 
displayed in figures 5.6 c and d. 
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a)                                    b) 
  
                                     c)                                      d) 
 
Figure 5.6: Spot 66 expression represented on 2D gel images.  Male saliva samples repeat 1 
and 2 (a and b respectively) and Female saliva samples repeat 1 and 2 (c and d 
respectively). 
 
Expression of protein from spot 81 (Cystatin SN) for repeat one of the male 
samples (Figure 5.5 a) was 4506 and for repeat two was 5396, almost 3 times the 
normalised volume noted for some of the other spots listed. For the female samples 
(Figure 5.5 b), the expression was shown to be lower; 3761 and 4270 for duplicates 
one and two respectively. A similar trend to spot 81 (Cystatin SN) was seen in 
protein spots 70 (Zinc-α-2 glycoprotein), 79 (immunoglobulin α) and 83 (actin-λ): 
expression was slightly higher in the male gel duplicates (Figure 5.5 a) than in the 
female gel duplicates (Figure 5.5b). Expression of protein spot 41(actin-λ) was 
consistent between the sex pools, with normalised volumes of 573 and 602 
(duplicate one male and female respectively) and 1075 and 1083 (duplicate two male 
and female respectively). Spots that showed a higher normalised volume in the 
female samples (Figure 5.5 b) compared to the male samples (Figure 5.5 a) were 59 
(Lipocalin-1) and 76 (Zinc-α-2 glycoprotein). Differences in the spot volume for these 
spots are shown in Figures 5.7 and 5.8 spot 59, Lipocalin-1 and spot 76, Zinc- α-2 
glycoprotein respectively. Male pool duplicates shown in panels a and b and female 
duplicates in panels c and d. 
 
 
 
Repeat 1 Repeat 2 
Male 
Female 
 
 
 
 
172 
 
 
  
a)                                    b) 
  
b)                                    d) 
 
Figure 5.7: Spot 59 expression represented in 2D gel images.  Male saliva samples repeat 1 
and 2 (a and b respectively) and Female saliva samples repeat 1 and 2 (c and d 
respectively). 
 
 
 
            
           a)                                 b) 
  
        c)                                      d) 
 
Figure 5.8: Spot 76 expression represented in 2D gel images.  Male saliva samples repeat 1 
and 2 (a and b respectively) and Female saliva samples repeat 1 and 2 (c and d 
respectively). 
 
 When assessing normalised spot volume it is important to consider the 2D gel 
as a 3D entity whereas these images only represent a 2D image of the spot.                                              
Repeat 1 Repeat 2 
Male 
Female 
Repeat 1 Repeat 2 
Male 
Female 
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5.3.2.2 Protein Expression Analysis of Saliva Samples – Age 
Comparison 
 
Samples were pooled according to age (Figure 5.9). Samples donated by individuals 
under the age of 24 years are represented in panel a, samples donated by 
individuals aged between 24 and 27 years in panel b, and samples donated by 
individuals aged between 28 and 32 in panel c. When the expression graphs for the 
saliva samples pooled into different age groups (Figure 5.9) were compared it was 
noted that the expression of spot 81 (Cystatin SN) was again the highest across all 
age groups. The expression of Cystatin SN increased with age ranging from 3078 
(24 - 27 duplicate 1) to 4938 (28 - 31 duplicate 2), double the expression of the rest 
of the proteins across all pools. One exception was spot 66 (Cystatin SA) that 
showed  greatest expression in the highest age pool (Figure 5.9 c) with 2397 
(duplicate 1) and 1609 (duplicate 2). Proteins 41 (actin-γ) and 70 (Zinc-α-2 
glycoprotein) decreased with age. Protein spot 79 (immunoglobulin α) showed the 
lowest expression across all the three pools. There was no similarity in the 
expression between the three Zinc-α-2 glycoprotein spots (70, 76 and 89). However, 
the two spots identified as actin-γ (spots 41 and 83) showed a decrease in 
expression from above 1000 to below 1000 in the two highest age ranges (Figure 5.9 
b and c) compared with the under 24 age group (Figure 5.9a).  
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a) 
 
 
 b) 
 
 
 c) 
 
Figure 5.9: Protein expression measured using normalised spot volume between donors 
aged a) < 24 years, b) 24 - 27 and c) 28 - 31. Gel repeat 1 represented by black bars and gel 
repeat 2 represented by grey bars. 
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5.3.2.3 Protein Expression Analysis of Saliva Samples – 
Sampling Time Comparison 
 
Samples were pooled depending upon the time of donation. Protein expression from 
the earliest (9am and 12 noon) are represented in panel a, with the samples taken 
over lunchtime between 12 noon and 2pm in panel b. Samples donated in the 
afternoon between 2pm and 5pm in panel c and finally, samples donated in the 
evening after 5pm  in panel d. Once again, expression of Spot 81 (Cystatin SN) was 
higher than the other spots represented in three out of the four graphs shown in 
Figure 5.10 (a, b and d). However, expression of spot 83 (actin-γ) was doubled in the 
samples taken between 2pm and 5pm (Figure 5.10 c) at approximately 2000 in 
comparison with the other expression values of approximately 1000. Spots 66 and 
spot 81 (Cystatin SA and Cystatin SN respectively) seemed to follow a similar 
expression trend to spot 59 (Lipocalin-1) with a decrease in expression as the time of 
sampling progressed throughout the day until the final evening sampling where 
expression was highest (Figure 5.10 d). Expression of Cystatin SN was particularly 
high in the evening (Figure 5.10 d) reaching 5574 and 3869 (duplicate 1 and 2 
respectively). Expression of spots 41 and 83 (actin γ) followed a similar trend with 
expression increasing as the time of day progressed but, finally decreasing in the 
evening (Figure 5.10 d). 
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 a)          b)    
 
c)          d) 
 
Figure 5.10: Protein expression measured using normalised spot volume between samples 
taken between a) 9am-12pm, b) 12pm and 2pm, c) 2pm and 5pm and d) after 5pm. Gel 
repeat 1 represented by black bars and gel repeat 2 represented by grey bars. 
 
5.3.2.4 Protein Expression Analysis of Saliva Samples After 
Food Consumption 
 
 Samples were pooled according to the time since the donor previously had 
consumed food or drink. Panel a represents those samples where the donor had last 
consumed food or drink up to 15 minutes prior to sample donation, panel b between 
15 minutes and 1 hour and panel c over 1 hour. Spot 81 (Cystatin SN) expression 
was again seen to be higher than the expression of other spots represented in Figure 
5.11 and expression is shown at a similar level in each graph. Expression of spots 41 
and 83 (actin-γ) as well as 59 (Lipocalin-1) was inversely related to the length of time 
since food or drink consumption, decreasing as the time since eating increased. 
Expression of spots 70, 76 and 89 (zinc-α-2 glycoprotein) increased with length of 
time since eating or drinking (over a range of approximately 200). Cystatin SA 
expression was the highest where time since eating ranged between 15 minutes to 
an hour (Figure 5.11 b). 
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       a) 
 
 
   b) 
    
 
      c)  
 
Figure 5.11: Protein expression measured using normalised spot volume between samples 
where the time since eating or drinking was a) <15 minutes, b) 15minutes <1 hour, and c) > 1 
hour. Gel repeat 1 represented by black bars and gel repeat 2 represented by grey bars. 
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5.3.3 Protein Expression Analysis of Vaginal Fluid Samples 
  
 Spot selection for vaginal fluid samples was processed in the same way as 
described in section 5.2 for saliva spot selection. Consistent expression was checked 
across all pools and the protein spot was selected for spot picking. The sixteen spots 
chosen for LC/MS-MS analysis are summarised in Table 5.7 and their gel position 
shown in figure 5.9. The fold differences between spots ranged from 2 to 19.30. The 
fold difference threshold of 1.20 (see section 4.2.5) was adhered to for comparison of 
samples for this experiment. Table 5.7 shows the fold difference determined by 
comparison of the highest normalised volume pool against the pool of lowest 
normalised volume for each individual spot. Spots were automatically ranked 
according to fold change by the Prodigy same spots software and thus allocated the 
spot numbers listed in Table 5.7. 
 
Table 5.7: A table to show vaginal fluid spot identification number and fold difference in 
expression for each spot cut. 
Spot Identification number Fold difference 
6 19.30 
19 15.00 
17 7.50 
39 6.20 
14 5.80 
8 5.50 
71 5.30 
53 4.70 
59 4.40 
74 4.20 
64 3.60 
73 3.50 
69 3.10 
85 2.90 
81 2.30 
86 2.00 
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All MOWSE scores for good protein hits (Table 5.8) were greater than 41 thus 
making them statistically significant. The lowest MOWSE score given for protein 
spots identified from the vaginal fluid samples was seen to be 56 for spot 17, 
identified as Serpin B3 (Squamous  cell carcinoma antigen (SCCA)1) and the highest 
was 184 for spot 59 ( leukocyte elastase inhibitor). Protein isoforms were 
represented by a line of protein spots with the same molecular weight and differing 
pI. This was seen with spots 17, 14 and 19. Spots 17 and 19 were identified as 
Serpin B3. Spot 14 was unsuccessfully identified possibly to due to the small size of 
the spot. Another example of this was seen with spots 85 and 86, identified as 
immunoglobulin κ light chain fragment. 
 IgG is the predominant class of antibody present within vaginal secretions, 
whose main function is to prevent microbial adhesion and invasion of the epithelial 
surface and neutralise toxins or other harmful substances. Levels of IgG have been 
shown to be higher before ovulation than in the luteal phase afterwards.  Two spots 
lying next to each other on the 2D gel image (Figure 5.12) were identified as IgG. 
This trend was found to be true for spot 86 with the highest expression shown in the 
sample pool representing the follicular phase of the menstrual cycle. Spot 85, also 
identified as IgG showed consistent expression at each phase of the menstrual 
cycle.  
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Figure 5.12: A 2D gel image to show positions and identification numbers of vaginal fluid 
spots chosen for spot cutting. 
 
Nine protein spots were successfully identified using LC-MS/MS data in a 
MASCOT search. The total ion count spectra can be found in Appendix VIII. The 
MOWSE scores for these proteins ranged from 56-184, with the number of peptides 
matching for a positive identification ranging from 2-5 (Table 5.8).  
Vaginal fluid protein identifications were; SERPINB3, Leukocyte elastase 
inhibitor, superoxide dismutase, fatty acid binding protein, calgranulin B and 
immunoglobulin. 
SERPINB3 or SCCA and leukocyte elastase inhibitor (SERPINB1) are serine 
protease inhibitors of the ov-serpin clade family (Vidalino et al. 2009).  
Leukocyte elastase inhibitor participates in phagocytosis degrading bacterial 
components. Elevated levels of SCCA are characteristic of advanced serological cell 
carcinomas and can be used to monitor the response of a patient to therapy 
(Cataltepe et al.  2000).  
Superoxide dismutases are enzymes expressed in seminal plasma and the 
vaginal epithelium that act to protect spermatozoa from oxidative stress within the 
vaginal tract (Zini et al. 2002).  
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Fatty acid binding proteins bind lipophilic molecules and have a role in 
maintaining cellular lipid balance and regulation of lipid pathways (Storch and 
Thumser 2000).  
Calgranulin B (Calprotectin) is a zinc and calcium binding protein with a 
protective role as its name suggests, produced by squamous mucosal epithelial 
cells.  It inhibits the growth of E.coli, Staph. aureus (Sohnle et al. 1991) and Can. 
Albicans (Sohnle et al. 2000) by preventing growth on  mucosal cells (Sohnle et al. 
1991) by competitive binding of zinc required for microbial growth.  Calgranulin B has 
been identified within a number of forensically relevant body fluids including; blood 
plasma (Dale 1990), saliva (Cuida et al. 1995) and urine (Holt et al. 1983).   
Both IgA and IgG have been shown to be present within the vaginal mucosa 
but IgG is the predominant antibody present. Secretions have shown to vary during 
the menstrual cycle with levels being dependent upon hormonal regulation. Half the 
IgG present are produced by the cells of the genital tract mucosa whereas the 
remaining half are derived from the circulation. High levels of IgG have been 
identified within semen and urine (Mestecky 2006) for this reason the protein posed 
no interest for further testing. 
LC-MS/MS data also showed three poor protein identifications with MOWSE 
scores ranging from 26-47 and the number of matching peptides from 1-3 (Table 
5.9). Hit distribution graphs for each spot can be found in Appendix IV. Because of 
insufficient data from LC-MS/MS, identification of spots 53, 71 and 81 using a 
MASCOT search was not possible. Therefore further analysis was not carried out on 
those spots. Database search results produced low MOWSE scores (Table 5.9) and 
mismatches between theoretical and observed data for mass and pI (Table 5.9). 
Spot 86 was identified with a high MOWSE score of 152 but the molecular weight 
data obtained from SwissProt only provides values for the whole protein. The 
fragment molecular weight was not identified so this spot not included in the table. 
Spot 85 was identified as expected from the spot position (Figure 5.12) but a similar 
mismatch in data was also seen.  
Expression graphs were drawn for the nine proteins positively identified by 
LC-MS/MS. A comparison of normalised spot volume was made for sample pools 
(Figures 5.13 - 5.15).  
Due to a gel effect running through the middle of the gel, this had hampered 
the analysis of spot expression data for the second gel image. Therefore vaginal pool 
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2 data is only based on results from one gel and hence only one data series is 
represented within the graph for this pool (Figure 5.13a). 
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5.3.3.1 Protein Expression Analysis of Vaginal Fluid Samples – 
Age Comparison 
 
Spot expression throughout the six age groups sampled is shown in Figure 
5.13. Both spots 73 and 69 were identified as fatty acid binding protein isoforms, they 
demonstrated different levels of expression across all the age groups examined. Spot 
73 showed the highest expression in all age groups except in the 50s age group where 
the expression was similar to one of spot 74 duplicates (calgranulin B). Spots 85 and 
86 (immunoglobulin κ) started with high expression in the teen‟s age group with the 
level dropping throughout the 20s and 30s. The highest level was found in the 40s 
group and eventually a decrease was observed in the 50s age group. Spot 86 
(immunoglobulin κ) had a lower normalised volume than spot 85 (immunoglobulin κ) for 
each age group. Spots 17 and 19 (SerpinB3) also showed a similar expression pattern 
with low expression throughout the teens and 20s increasing to a maximum in the 30s 
age group. A decrease was noted in the 40s and 50s age groups. Spot 19 (SerpinB3) 
demonstrated a slightly greater expression than that of spot 17 (SerpinB3). Expression 
of spots 59 (leucocyte elastase inhibitor) and 64 (superoxide dismutase) peaked in the 
20s age group and decreased again in the 50s age group. 
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     a)                      b)  
  
       c)                      d)  
 
    
       e) 
 
Figure 5.13: Bar charts to show each sample pool for donor‟s age; a) teens, b) 20s, c) 30s, d) 
40s and e) 50s showing normalised spot volume to measure protein expression for each spot 
cut. Gel repeat 1 represented by black bars and gel repeat 2 represented by grey bars. 
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5.3.3.2 Protein Expression Analysis of Vaginal Fluid Samples– 
Contraception Comparison 
 
 
Samples were pooled according to the method of contraception that the donors 
were using (Figure 5.14). Hormonal and non-hormonal methods of contraception were 
compared. In an examination of the groups according to hormonal methods; the 
combined pill is represented in panel a, the pill represented in panel b, the implanon 
implant and Depo-provera injection, represented in panels c and d respectively. Non 
hormonal methods of contraception (e.g. women using the condom) represented in 
panel e and panel f includes women not using any contraceptives. 
Once again the expression of spot 73 (fatty acid binding protein) was 
consistently high in all groups except the pill. The highest levels were found for the 
combined pill and the contraceptive implant – implanon. In contrast spot 69 (fatty acid 
binding protein) showed a lower level of expression in all graphs, except for the 
combined pill (Figure 5.14 a) with a spot volume value under 500. Spots 85 and 86 
(Immunoglobulin κ) showed a consistent level of expression across each pool. Spot 86 
expression was lower (ranging from 384-670) in each pool than spot 85 (ranging from 
695 -1364). Spots 17 and 19 (SerpinB3) displayed a slightly higher expression in the 
pools where no contraceptive method was being used and where condoms are used. 
The lowest expression was seen in the pool where donors were using the Depo-
provera injection (Figure 5.14 c). Spot 59 (Leucocyte elastase inhibitor) showed 
reduced expression where no contraceptive was being used (Figure 5.14 f) whereas 
the highest levels were seen with both the combined pill (Figure 5.14 a) and pill (Figure 
5.14 b) pools. Spot 64 (Superoxide dismutase) expression was low (less than 500) for 
each pool with the lowest expression of all the protein spots described so far. 
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   a)         b) 
    
      c)                d) 
     
    e)                                                                          f) 
 
Figure 5.14: Bar charts to show each sample pool for donor‟s method of contraception; a) 
combined pill, b) pill, c) Implanon, d) Depo-Provera injection e) condom and f) none showing 
normalised spot volume to measure protein expression for each spot cut. Gel repeat 1 
represented by black bars and gel repeat 2 represented by grey bars. 
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5.3.3.3 Vaginal Fluid Samples – Menstrual Cycle Comparison 
 
The expression of each protein throughout the menstrual cycle is shown in 
Figure 5.15. Samples were pooled by the day of the cycle upon which they were 
sampled. Samples from women not menstruating were pooled together and the results 
represented in panel a. Samples taken in the follicular stage (day 8-12) are shown in 
panel b, those in the ovulatory stage (day 13- 15) are shown in panel c, and those in 
the luteal stage (day 16-28) are shown in panel d.  
Spot  73 (Fatty acid binding protein) exhibited the highest expression of all the 
spots identified in each stage of the menstrual cycle, with expression increasing from 
the follicular phase (Figure 5.15 b), peaking in the ovulatory stage (Figure 5.15 c) and 
remaining high in the luteal stage (Figure 5.15 d) of the menstrual cycle. The other spot 
identified for fatty acid binding protein (spot 69) also followed a similar pattern but with 
expression much lower than spot 73. Similarly, its lowest level was in the follicular 
phase (Figure 5.15 b) increased to a maximum at ovulation (Figure 5.15 c) and then 
decreased again in the luteal phase (Figure 5.15 d).  
Spots 86 (immunoglobulin κ), 69 (fatty acid binding protein), and 17 (SerpinB1) 
showed expression levels lower than the follicular stage (Figure 5.15 b) in the pools 
from the women not menstruating (Figure 5.15 a) All the other spots showed a level of 
expression slightly higher than the levels seen in follicular phase (Figure 5.15 d).  Spots 
85 and 86 (Immunoglobulin κ) showed consistent expression levels across each pool 
with spot 85 being approximately twice as high in expression as spot 86 (as 
demonstrated in Figures 5.13 and 5.14).  
SerpinB3 (spots 17 and 19) had similar expression patterns to one another. 
Expression increased from the follicular phase (Figure 5.15 b), peaking at the ovulatory 
phase (Figure 5.15 c) and decreased at the luteal phase (Figure 5.15 d). The only 
difference as mentioned above was that Spot 17 showed the lowest level of expression 
in the pool from non menstruating women (Figure 5.15 a), whereas for spot 19 this pool 
showed a higher expression than shown in the follicular pool (Figure 5.15 b). Spot 74 
(Calgranulin B) and spot 59 (Leucocyte elastase inhibitor) showed an increase in 
expression from the follicular phase (Figure 5.15 b) peaking at the ovulatory phase 
(Figure 5.15 c) and decreasing slightly in the luteal phase (Figure 5.15 d).  
The level of expression in the non-menstruating pool (Figure 5.15 a) was 
slightly higher than the level seen in the follicular phase (Figure 5.15 b) for these two 
spots. Expression of spot 64 (superoxide dismutase) decreased throughout the 
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menstrual cycle with the highest expression seen in the samples from the women not 
menstruating (Figure 5.15 a). 
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                                         a) 
                             
                                         b) 
                             
                                                    c) 
                                       
                              d) 
Figure 5.15: Bar charts to show each sample pool to show the stage of menstrual cycle when 
each sample was donated; a) not menstruating, b) Follicular (day 8-12) , c) Ovulatory (day 13-
15), and d) Luteal (day 16-28),  showing normalised spot volume to measure protein expression 
for each spot cut. Gel repeat 1 represented by black bars and gel repeat 2 represented by grey 
bars. 
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5.4 Discussion 
 
5.4.1 Protein Expression Analysis 
 
A limitation of 2DGE is the inability to resolve all the proteins present in the 
body fluid. It is estimated that the protein complement of a cell could contain at least 
10,000-30,000 different proteins with between 2000-10,000 visible on a silver stained 
gel and not all of these would occur at sufficient levels for MS analysis (Martins de 
Souza, Oliveira et al. 2008). The number of protein spots identified in this study was 
considerably less than the figures stated above. A total of 268 and 193 spots were 
identified in the saliva and vaginal samples respectively. In cervical-vaginal fluid 400 
spots were detected in one recent study with 157 protein identifications made (Di 
Quinzio, Oliva et al. 2007) whereas in another publication, the number of spots was 
considerably lower with only 147 identified (Tang, De Seta et al. 2007).  The 2DGE 
running conditions in this study differed from those used in recent studies mentioned 
above. For example longer IPG strips (11cm and 13 cm respectively) were used for 
separation with different pH ranges (pH 3-11 and pH 4-7 respectively). More spots 
were detected when SYPRO Ruby stain was used (Di Quinzio, Oliva et al. 2007) rather 
than CBB (Tang, De Seta et al. 2007). It would seem that the number of spots resolved 
can be limited by size of the gels and the pH range of the IPG strip used as well as the 
post electrophoretic staining method employed. Tang et al (2007) used larger sized 
gels and more than one pH range IPG strip per sample resulting in an increased the 
number of proteins resolved. However the disadvantage is that the image analysis 
would require more time with the increase in gel numbers and the comparison of more 
than one pH range.   
The number of samples within the sample population used for proteomics 
studies of saliva and vaginal fluid has seen great variability. In this study, 25 saliva and 
vaginal fluid samples were considered a suitable representation for a pilot experimental 
study within the geographic location used. To comply with ethical approval the number 
of samples obtained should be relevant to the study itself without collecting and 
sampling from donors unnecessarily. A broad range of samples should be collected if 
an unbiased view of the population is to be represented. Of course there are limitations 
of this, time and labour of processing a large number of samples would be 
inappropriate and not productive to the results for the study. For saliva proteomic 
studies the number of samples used has been seen to range from using a single donor 
(Hu, Xie et al. 2005) to using 12 donors (Giusti, Baldini et al. 2007). For vaginal fluid 
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proteomic studies donor samples have been taken from between 6 (Zegels, Van 
Raemdonck et al. 2009) and 29 (Tang, De Seta et al. 2007) women. From comparison 
of the number of samples used in this study with previous work, the population used in 
this study (n=25) was of similar size. 
 
5.4.1.1 Using IgG Standards as an Internal Control for LC-
MS/MS Output. 
 
 A blind control protein was tested to act as a quality control for the protein 
identifications produced. The identification hits with significant MOWSE scores 
obtained for blind control sample 1C can be discounted firstly, as the protein loaded to 
the 2D gel was a known control sample of pure IgG. Secondly the theoretical pI and 
molecular mass for the protein hits identified in Table 4.4 showed a mis-match with the 
position that the protein spot was removed from the gel. Spot 1C was removed from 
the 2D gel at approximately 75 kDa and pI of approximately 6.2 in the middle of the gel. 
The theoretical pI for Putative anti-CNG protein was given as 11.39, which was out of 
the range of IPG strip (pH 3-10) used in the 1st dimension of this gel hence a protein 
with this pI would not be visible within the gel range. The molecular weight for this 
protein was also seen to be much lower than that of the spot taken for analysis. The 
second significant hit for Centrosomal protein 2 had a lower pI than that of the spot 
picked and the molecular weight once again was much lower than that of the location 
the spot was selected from on the gel. In addition to the mis-matched theoretical 
molecular mass and pI data of the 2D gel image, the distribution of protein hits and 
their MOWSE score shown in Figure 5.3 showed that the majority of hits for control 
sample 1C are below the significance threshold of 40, with the hits that were significant 
not yielding a true identification. Control spot 2C on the other hand showed one 
successful immunoglobulin identification hit with a MOWSE score of 45, and the rest 
with very low MOWSE scores and hence were not considered for analytical purposes. 
A real match, which is a non-random event, gives a score which is beyond the green 
shaded area (Figure 5.2 and 5.3). This successful hit also yielded matching theoretical 
molecular mass and pI data with the location the spot was picked from the 2D gel 
image. The two spots chosen were different in size and their stain intensity. The 
relative expression differences between these spots may account for the differences in 
the identifications between them.  
Advances in the stain sensitivity, such as the fluorescent stain SYPRO Ruby 
being used in this study has meant that some spots chosen may be too small to be 
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successfully identified by the LC-MS/MS system. This is why some laboratories still use 
Colloidal CBB (personal communication). Insufficient protein in the spot could lead to a 
failure to obtain a statistically significant positive identification from the MASCOT 
search. It is believed to be the case with control spot 1C, as the spot chosen was 
considerably smaller than spot 2C. This meant that the level of material in the spot 
selected for analysis was insufficient for a positive identification using the system 
employed. This problem was overcome by submitting two identical spots per sample 
submitted for analysis from the two repeated gels providing more protein material per 
sample in the spots selected. 
 
5.4.2 Protein Expression Analysis of Saliva Samples  
 
 All the protein hits described as “good” identifications had MOWSE scores 
greater than 41 while the highest MOWSE score observed was 120. All these protein 
identifications were considered statistically significant based upon their MOWSE score.   
 MOWSE score is not directly dependent on protein quantity as spot 81 was 
shown to be the most intense spot on the gel (Figure 5.4) but its MOWSE score was 
shown to be the second lowest of all the spots identified.  Some of the MOWSE scores 
for the poor protein identifications were high, for example spots 43, 46, 47 and 72 all 
have MOWSE scores over 45. A mismatch was seen between the theoretical mass 
and pI compared with the actual mass and pI shown by the position the spots were cut 
from the gels.  Some of the smaller protein spots, such as spot 33 and 47 did not 
provide a positive identification.  Their small size or an insufficient amount of protein 
present within the spot to be able to provide an accurate protein identity may explain 
this. Other spots with poor identifications were spots larger in size but the intensity of 
staining shown on these spots was quite faint (spots 6, 13, 27, 43, 46, 72 and 85). A 
mismatch can be seen for the theoretical molecular mass and pI and the observed 
mass and pI estimated from the 2D gel image for these spots. The sensitivity of 
SYPRO Ruby may limit the proteomic identification obtained by LC-MS/MS, since 
although the spot can be seen on the gel there may not be enough material within the 
spot itself to accurately determine an identity.   
A major limitation of the MASCOT search database is that accuracy depends 
on the quality of the data held within it. As the proteomics field develops the number of 
protein entries held on the database will increase and thus so will the accuracy of the 
search hits performed. A downside to this is that a search is likely to yield slightly 
different results if repeated at a later date due to the changes in the database. 
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 The nine good salivary protein identifications determined by the MASCOT 
search have all been positively identified previously in saliva either by 2DGE followed 
by MALDI-TOF (Ghafouri, Tagesson et al. 2003; Huang 2004; Hu, Loo et al. 2007) or 
by LC-MS/MS (Hu, Loo et al. 2007).  
Direct comparisons cannot be made between the gel images produced in this 
study with those produced in the previously published literature above due to 
differences in experimental conditions, as discussed earlier (sections 7.1.2.2 and 
7.1.3.2). Small gels were cast in this study using 7 cm IPG strips with a pH range of 5-
8. The size of the gels was limited due to the equipment available. Longer IPG strips, 
11cm IPG strips (Hu, Loo et al. 2007) and 13 cm IPG strips (Huang 2004) have been 
used previously to provide greater spot separation in the first dimension. The pH 
ranges of the strips used also differed from those in this study. Strips with a pH range 
of 3-10 (Huang 2004; Hu, Loo et al. 2007) and strips with a pH range of 4-7 (Ghafouri, 
Tagesson et al. 2003) have been used with saliva. As was shown in Chapter 3 section 
3.2.3.2 (i) the pH strip range alters the 2D pattern shown on the gel and direct 
comparisons are made difficult.  
Saliva protein expression is under neurological control, with protein output 
being dependant upon the stimulus. When attempting to discover potential biomarkers 
of saliva it is important to consider the dynamic environment of the oral cavity where 
there is a continuous supply of newly synthesised proteins and their removal by 
swallowing (Helmerhorst and Oppenheim 2007). It is also important to be aware of 
variables which could affect protein expression between individuals; a forensic 
biomarker would need to be expressed population wide and at a consistent level 
throughout the day, not having expression affected by external factors. 
 
5.4.2.1 The Effect of Gender on Saliva Protein Expression 
 
 Spot expression was higher in the male sample pool than in the female pools 
(Figure 5.5), for proteins Cystatin SN, and IgA.  Although ZA2G (spots 70 and 89) 
showed higher expression in the male sample pool the other ZA2G spot (76) was 
higher in the female pool. Lipocalin-1 was the only other spot to show higher 
expression in the female pool. Expression of actin was not gender specific in spot 41 
but shown to be higher in male pool (spot 83). There was variability between the 
repeats of spot 41 although the same trend was followed and the expression of spot 
83. There no published proteomic studies to date investigating gender differences in 
saliva.   
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Gene expression studies have shown that some genes exhibit gender 
differences in their expression with both the female showing higher expression in some 
genes and the male of others (Srivastava et al 2008).  
 
5.4.2.2 The Effect of Age on Saliva Protein Expression 
 
 Figure 5.7 showed that each spot identified as ZA2G showed a general trend of 
decreasing in the age group between 24 - 27 and then increasing again in the age 
group 28 - 31. A general increase with age was shown for cystatins SN (spot 81) and 
SA (spot 66) as well as Lipocalin-1. The trend shown for IgA differed between the gel 
repeats as an increase was shown with age for one repeat whereas the second repeat 
showed a decrease in the highest age pool. Proteomic analysis of two age range pools 
of parotid saliva showed an increase in IgA expression in the pool of the older donor‟s 
saliva (Ambatipudi 2009). With increasing age the parenchyma of salivary glands is 
replaced by connective tissue and fat (Nagler 2004). Salivary secretion has also been 
seen to decrease with age (Yaegaki 1985) which could be a result of the deterioration 
of the salivary glands.  
  
5.4.2.3 The effect of Sample Donation Time on Protein 
Expression in Saliva    
 
Before potential biomarkers can be identified, any expression variation due to 
time of day expression variation needs to be excluded or taken into consideration. For 
example identifying a protein as a saliva specific forensic marker would be useless if 
fluctuations in its expression throughout the day were considerable. Ideally a marker 
used for identification should have consistent expression levels unaffected by changes 
in time of day or by age or sex of the individual. 
 If particularly low expression levels were shown at a certain time point during 
the day this could be mistaken for a small amount of saliva deposited at a scene or on 
an exhibit. The abundance of markers Histatins 1, 3 and 5 as well as Statherin have 
been shown to vary during the day (Gusman, Leone et al. 2004). Histatin levels have 
also shown to decrease with age (Johnson, Yeh et al. 2000). These fluctuations should 
be taken into account if Histatin 3 or statherin are to be used as a saliva markers as 
proposed by Juusola and Ballantyne. (2003).  
The proteome of human saliva is highly variable dependent on time and 
susceptible to a variety of factors. Secretion is controlled by the autonomic nervous 
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system which can be affected by different stimuli such as the sight and smell of food. 
Secondly once glandular secretions enter the oral cavity proteins are subjected to 
further modifications leading to proteolytic cleavage by bacterial or host enzymes. 
Examples of such proteins are histatins and statherin (Helmerhorst 2007). For these 
reasons it is sensible to study saliva at the proteome level rather than the mRNA level 
where these changes would not be discovered (Helmerhorst 2007). 
Although salivary cystatins are partially degraded in the oral cavity (decreased 
by 8 residues) they are still capable of exhibiting cysteine protease activity (Bobek 
1994). For all proteins identified in this study expression was highest in the pool of 
samples taken after 6pm. This would follow the same trend as shown by α-amylase 
(Ferguson, Fort et al. 1973). However this pool only contained two male samples so  
could be biased. Ideally a repeat would be performed with a pool comprised of more 
samples preferably from both sexes. Protein expression was shown to be lowest in the 
afternoon (Figure 5.8c) for, Lipocalin-1 (Spot 59), Cystatin SA (Spot 66), Cystatin SN 
(Spot 81) and Zinc-α-2 glycoprotein (Spots 70 and 76).   
 Three spots were identified as the Zinc-alpha-2-glycoprotein (70,76 and 89). 
When looking at the gel image (Figure 5.4) these spots appear in a line which can be 
referred to as a spot “train” in the top left of the gel at approximately 39kDa. This term 
is used to describe spots with approximately the same molecular weight with varying 
isoelectric points. Spots form a horizontal line on the gel, characteristic of protein 
isoforms with different post translational modifications for example, an increasing 
number of phosphorylations (Sackmann-Sala, Ding et al. 2009).   
 
5.4.2.4 The Effect of Food Consumption on Protein Expression 
in Saliva 
 
   Brushing teeth without toothpaste has shown that mechanical stimulation can 
increase salivary flow and change the composition of saliva. An increase in albumin 
and a decrease in amylase and IgA has been seen after brushing (Hoek, Brand et al. 
2002). Although this could also be considered to be relevant with the time of day and 
saliva expression, the mechanical aspect of tooth brushing would be considered more 
relevant to the effect than of eating on saliva. 
 During food consumption the proportion of parotid saliva in whole saliva can 
increase to 50% (Humphrey and Williamson 2001). Thus the composition of saliva 
changes at this time. The mechanical stimulation of chewing food could also increase 
the amount of saliva within the oral cavity aiding with digestion and bolus formation. As 
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saliva is continually being deposited and removed by swallowing it was thought that the 
protein levels potentially elevated during food consumption would be short lived in the 
oral cavity. Cystatin SA (spot 66) expression increased up to an hour after food 
consumption and then decreased (Figure 5.9b). A similar trend was seen with ZA2G 
(spots 76 and 89). A decrease with time since eating was seen with actin (spot 83) and 
Lipocalin-1 (spot 59). 
 
5.4.3 Protein Expression Analysis of Vaginal Fluid Samples  
 
 The composition and volume of vaginal fluid can vary with different stages of 
the menstrual cycle (Wilson 2005) and with age. At menopause the vaginal epithelium 
thins and cervico-vaginal secretions become sparse (Farage 2006). The vaginal fluid 
proteome has not been studied to the extent that the saliva proteome has been. Of 
those studies many have used samples obtained from pregnant women (Gravett et al. 
2007; Pereira et al. 2007; Klein et al. 2008) whose protein expression may differ from 
non-pregnant women.  Previous work has showed that Serpin B3, Fatty acid binding 
protein, Calgranulin B and immunoglobulin κ light chain  were also positively identified 
using samples from a range of women aged 24-48 (Tang et al. 2007). Once again 
difficulties are posed when trying to make comparisons between gel images from 
previous work and this study due to different running conditions of the 1st dimension. 
Tang et al. (2007) used 13cm strips with a wider pH range (pH 3-11) than those that 
were used in this study. Bearing this in mind the protein spot locations identified in this 
study are supported by those presented by Tang et al. (2007).   
 
 
5.4.3.1 The Effect of Age on Protein Expression in Vaginal Fluid  
 
 Peaks in IgG expression (spots 85 and 86) were shown in the teens and the 
40s age groups with a decrease in the 50s age group. Serpin B3 showed an increase 
in expression in the 20s age group (spot 17) and 30s age group (spot 19). Calgranulin 
B peaked in the 20s group and tailed off finally increasing in the 50s age group. 
Physiological changes occur throughout the lifetime being linked to puberty, the 
menstrual cycle, pregnancy and menopause (Farage and Maibach 2006) and 
ultimately these changes are due to hormonal control. In post-menopausal women the 
pH rises in the vagina and there is an increase in microbial colonisation, this could 
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explain the increase in proteins associated with protection of the vagina from infection 
at this age for example, calgranulin B. 
 
 
5.4.3.2 The Effect of Contraception on Protein Expression in 
Vaginal Fluid  
 
 Gene expression and hence protein expression can be affected by hormones, 
for this reason hormonal contraceptives were thought to affect the proteins expressed 
within vaginal fluid. When asked their method of contraception some donors only listed 
the pill without stating whether that was progesterone only or the combined pill. For this 
reason pools were produced for the donors stating just pill on their consent form and 
for those stating combined pill.  As well as the pill, other forms of hormonal 
contraception studied were the progesterone only implanon™ implant and Depo-
provera injection. In comparison, samples donated from individuals using condoms and 
those not using any contraception were also studied. An increase in expression of 
Serpin B3 (spot 19) was seen in the pools from donors not using hormonal 
contraception compared with those taking hormonal contraceptives (Figure 5.12). The 
opposite was seen with leukocyte elastase inhibitor (spot 59) where a decrease in 
expression was seen in the pools where no hormonal contraception was being used.  A 
decrease in expression was seen for Serpin B3 (spot 17) and calgranulin B (spot 74) 
when implanon was being used compared with the other pools tested. It was thought 
that if protein expression was affected by contraceptive hormones, differences would 
be visible between those samples and the samples donated from individuals not taking 
hormonal contraception. For most pills taken daily, the level of hormones would be kept 
relatively constant throughout the month. Although there would be a constant low level 
of progesterone released with the implant or the injection, differences in the hormone 
levels would be seen depending how far through the course of medication the donor 
was. The lifespan of an implant is 3 years with the release rate of etonogestrel at 
approximately 60–70 µg/day in the first 5–6 weeks, decreasing to 35–45 µg/day by the 
end of the first year of use, to 30–40 µg/day by the end of the second year and to 25–
30 µg/day by the end of the third year (The Electric Medicine Compendium a [online]). 
The injection has a lifespan of 3 months; it contains Parenteral medroxyprogesterone 
acetate (MPA) and is a long acting progestational steroid. The long duration of action 
results from its slow absorption from the injection site. Immediately after injection of 
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150 mg/ml MPA, plasma levels were 1.7 ± 0.3 nmol/l. Two weeks later, levels were 6.8 
± 0.8 nmol/l (The Electric Medicine Compendium b [online]). 
 
 
5.4.3.3 The Effect of the Menstrual Cycle on Protein Expression 
in Vaginal Fluid 
 
  Calgranulin B expression was higher in the absence than in the presence of 
menstruating women (Figure 5.13). As mentioned previously, the majority of women in 
this pool were post-menopausal age and hence the volume of vaginal fluid produced by 
them was expected to be much lower. Calgranulin is a protein associated with 
protection against pathogens and hence a higher expression could be expected. Lower 
expression was seen with Serpin B3, epidermal fatty acid binding protein and one of 
the spots representing IgG (spot 86) than in the pools of menstruating women. IgG 
levels were reported previously to decrease from the proliferative phase to the luteal 
phase (Usala, Usala et al. 1989) 
 A previous study has demonstrated that the concentration of Leukocyte 
elastase inhibitor has reached a maximum at the middle of the menstrual cycle 
(Ovulatory Phase). Shot gun proteomics using samples from pregnant women (Klein et 
al. 2008) have shown this increase to be 5 times that shown in the follicular and luteal 
phases of the menstrual cycle. This was found to be untrue for the results using 2D 
proteomics, there was a difference between the duplicates for the ovulatory phase with 
the second repeat showing a greater expression than in the follicular phase. The 
highest expression was seen in the luteal phase. It could be proposed that differences 
in expression of Leukocyte elastase inhibitor are noted between pregnant and non 
pregnant women.  
Of those pools looking at the menstruating women and cyclical changes, there seems 
to be a trend for a peak in expression during the ovulatory phase, which is seen with 
Fatty acid binding protein, calgranulin and Serpin B3.   
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5.5 Chapter Summary 
 
A total of 268 and 193 spots were identified in the saliva and vaginal fluid 
samples respectively (Appendix VIII). Of those spots 19 saliva and 16 vaginal fluid 
spots were analysed by LC-MS/MS. Approximately half the spots cut for analysis 
yielded good protein hits in the database.  
The quality of MASCOT search results obtained is dependent upon the size and 
intensity of the spot selected from the 2D gel.  
Cyststain SN (spot 81) consistently showed the highest expression across all 
the saliva gel pools. Whilst Fatty acid binding protein (spot 73) showed the highest 
expression in all vaginal pools except of those samples from women in their 50s. 
Lower protein expression was generally shown in the saliva samples from 
females compared with males with Cystatin SN (spot 81) Zinc-α-2 Glycoprotein (spots 
70 & 89) and Immunoglobulin-α (Spot 79) actin-γ (spot 83) following this trend. 
Some saliva proteins were seen to have an increasing expression with age 
(Immunoglobulin-α, Cystatins SA and SN) whilst Actin-γ (spots 83 and 41) showed a 
decrease.  
Daytime variation in protein expression was seen with the majority of saliva 
proteins, showing reasonably high expression in the morning with a decrease in the 
afternoon between 2pm and 5pm then an increase again in the evening except for 
actin-γ (spots 41 and 83) that showed the opposite trend starting low and increasing in 
the afternoon then decreasing in the evening. 
An inverse relationship was seen between expression and time since eating 
with Cystatin SN and Lipocalin. Immunoglobulin-α expression increased as the time 
since eating also increased. Expression changes in the other protein spots were 
contradictory between the repeated gels and no clear conclusions could be drawn from 
them. 
The general trend shown for vaginal proteins when pooled by age was that 
expression decreased as age increased. This was not true for epidermal fatty acid 
binding protein (spot 69) and calgranulin (spot 74). 
Expression of immunoglobulin seemed to be independent of contraceptive 
method. SerpinB3 (spots 17 and 19) was highest in the non hormonal pools (no 
contraceptive or condoms) whereas leukocyte elastase inhibitor (spot 59) and 
calgranulin (spot 64) were lowest in these groups. The different forms of hormonal 
contraceptives did not seem to affect the protein expression in the same way. Hiigher 
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levels were seen with the majority of the proteins in the pools with the pill or combined 
pill compared with the depo-provera injection or the implanon implant. 
The stage of menstrual cycle showed a peak in expression of the majority of the 
proteins in the ovulatory phase then decreasing in the luteal phase. Expression was 
shown to be highest after menstruation in the follicular phase and lowest in the luteal 
phase for the majority of proteins (leukocyte elastase inhibitor (spot 59), superoxide 
dismutase (spot 64), calgranulin B (spot 74) and immunoglobulin (spot 85)). Whlist two 
proteins opposed ths trend (immunoglobulin (spot 86), Serpin B3 (spot 19), epidermal 
fatty acid binding protein (Spots 73 and 69)) with a lower expression after menstruation 
in the follicular phase.  
From this evaluation, candidate biomarkers for saliva are cystatins SA and SN, 
lipocalin-1 and zinc-α-2 glycoprotein. For vaginal fluid candidate biomarkers are serpin 
B3 and leukocyte elastase inhibitor. Further testing for the specificity of these proteins 
would determine their suitability for biomarkers for forensic purposes. 
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CHAPTER 6 – Confirmation of Candidate 
Biomarkers and their Body Fluid Specificity 
6.1 Introduction 
 
 The aim of the work described in this chapter was to determine whether the 
proteins identified in chapter 5 would be suitable markers for either saliva or vaginal 
fluid. Of the six protein identifications made for both saliva and vaginal fluid, four saliva 
proteins (Zinc-α-2 Glycoprotein, Lipocalin-1 Cystatin SA and Cystatin SN) and two 
vaginal proteins (Leukocyte Elastase Inhibitor and Serpin B3) were chosen for further 
analysis.  
 
6.1.1 Verification of Protein identification 
 
 It is important to verify the identity of the proteins that could be candidates for 
body fluid identification. There are several ways of doing this. Ideally this would be 
performed using a 2D Western blot demonstrating that the spot identified is the exact 
spot cut from the gel. Furthermore it would also highlight multiple protein spots of the 
same protein (Lubec et al. 2003). In practice the Western blot spots may vary due to 
the exact positioning of the gel onto the transfer membrane especially in areas with a 
high density of spot coverage.  
An alternative is to use simpler immunological techniques with the potential 
marker proteins. The resulting data can then be used in the development of a 
diagnostic method for body fluid testing.  
ELISA and dot blots were chosen initially to test for body fluid specificity of the 
proteins previously identified by LC-MS/MS (Chapter 5). Both techniques have been 
used previously to identify body fluids for forensic purposes. ELISA has been used to 
identify semen, (Graves et al. 1985; Kyurkchiev et al. 1989; Simich et al. 1999; Sato et 
al. 2004), blood (Cattaneo et al. 1992; Sato et al. 1999) and saliva (Quarino et al. 
2005). Dot blots have been used for ABO blood typing in saliva (Rao and Kashyap 
1992; Hamada et al. 2002) and for the identification of semen (Rao and Kashyap 1992; 
Sato et al. 2001). 
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6.1.1.1 Dot Blot 
 
 Dot blots have been used previously in forensic science. Antibodies against 
semenogelin a marker in seminal plasma showed no cross reactivity with saliva, urine, 
vaginal fluid sweat or serum (Sato et al. 2001) and were also used for species 
identification. Anti-human IgG antibodies were tested against blood from a range of  
animal species including human (Matsuzawa et al. 1993). ABO antigens were identified 
in saliva stains using as little as 0.00005 µl of saliva sample and offering a simple and 
non invasive method for ABO typing (Hamada et al. 2002). A simple Dot-ELISA was 
performed with a heat step introduced blocking non-specific reactions of the samples 
with secondary antibody. 
 
6.1.1.2 ELISA 
 
  ELISA has been used for the detection of salivary amylase (Quarino et al. 
2005) with monoclonal anti-human salivary amylase antibodies. However false 
positives were obtained with some semen, urine and sweat samples at low 
concentrations. For this reason a threshold value is needed for saliva to eliminate false 
positives. The ELISA could also be adapted to decrease sensitivity. 
 Blood was tested for, with an ELISA using IgG and albumin (Cattaneo et al. 
1992) in buried blood samples over a period of 65 weeks. This was not to determine 
the presence of blood but to test the protein degradation in blood over that time. 
 The P30 antigen in semen, although found to be male specific was also present 
in male urine (Graves et al. 1985). Monoclonal antibody (mAb) 4E6 a sperm coating 
antigen, has successfully been used to identify both ejaculated spermatozoa and 
seminal plasma by ELISA. Although this antigen is a sperm protein it has also been 
detected in azoospermic samples (Kyurkchiev et al. 1989). PSA, the most common 
antigen used for detection of semen has been shown using ELISA that levels present 
in saliva (0.16 and 0.11 ng/ml) are close to those of semen samples (0.20 ng/ml) 
(Simich et al. 1999). In more recent years a commercial ELISA (SEMA test, Humagen 
fertility diagnostics) has become available to test for the presence of semen using 
mouse anti-human sperm no. 5 (MHS-5) antibodies which recognise the seminal 
vesicle specific antigen (SVSA) in the post ejaculated fragmented semenogelin.  
 For forensic identification purposes an ELISA would not be suitable, due to the 
high sample throughput required for each ELISA plate. The semenogelin antibodies 
described by Sato et al. (2001) were used to develop an immunochromatographic 
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assay for the detection of semen (Sato et al. 2004).  Later commercialised as RSID-
Semen (Independent Forensics). As described in Chapter 1 Independent Forensics 
also manufacture RSID immunochromatographic test cassettes for blood and saliva. 
 
6.1.2 Salivary Proteins Identified by 2DGE and LC-MS/MS 
 
6.1.2.1 Salivary Cystatins  
 
In human saliva cystatins are abundant proteins (Dickinson 2002a). Salivary 
cystatins are extracellular, secreted proteins (Turk et al. 2008). They are members of a 
group of proteins known as cysteine protease inhibitors. Cysteine proteases are 
proteolytic enzymes which cleave peptide bonds through a reactive cysteine residue at 
the catalytic site of the protein (Bobek and Levine 1992). Cystatins are reversible 
competitive inhibitors of Cysteine proteases (Hiltke et al. 1999) responsible for the 
proteolytic destruction of cysteine proteinases from the host, bacteria or viruses. Many 
bacteria use cysteine proteases for colonisation and proliferation (Hiltke et al. 1999) 
which is of particular importance in the oral cavity where saliva plays a protective role 
against pathogens. The absence of cystatins in saliva would lead to infection of the soft 
tissue in the mouth leading to the onset of periodontal disease.  
Cystatins also play a minor role in regulation of salivary calcium levels 
(Humphrey and Williamson 2001). It has been proposed that cystatins may participate 
in the regulation of proteinase activity (Henskens et al. 1994) from bacteria involved 
with dental plaque formation but this has yet to be demonstrated. Investigations have 
centred on correlations between the levels of salivary cystatins and peridontal disease 
states (Bobek and Levine 1992). Elevated levels of salivary cystatins were reported in 
patients with gingivitis and peridontal disease due to inflammation and bleeding of the 
gums (Henskens et al. 1994).  
Cystatins were first isolated from human saliva in 1979 (Juriaanse and Booij 
1979) but their cysteine protease inhibitory function and hence their name was not 
given until 1984 (Isemura et al. 1984) when Cystatin S was isolated and sequenced. 
 
6.1.2.1 (i) Cystatin SN 
 
 After cystatin S the next salivary cystatin isolated by Ion-exchange 
chromatography was a neutral cysteine proteinase inhibitor. This protein was identified 
as Cystatin SN, having an immunological cross reactivity and thus some homologous 
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structure to Cystatin S and a pI value near neutrality (Isemura et al. 1986). 
Confirmation is seen in Figure 5.4 where the position of spot 81 (Cystatin SN) lies 
between pH 6 and pH 8 on the gel. This structural similarity was further supported by 
amino acid sequencing (Isemura et al.1987) which showed 10 amino acid substitutions 
present in Cystatin SN compared with Cystatin S. 
 
6.1.2.1(ii) Cystatin SA 
 
 Cystatin SA was another cysteine proteinase inhibitor isolated from human 
saliva by Ion-exchange chromatography (Isemura et al. 1987). This protein was named 
Cystatin SA because it had an acidic pI value, confirmation of this was shown in Figure 
5.4 where the position of spot 66 (Cystatin SA) is on the acidic, left hand side of the 
gel. Sequence homology was shown between this protein and previously identified 
Cystatins, 90.10% to Cystatin S 87.40% to Cystatin SN and 57.70% to Cystatin C. 
 
6.1.2.2 Zinc-α-2 glycoprotein (ZA2G) 
 
 ZA2G is a single chain polypeptide with a molecular mass of 41 kDa. It‟s name 
is derived from its action in precipitating zinc ions (Shibata and Miura 1982; Schenkels 
et al. 1995). After the initial discovery in human plasma by ion-exchange 
chromatography (Burgi and Schmid 1961). ZA2G has been identified in a number of 
different body fluids and tissues including forensically relevant types such as urine 
(Shibata and Miura 1982), seminal plasma (Frenette et al. 1987), breast milk, sweat, 
saliva (Ohkubo et al. 1990) and skin (Tada et al. 1991). A recent review article (Hassan 
et al. 2008) confirms that the function of ZA2G is still unknown. It has been suggested 
that ZA2G plays a role in lipid metabolism (Rolli et al. 2007). ZA2G knockout mice have 
been used to test this theory (Rolli et al. 2007) where mice with both depleted ZA2G 
genes gained more weight than the wild type mice fed on the same diet. This function 
also supports the presence of ZA2G in semen where it may act as a factor involved in 
sperm motility regulation (Ding et al. 2007). 
 
6.1.2.3 Lipocalin-1/ Von-Ebner’s Gland Protein 
 
 Lipocalin-1 or Von Ebner‟s gland protein (VEGh) is named due to its secretion 
from the Von Ebner‟s gland contained within the tongue (Li and Snyder 1995). 
Lipocalin has a molecular weight of approximately 20 kDa and a pI of approximately 5 
(Schenkels et al. 1995). This was confirmed in Figure 5.4 where the position of the 
    208 
protein identified (spot 59) lay within this range on the gel. Lipocalins are small 
secreted extracellular proteins with small lipophilic molecules. In saliva lipocalin 
function is thought to be associated with the taste function potentially binding bitter 
compounds (Schmale et al. 1990). Initially expression was thought to be localised to 
saliva but amino acid sequence homology to tear prealbumin has shown they are the 
same protein (Redl 2000) thus expression is not localised exclusively in saliva.  
 
6.1.3 Vaginal Fluid Proteins Identified by 2DGE and LC-MS/MS 
 
6.1.3.1 Serpins  
 
 Serpins are a family of proteins with tertiary structure homology each consisting 
of nine α-helices and three β-sheets. The proteins were initially named due to their 
serine proteinase inhibitor function. Since then serpins within the group have been 
identified without protease function.  The serpin family has been categorised into 
clades (Gettins 2002), the two serpins identified by proteomic methods within this study 
are members of the clade B serpins with 82% amino acid sequence homology 
(Remold-O'Donnell 1993).  
 
6.1.3.1 (i) Serpin B3 – Squamous Cell Carcinoma Antigen 1 
(SCCA1) 
 
 First identified as a tumour antigen TA-4 (Kato and Torigoe 1977) from a 
cervical squamous cell carcinoma.  Previous electrophoretic studies resulted in a single 
band with an approximate molecular weight of 45 kDa (Cataltepe et al. (2000). 
Separation of this single band by isoelectric focussing resulted in two major groups with 
differing pH ranges; acidic (pI 5.9-6.2) and neutral (pI 6.3-6.6) (Kato et al. 1984). The 
squamous cell carcinoma antigen (SCCA) has a misleading name as the neutral form 
of the antigen (SCCA1) is detected in the cytoplasm of normal and some malignant 
squamous cells, whereas the acidic form (SCCA2) is found exclusively within malignant 
tumours. SCCA1 is localised within squamous cells whereas SCCA2 is released from 
the cell and found in circulating plasma (Kato 1992). 
  Recent findings support the theory that SCCA has a function in programmed 
cell death, a process critical for autoimmunity. SCCA is typically found overexpressed 
in cancer cells with epithelial origin. Studies have shown that in its absence cells had 
an increased susceptibility to drug induced apoptosis, supporting the role of Serpin B3 
in apoptosis resistance (Suminami et al. 2001). 
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 SCCA has been used as a plasma marker for the identification of patients with 
cervical SCC. Post treatment levels have also been monitored as an indicator of 
therapeutic response (Cataltepe et al. 2000). 
 Immunohistochemistry positively identified SCCA within the squamous 
epithelium of the tongue and vaginal as well as the skin epidermis of normal tissues 
(Suminami et al. 2001).   
 
 
6.1.3.1(ii) Serpin B1 Leukocyte Elastase Inhibitor 
 
 Serpin B1 is a 42 kDa (Cooley et al. 2001) protein that inhibits neutrophil 
elastase and Cathepsin G (Vidalino et al. 2009) in cells. It degrades bacterial 
components during phagocytosis. Small amounts of serpin B1 can be released from 
the cell protecting it from proteases released into the cytoplasm (during an 
inflammatory stress response), (Gettins 2002). Serpin B1 has been found in high 
amounts in neutrophils and monocytes (Cooley et al. 2001). 
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6.2 Results 
 
6.2.1 Confirmation of Body Fluid Specificity using ELISA  
 
Positively identified protein markers were tested for identity and specificity using 
commercially available ELISA kits. The CanAg SCC EIA kit (Fujirebio™) was used to 
test for the presence of squamous cell carcinoma antigen/leucocyte elastase inhibitor 
(vaginal fluid sample spots 17 and 19) and the Human Zinc-α -2 Glycoprotein ELISA kit 
(BioVendor) was used to test for the presence of Human Zinc-α-2 Glycoprotein (saliva 
sample spots 70, 76 and 89). 
 
6.2.1.1 Confirmation of Leucocyte Elastase Inhibitor Specificity 
using CanAg SCC EIA Kit (Fujirebio™) 
 
Initial results for this ELISA test showed that the samples assayed using a 1:50 
dilution were too concentrated to recover any quantitative data regarding SCC 
expression for vaginal fluid samples.  All other body fluids tested gave values within the 
standard curve at 1:50 dilution, except for menstrual blood which also was too high. 
The ELISA plate was photographed for reference to show the intensity of each well 
assayed (Figure 6.1a). Readings were only obtained for vaginal samples 9, 10 and 18 
at this dilution. Schematic diagrams were drawn to show the ELISA plate layout 
showing which samples were placed into which wells. The calibration standards (Cal) 
are outlined in red whilst the body fluid comparison samples are outlined in blue, 
vaginal fluid samples (Vag) are left without an outline. 
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  a) 
 
 
  b) 
Figure 6.1: a) A digital photograph of the 96 well CanAg SCC EIA ELISA plate taken 
immediately after readings were taken for samples with a 1:50 dilution, b) schematic diagram 
showing CanAg SCC EIA ELISA plate layout showing the calibrator standards outlined in red 
and the body fluid comparison samples outlined in blue.  
 
The ELISA was repeated on the remaining vaginal fluid samples and the 
menstrual blood sample using a dilution of 1:200. The ELISA plate was photographed 
(Figure 6.2) and a schematic diagram was drawn.  
 
1     2     3     4     5    6     7    8    9    10  11  12
A
B
C
D
E
F
G
H
H
G
F
E
D
C
B
A
121110987654321
UrineSemenVag 23Vag 19Vag 15Vag 11Vag 7Vag 3Cal D
24 µg/L
UrineSemenVag 23Vag 19Vag 15Vag 11Vag 7Vag 3Cal D
24 µg/L
SalivaBloodVag 22Vag 18Vag 14Vag 10Vag 6Vag 2Cal C
5.1 µg/L
SalivaBloodVag 22Vag 18Vag 14Vag 10Vag 6Vag 2Cal C
5.1 µg/L
Breast 
milk
Vag 25Vag 21Vag 17Vag 13Vag 9Vag 5Vag 1Cal B
1.1 µg/L
Breast 
milk
Vag 25Vag 21Vag 17Vag 13Vag 9Vag 5Vag 1Cal B
1.1 µg/L
Menstrual 
blood
Vag 24Vag 20Vag 16Vag 12Vag 8Vag 4Cal E
46 µg/L
Cal A
0 µg/L
Menstrual 
blood
Vag 24Vag 20Vag 16Vag 12Vag 8Vag 4Cal E
46 µg/L
Cal A
0 µg/L
    212 
             
                                    a) 
 
 
                                  b) 
Figure 6.2: a) A digital photograph of the 96 well CanAg SCC EIA ELISA plate taken 
immediately after readings were taken for samples with a 1:200 dilution, b) schematic diagram 
showing CanAg SCC EIA ELISA plate layout showing calibrator standards outlined in red and 
the menstrual blood sample outlined in blue.  
 
 
Bar graphs were drawn to show the SCC concentration of each vaginal fluid 
sample (Figure 6.3) and for other body fluid samples (Figure 6.4). SCC was positively 
identified in all vaginal fluids ranging from 812.75 µg/l in sample 9 to 17464 µg/l in 
sample 13. Sample 10 was an exception, where the SCC concentration was 
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determined as being below the threshold of the standard calibrators. The optical 
density at 450nm for the 0 µg/l was read as 0.08 and the reading for sample 10 was 
determined as 0.08. Therefore a concentration for that sample was determined as 0 
µg/l. Future work would include another ELISA to be run with more diluted samples 
since some of the sample concentration values were calculated by extrapolation of the 
standard curve. The upper limit of the ELISA kit standards is shown on Figure 6.3 
represented by a red line. 
 
 
Figure 6.3: SCC concentration of each vaginal fluid sample measured by CanAg SCC EIA 
ELISA kit using optical density readings at 405nm. The red line represents the level above 
which sample concentrations were extrapolated. 
 
Figure 6.4 displays results for the other body fluid samples assayed for SCC. 
Although all body fluid samples showed positive results for SCC the levels detected by 
the ELISA kit were much lower for the majority of the fluids tested in comparison with 
vaginal fluid. The lowest level of SCC was detected in the breast milk sample (0.65 
µg/l) with the next lowest SCC concentration was seen in the blood sample (2.50 µg/l). 
These two readings are hardly visible in Figure 6.4 as they are so low in comparison to 
the other readings determined from the assay. The SCC concentration determined for 
the semen sample tested was 351.15 µg/l. The SCC concentration found in urine was 
664.25 µg/l just under double that seen in semen with the next highest SCC 
concentration of 845.95 µg/l found in saliva. These body fluid samples were determined 
using a 1:50 dilution of the body fluid sample. The menstrual blood sample was seen to 
be too concentrated at that dilution and the concentration of this sample could not be 
SCC
0
2000
4000
6000
8000
10000
12000
14000
16000
18000
20000
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25
Vaginal Fluid Sample Number
S
C
C
 C
o
n
c
e
n
tr
a
ti
o
n
 µ
g
/L
S
C
C
 C
o
n
c
e
n
tr
a
ti
o
n
 µ
g
/L
    214 
determined without a further dilution of the sample. A 1:200 dilution of the menstrual 
blood sample provided a SCC concentration of 9309.20 µg/l. This was the only body 
fluid sample that showed a SCC concentration in a similar range to that of the vaginal 
fluid samples. From Figure 6.3 it can clearly be seen that there are six vaginal fluid 
samples with SCC concentrations that are below that of the menstrual blood sample.  
 
Figure 6.4: SCC concentration of each body fluid sample measured by CanAg SCC EIA ELISA 
kit using optical density readings at 405nm. 
 
The sensitivity and specificity (Tze-Wey Loong. 2003) of the CanAg SCC EIA 
ELISA was calculated (Table 6.1). A total of 31 samples were tested, 25 vaginal fluid 
and 6 other body fluid samples. The cut off level for this calculation was set at 2000 
µg/l. The sensitivity was defined as the number of vaginal fluid samples positively 
identified by ELISA divided by the total number of vaginal fluid samples tested. The 
specificity was defined as the number of other body fluid samples to give a negative 
result  divided by the total number of samples tested by the ELISA that were not 
vaginal fluid.  
 
Sensitivity   =                            Number  of True Positives (TP)                                             
                    Number of True Positives (TP) + Number of False Negatives (FN) 
 
Specificity =                         Number of True Negatives (TN) 
                     Number of True Negatives (TN) + Number of False Positives (FP) 
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Table 6.1 Sensitivity and Specificity of the CanAg SCC EIA ELISA kit. 
 Vaginal Fluid samples 
CanAg 
EIA ELISA kit  
Results 
 Positive Negative 
Positive 23 (TP) 1(FP) 
Negative 2 (FN) 5 (TN) 
  (23/25) x 100 = 92% (5/6)x 100 = 83% 
  Sensitivity Specificity 
  
This ELISA was shown to be 92% sensitive and 83% specific (Table 6.1) with 
the range of samples tested. 
 
6.2.1.2 Confirmation of Human Zinc-Alpha-2-Glycoprotein 
(ZA2G) Specificity using ZA2G ELISA (BioVendor) 
 
Initial results for the ZA2G ELISA test showed that the undiluted samples 
assayed were too concentrated to recover any quantitative data from saliva samples. A 
second ELISA was performed after diluting the samples 1:2. A digital photograph of the 
ELISA plate was taken for reference to show the intensity of each sample well (Figure 
6.5). A schematic diagram was also drawn showing sample placement. The standards 
(std) are outlined in red whilst the body fluid comparison samples are outlined in blue. 
Saliva samples (Sal) are left without an outline. Figure 6.5 showed that every sample 
well gave a positive result for ZA2G. 
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                                      a) 
 
 
                                            
                                             b) 
Figure 6.5: a) A digital photograph of the 96 well Human Zinc-α-2-Glycoprotein ELISA plate 
taken immediately after readings were taken, b) schematic diagram showing Human Zinc-
Alpha-2-Glycoprotein ELISA plate layout showing the calibrator standards outlined in red and 
the body fluid comparison samples outlined in blue. 
 
Bar graphs were drawn to show the ZA2G concentration of each saliva sample 
(Figure 6.6) and for other body fluid samples (Figure 6.7). ZA2G was positively 
identified in all saliva samples assayed. The range that the standards cover and hence 
the concentration range calculated with confidence is shown by the two red lines on 
Figure 6.6 indicating the upper and lower limits of the calibrator standards. Samples 1, 
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11 and 16 showed low concentrations of ZA2G compared to the other 22 samples 
assayed (5.94 ng/ml, 2.45 ng/ml and 17.72 ng/ml respectively). The range of ZA2G 
concentrations for the other samples was between sample 13 (126.22 ng/ml) and 
sample 2 (216.38 ng/ml).  
 
Figure 6.6: ZA2G concentration of each saliva sample measured by Human Zinc-α-2-
Glycoprotein ELISA kit using optical density readings at 450nm. The red lines represent the 
range of the calibrator standards, the concentration of samples outwith this range were 
determined by extrapolation. 
 
Looking at the other body fluid samples, (Figure 6.7) it can be seen that ZA2G 
is present within all the body fluid samples tested. The levels of expression were similar 
for each sample. The highest concentration of ZA2G was seen in menstrual blood 
(195.72 ng/ml) and the lowest concentration other than for saliva was breast milk 
(169.20 ng/ml). Since the levels of ZA2G seen in each fluid were similar and within the 
range of the saliva samples tested, it was not possible to identify sample type (Figure 
6.7) from this ELISA test.  
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Figure 6.7: ZA2G concentration of each body fluid sample measured by Human Zinc-α-2-
Glycoprotein ELISA kit using optical density readings at 450nm. 
 
 
The sensitivity and specificity (Tze-Wey Loong. 2003) of the Human Zinc-α-2-
Glycoprotein ELISA kit was calculated (Table 6.2). A total of 31 samples were tested, 
25 saliva and 6 other body fluid samples. The cut off level for this calculation was set at 
50 ng/ml. The sensitivity was defined as the number of saliva samples positively 
identified by the ELISA divided by the total number of saliva samples tested. The 
specificity was defined as the number of other body fluid samples to give a negative 
result  divided by the total number of samples tested by the ELISA that were not saliva  
 
Sensitivity   =                            Number  of True Positives (TP)                                             
                    Number of True Positives (TP) + Number of False Negatives (FN) 
 
Specificity =                         Number of True Negatives (TN) 
                     Number of True Negatives (TN) + Number of False Positives (FP) 
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Table 6.2 Sensitivity and Specificity of the Zn-α-2-Glycoprotein ELISA kit. 
 Saliva samples 
Human Zn-α-2-
Glycoprotein  
ELISA kit Results 
 Positive Negative 
Positive 22 (TP) 6 (FP) 
Negative 3 (FN) 0 (TN) 
  (22/25) x 100 = 88% (0/6)x 100 = 0% 
  Sensitivity Specificity 
  
Ideally a test should be both sensitive and specific; this ELISA was 88% 
sensitive and 0% specific (Table 6.2) for the range of body fluid samples tested. 
 
6.2.2 Confirmation of Specificity using a Dot Blot  
 
6.2.2.1 Testing the Detection Limits of the Dot Blot with 
Recombinant Protein 
 
Four protein markers were tested for body fluid specificity in the same range of 
body fluids as the ELISA kits. Cystatin SA, Cystatin SN, and Lipocalin-1 identified in 
saliva and SERPINB1 in vaginal fluid, were tested with antibodies specific to each 
protein (Figure 6.8). A serial dilution (Table 6.3) of commercial recombinant protein, 
was performed to determine the antibody limits for each protein tested (Figure 6.9). 
The volume of sample loaded to the membrane was 10 µl.  
Each dot in the dot blots performed appeared as a narrow slot type band due to 
the loading device used. It can be seen that the background was relatively high in all 
the photographs. Bands were seen up to a 1:10 dilution for panels Cystatin SA (Figure 
6.9 panel a), Cystatin SN (Figure 6.9 panel b), and SERPINB 1 (Figure 6.9 panel d). 
There were no bands visible with Lipocalin-1 (Figure 6.9 panel c). This experiment was 
repeated and the same results observed. 
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Table 6.3: Recombinant protein concentrations of each serial dilution. 
 
Dilution Recombinant Protein Concentration (µg/ml) 
Cystatin SA Cystatin SN Lipocalin-1 SERPINB1 
Neat 100µg/mL 100µg/mL 132µg/mL  90µg/mL 
1:2 50µg/mL 50µg/mL 66µg/mL 45µg/mL 
1:10 10µg/mL 10µg/mL 13.2µg/mL 9µg/mL 
1:50 5µg/mL 5µg/mL 6µg/mL 4.5µg/ml 
1:100 1µg/mL 1µg/mL 1.32µg/mL 0.9µg/mL 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.8: A schematic diagram of dot blot of recombinant protein in serial dilution  
 
 
    
 
a)                   b) 
 
 
c)                 d) 
Figure 6.9: Detection limits of a) Cystatin SA, b) Cystatin SN, c) Lipocalin-1, and d) SERPINB1. 
Each antibody was tested against recombinant proteins in serial dilution (neat, 1:2, 1:10, 1:50 
and 1:100).  
 
 
 
 
 
Neat   1:2     1:10       1:50     1:100             Neat       1:2       1:10       1:50     1:100 
            Neat   1:2     1:10       1:50     1:100 Neat     1:2        1:10       1:50        1:100 
DAB
Mouse anti-human Cystatin SA
or
Goat anti-human Cystatin SN, 
Lipocalin-1 or SERPIN B1
Anti-mouse or anti-goat IgG (peroxidase
conjugate)
Serial dilution of 
recombinant protein 
(Cystatin SA, Cystatin SN, 
Lipocalin or SERPINB1)
Y Y
Y Y Y Y Y Y
Y Y Y Y
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6.2.2.2 Testing the Detection Limits of the Dot Blot with a Serial 
Dilution of Body Fluids  
 
Each antibody was tested with the body fluid where it was initially isolated by 
2DGE (Figure 6.10). Cystatin SA, Cystatin SN and Lipocalin-1 were tested against a 
saliva sample in serial dilution and SERPINB1 was tested with a vaginal fluid sample in 
serial dilution (Figure 6.11). The range of dilutions tested were undiluted, 1:2, 1:10, 
1:50 and 1:100. The volume of sample loaded to the membrane was 10 µl.  
 
 
 
 
 
 
 
 
 
 
 
Figure 6.10: A schematic diagram of dot blot of saliva or vaginal fluid in serial dilution  
 
  
            
a) b) 
 
 
                                                                   
      c)  d) 
Figure 6.11: Detection limits of a) Cystatin SA, b) Cystatin SN, c) Lipocalin-1 with saliva in 
serial dilution (neat, 1:2, 1:10, 1:50 and 1:100), and d) SERPINB1 with vaginal fluid in serial 
dilution (neat, 1:2, 1:10, 1:50 and 1:100). 
 
From these results it can be seen that Cystatin SA (Figure 6.11 a) and Cystatin 
SN (Figure 6.11 b) can be detected in up to a 1:100 dilution of saliva. The Lipocalin 
antibody failed to detect saliva at any of the dilutions tested including the undiluted 
 Undiluted     1:2     1:10    1:50   1:100 
        Undiluted    1:2     1:10      1:50   1:100 
 Undiluted     1:2     1:10    1:50   1:100  Undiluted     1:2       1:10    1:50   1:100 
DAB
Mouse anti-human Cystatin SA
or
Goat anti-human Cystatin SN, 
Lipocalin-1 or SERPIN B1
Anti-mouse or anti-goat IgG (peroxidase
conjugate)
Serial dilution of human 
saliva or vaginal fluid
Y Y
Y Y Y Y Y Y
Y Y Y Y
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saliva (Figure 6.11 c). SERPINB1 detected vaginal fluid up to a 1:50 dilution (Figure 
6.11 d). 
 
6.2.2.3 Testing the Detection of the Dot Blot with Lipocalin 
Primary Antibody Direct to the Membrane 
 
No bands were visible with either recombinant Lipocalin-1 protein or saliva in 
the dot blot. The lipocalin dot blot failure might have been caused by the primary or 
secondary antibody functioning incorrectly. To test the performance of the secondary 
antibody, a dot blot was performed with the primary goat anti-Lipocalin antibody (10 µl) 
spotted onto a membrane and the secondary antibody applied (Figure 6.12). The 
results for this dot blot are shown in Figure 6.13. No dilution was performed for this 
experiment. 
 
 
 
 
               
 
 
 
Figure 6.12: A schematic diagram of dot blot of Lipocalin-1 antibody  
 
 
 
Figure 6.13: Dot blot of Goat anti- Lipocalin-1 antibody directly added to the membrane. 
 
Bands were visible when the goat anti-Lipocalin was directly applied to the 
membrane and treated with secondary antibody and DAB as in previous experiments, 
although the background signal was high making the bands hard to visualise. Thus 
confirming the primary-secondary antibody reaction to be working.  
However due to no positive reactions being shown with the positive control 
(recombinant protein) or the saliva sample no further dot blots were performed using 
this antibody.  
 
  10 µl    10 µl    10 µl  10 µl      
 
 
 
 
Anti-Goat IgG (peroxidase conjugate)
DAB
Y
YY YY Y
Y Y YY
Goat anti-human Lipocalin-1
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6.2.2.4 Dot Blot Detection using a Range of Body Fluids 
 
Each antibody was tested with a range of body fluids; menstrual blood, blood, breast 
milk, semen, saliva, vaginal fluid and urine in order to test for protein specificity (Figure 
6.14). 10 µl of undiluted body fluid was used for the dot blot with each antibody. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.14: A schematic diagram of dot blot of body fluid panel with primary and secondary 
antibodies 
 
A positive reaction was seen for all body fluids (Figure 6.15).  All the antibodies 
exhibited positive signals with the saliva samples. However, the antibody for Cystatin 
SA (Figure 6.15 a) showed strong positive signals with menstrual blood and semen 
samples. Weak signals were obtained with blood, breast milk, urine and vaginal fluid. 
Cystatin SN (Figure 6.15 b) showed strong signals with blood and menstrual blood that 
appeared stronger than saliva. Signals with a similar intensity to the band observed in 
the saliva sample were shown with semen and vaginal fluid, whereas weak positive 
signals were shown with breast milk and urine. SERPINB1 that was originally detected 
in vaginal fluid showed strong signals with saliva, semen, menstrual blood (Figure 6.15 
c) and as was expected, with vaginal fluid. Weak signals were also shown with blood, 
breast milk and urine. 
 
 
 
 
 
 
DAB
Mouse anti-human Cystatin SA
or
Goat anti-human Cystatin SN, 
Lipocalin-1 or SERPIN B1
Anti-mouse or anti-goat IgG (peroxidase
conjugate)
Body fluid panel
Y Y
Y Y Y Y Y Y
Y Y Y Y
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Figure 6.15: A dot blot to show antibody specificity tested with 10 µl of a range body fluids 
using a) Cystatin SA, b) Cystatin SN and c) SERPINB1 antibodies.  
 
6.2.2.5 Dot Blot Detection using Blood Samples with Direct DAB 
Development 
 
It was noted that in the previous experiment bands were visible on the 
membrane prior to DAB antibody detection (Figure 6.17). It was thought this might be 
due to haemoglobin staining the membrane from the blood samples. To test this a dot 
blot was performed using blood and menstrual blood in serial dilution (neat, 1:2, 1:5, 
1:10, 1:50, 1:100, 1:200, 1:500 and 1:1000), treating the membrane immediately with 
DAB without antibody addition (Figure 6.16). This would determine whether the signals 
shown for blood are present without antibody addition, thus testing whether the 
haemoglobin levels present in the blood samples are high enough to react with DAB 
creating false positive results. The results from this reaction are shown in Figure 6.18. 
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Figure 6.16: A schematic diagram of dot blot of blood and menstrual blood with or without 
peroxidase treatment 
 
 
 
Figure 6.17: A digital photograph to show haemoglobin staining on the dot blot membranes 
(outlined in white) prior to DAB development.  
 
 
 
 
 
 
 
 
 
 
 
 
Blood or Menstrual blood
With or without peroxide 
treatment
DAB
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Figure 6.18: A DAB stained membrane loaded with a serial dilution (neat, 1:2, 1:5, 1:10, 1:50, 
1:100, 1:200, 1:500 and 1:1000) of blood and menstrual blood samples without antibody 
addition. 
 
Negative staining (appearing as white bands) was observed for the blood 
samples up to a 1:10 dilution. No blue staining, a characteristic of the previous positive 
signals, was seen with the menstrual blood samples (Figure 6.18) although brown 
stains were observed on the membrane.  
 
6.2.2.6 Dot Blot Detection with a Peroxidase Treatment of Blood 
Samples 
 
In an attempt to try and eliminate the background from the haemoglobin and 
DAB reaction. Endogenous peroxidase activity can be inhibited using methanolic 
hydrogen peroxide (Andrew and Jasani 1987). The experiment was repeated with both 
the blood and the menstrual blood samples. This time the samples were treated with 
3% hydrogen peroxide in methanol, at 37°C for 1 hour before the dot blot was 
performed.  A negative control of PBS and a positive control of untreated blood and 
menstrual blood were also blotted (Figure 6.19). 
 
 
 
 
 
 
 
 
 
 
 
Blood 
 
Menstrual 
Blood 
     Neat           1:2             1:5            1:10          1:50          1:100                          1:200       1:500       1:1000 
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Figure 6.19: A DAB stained membrane loaded with a serial dilution (neat, 1:2, 1:5, 1:10, 1:50, 
1:100, 1:200, 1:500 and 1:1000) of peroxidase treated blood and menstrual blood samples 
without antibody addition as well as a positive control of untreated blood and menstrual blood 
and a negative control of PBS. 
 
In Figure 6.19, the positive control of untreated blood and menstrual blood gave 
strong positive blue reactions with DAB. Only the neat blood and menstrual blood 
samples exhibit a positive reaction when treated with hydrogen peroxide prior to 
performing the dot blot. This positive result is much weaker than that shown with the 
untreated blood samples. PBS showed a negative result as expected, which was 
consistent with the most diluted samples of blood and menstrual blood on the 
membrane.  
 
6.2.2.7 Testing the Detection of the Dot Blot with a Range of 
Body Fluids after Protein Quantification 
 
It was thought that the concentration of protein within each body fluid may have 
had an effect upon the results obtained. With this in mind a protein assay was 
performed in order to ensure that the same amount of protein was loaded in each body 
fluid tested (Figure 6.20).  
       Neat           1:2         1:5          1:10        1:50       1:100      1:200       1:500       1:1000   PBS    untreated 
 
Blood 
 
 
Menstrual 
Blood 
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Figure 6.20: The concentration of each body fluid sample measured by RCDC protein assay. 
 
The results demonstrate that the variation in protein concentration among body 
fluid samples was high, ranging from 0.181mg/ml for urine to 9.09 mg/ml for menstrual 
blood. It seemed possible that variation obtained could be due to different total protein 
loadings for each fluid. 
 
 
 
Figure 6.21: A schematic diagram of dot blot of body fluid panel 
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The body fluid dot blots were repeated with a protein loading of 10 µg/dot. Blood and 
menstrual blood samples were pre-treated with peroxidise (Figure 6.21). 
These results (Figure 6.22) show that on each the PBS negative control gave 
no signal with DAB. The results for Cystatin SA antibody (Figure 6.22 a) gave a 
positive result for saliva, but semen, menstrual blood, breast milk and vaginal fluid were 
also positive. As before, a weak positive signal was shown with blood. It would appear 
that treating the samples with peroxidase has enhanced the signal produced on the 
membrane for the blood sample while the menstrual blood sample gave a similar 
intensity with or without peroxidase treatment.  
For Cystatin SN (Figure 6.22 b), unlike the previous results in section 6.2.2.4, 
the fluids producing strong signals other than saliva were vaginal fluid and the 
peroxidase treated blood sample. The rest of the body fluids yielded weak signals. 
Strong signals were produced using the SERPINB1 antibody (Figure 6.22 c) with saliva 
as well as vaginal fluid. Semen and menstrual blood gave a medium strength signal 
with blood and breast milk producing the weakest signals. The peroxidase treatment 
appeared to enhance the result for the menstrual blood sample but reduced the blood 
sample signal on the membrane.  
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Figure 6.22: Dot blots to show antibody specificity tested with a range body fluids using a) 
Cystatin SA, b) Cystatin SN and c) SERPINB1 antibodies. Samples treated with peroxide have 
Px after them. 
 
 
6.2.2.8 Testing the Detection of the Dot Blot for Secondary 
Antibody Specificity 
 
As a result of unexpected positive results in blood samples after treatment with 
hydrogen peroxide and by body fluid samples in the dot blots (section 6.2.2.6) the 
secondary antibodies were tested directly for cross reactivity with each body fluid 
(Figure 6.23).  
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Figure 6.23: A schematic diagram of dot blot of body fluid panel with secondary antibodies 
     
 
 
     
     
 
  
 
Figure 6.24: A dot blot to show secondary antibody specificity tested with a range body fluids 
using a) Anti-Mouse IgG and b) Anti-Goat IgG. Samples treated with peroxide have Px after 
them. 
 
Weak positive results can be seen with Anti-Mouse IgG (Figure 6.24 a) for all 
body fluids. The PBS negative control remained negative in both secondary antibody 
dot blots. Weak positive results can be seen with Anti-Goat IgG (Figure 6.24 b) for 
semen, menstrual blood, breast milk, vaginal fluid and urine. Strong positive reactions 
were observed with the blood sample and hydrogen peroxide treatment seemed to 
enhance the positive reaction signal produced from both the blood and the menstrual 
blood sample. The menstrual blood sample in particular showed a dramatic change in 
intensity from a weak positive (without peroxide) to a strong positive (with peroxide). 
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The only sample not to show a positive result with Anti-Goat IgG was the saliva 
sample. 
 
6.2.2.9 Testing the Detection of the Dot Blot for Secondary 
Antibody Specificity Reacting with Human IgG 
 
Since it was also noted that the secondary antibodies were not specific to either 
Mouse IgG or Goat IgG, Human IgG was blotted and tested with both Anti-Goat IgG 
and Anti-Mouse IgG secondary antibodies and the colour developed with DAB (Figure 
6.25).  Human IgG was blotted with and without incubation with hydrogen peroxide at 
three different protein loads; 10 µg, 5 µg and 1 µg.  
 
 
Figure 6.25: A schematic diagram of dot blot of Human IgG or albumin with secondary 
antibodies 
 
 
 
 
 
 
Figure 6.26: A digital photograph to show a DAB stained membrane loaded with human IgG 
protein, incubated with secondary Anti-Goat IgG, developed with DAB 
 
 
 
 
 
 
 
 
DAB
Anti-mouse or anti-goat IgG (peroxidase
conjugate)
Y Y Y YY Y
Human IgG or Albumin
    10µg          5µg         1µg        10µg         5µg           1µg        PBS 
        Px            Px             Px 
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Figure 6.27: A digital photograph to show a DAB stained membrane loaded with human IgG 
protein, incubated with secondary Anti-Mouse IgG, developed with DAB 
 
The negative PBS control was not detected by Anti-Goat (Figure 6.26) or Anti -  
Mouse IgG (Figure 6.27) secondary antibodies. Anti-Goat IgG (Figure 6.26) gave a 
weak positive reaction with each of the protein loads tested. This signal was enhanced 
in the samples that were incubated with hydrogen peroxide prior to blotting. A weak 
positive result can be seen for the 10 µg protein load when incubated with Anti-Mouse 
IgG but the other loads showed negative results. The samples incubated with hydrogen 
peroxide prior to blotting gave positive results for each protein load down to 1 µg.  
 
6.2.2.10 Detection for DAB Specificity by Dot Blot  
  
It was concluded that DAB was not binding specifically to the labelled 
antibodies but reacting with other proteins within the human body fluid samples. For 
this reason human albumin protein was tested with and without hydrogen peroxide 
treatment (Figure 6.28). An attempt was made to block the membrane with milk protein 
(1hour) in order to reduce the background signal. This would distinguish whether 
positive results were true positives or due to the loading buffer staining the membrane 
prior to DAB development (Figure 6.29) 
 
 
 
 
 
 
 
Figure 6.28: A digital photograph to show a DAB stained membrane loaded with human 
albumin protein without blocking developed with DAB (Peroxidase treated samples marked Px). 
  10µg       5µg          1µg           10µg         5µg         1µg           PBS 
       Px             Px           Px      
 
  
  10µg        5µg         1µg         10µg         5µg       1µg        PBS 
     Px            Px         Px      
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Figure 6.29: A digital photograph to show a DAB stained membrane loaded with human 
albumin protein with milk blocking prior to development with DAB (Peroxidase treated samples 
marked Px). 
 
 The results from Figure 6.28 show that an outline of each sample blotted can be 
seen on the membrane, including the negative control PBS. The background of this 
membrane is also relatively high. In the replicate membrane (Figure 6.29) (incubated in 
milk for one hour prior to DAB development), the sample outlines had disappeared and 
no positive bands were shown with albumin and DAB development. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  10µg        5µg         1µg          10µg         5µg         1µg         PBS 
       Px           Px           Px      
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6.3 Discussion 
 
 6.3.1 Selection of Biomarkers for Testing Specificity 
 
 It was not viable to test all the proteins identified. In some cases this was due to 
the lack of specificity of the protein itself e.g. Actin, immunoglobulins and superoxide 
dismutase. These proteins are expressed in all body fluids and cell types and would 
therefore not be suitable biomarkers of either saliva or vaginal fluid. Epidermal fatty 
acid binding protein, as its name suggests, seemed an unlikely candidate as it is 
present within skin and likely to have been deposited onto the swab during vaginal fluid 
sample donation it would probably contaminate menstrual blood, breast milk, semen 
and blood also.  
Another problem encountered when assessing the specificity was the difficulty 
in obtaining commercial ELISA kits or antibodies for the proteins identified at the time 
of searching. Those available were tested, however since this time, an ELISA to detect 
calgranulin B has become available and so further work would involve incorporation of 
this ELISA. This ELISA is primarily used for the detection of colon cancer by testing 
stools and therefore Calgranulin would be present in faeces. Although it is likely that 
this ELISA may have low specificity, if the levels present in the stool samples differ 
considerably from the levels in the other body fluid samples tested, this marker could 
still be used for vaginal fluid identification. 
 
6.3.2 Confirmation of Protein Specificity - ELISA  
 
6.3.2.1 Confirmation of Leucocyte Elastase Inhibitor Specificity 
using CanAg SCC EIA kit (Fujirebio™) 
 
 Spots 17 and 19 in vaginal fluid were positively identified as SCCA1 (Table 5.8) 
in vaginal fluid. CanAg SCC EIA kit was used to test the vaginal fluid samples 
individually. Sample 10 was the only sample to give a reading below the 0 µg/l 
calibrator and hence negative for SCC. If sample 10 does not contain SCC yet the 
pools containing sample 10 show expression of both spots 17 and 19 the other 
samples contributing to the pool could be showing the expression for the spots.  
Sample 10 was provided by an individual not using any form of contraception 
and taken just before menstruation; no other samples were taken at this stage of the 
cycle. But samples from other donors not using any contraception showed positive 
ELISA results. The result could be due to the stage of the cycle, or genetic differences. 
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 Although positive reactions were shown for body fluids other than vaginal fluid, 
namely, semen, saliva and urine the levels were lower than those seen in the vaginal 
fluid samples thus the ELISA could be deemed suitable for distinguishing vaginal fluid 
from these other body fluids if a lower limit was set for the test. The lowest 
concentration seen in a vaginal fluid sample (Figure 6.4) was 812.75 µg/l, due to its 
similarity to the saliva sample this could be considered a false negative. Further testing 
would need to be performed on a larger number of samples to determine the range of 
SCCA concentration for vaginal fluid and the other body fluids yielding a positive ELISA 
result. Menstrual blood was the only fluid to give a concentration in the region of the 
majority of the vaginal fluid samples. This could be due to menstrual blood being 
composed of vaginal secretions, blood and endometrium. 
 When calculating the sensitivity and specificity of the CanAg SCC EIA kit (Table 
6.1) a threshold of 2000 µg/l was used. At this threshold, the ELISA was shown to be 
92% sensitive and 83% specific within the range of the samples tested. The test shows 
an appropriate level of sensitivity to discount the false positives and negatives 
produced and is specific enough to differentiate between vaginal fluid and menstrual 
blood compared with the other body fluids tested.  
 The ELISA could not be used to differentiate between vaginal fluid and 
menstrual blood as the menstrual blood concentration determined in the ELISA was 
within the range of concentrations determined for vaginal fluid. Unfortunately the upper 
limits of the calibrator standards in this kit were below the concentration of many of the 
sample. If more time and kits were available this would be repeated once more diluting 
those samples where the concentrations were extrapolated. The SCC antigen is 
present in normal squamous cell epithelia which explains the positive results obtained 
for vaginal fluid in this ELISA. Elevated SCC levels may also be present in skin 
disorders such as psoriasis (Cataltepe et al. 2000). The SCC ELISA is routinely used 
for processing serum samples where the normal range for SCC concentration is 0.16 
µg/l – 1.5 µg/l. This is 4 orders of magnitude lower than the average concentration 
found in vaginal fluid. The normal blood concentration obtained in this assay was 2.5 
µg/l which was higher than the stated range from the manufacturers (see above). It 
must be noted that this was in whole blood rather than the serum concentrations noted 
above. The ELISA does not distinguish SCCA2 from SCCA1 so false positives could 
be identified due to the detection of SCCA2  
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6.3.2.2 Confirmation of Human Zinc-α -2-Glycoprotein (ZA2G) 
Specificity using ZA2G ELISA (BioVendor) 
 
Human ZA2G ELISA was used to test the saliva samples individually. All saliva 
samples tested positive for ZA2G using the ELISA although some of the samples had 
concentrations that were determined by extrapolation from the standards within the 
assay. Once again this ELISA was manufactured for use with serum and therefore the 
range of standards were appropriate to that sample type. The manufacturers advise 
samples with a concentration higher than 500 ng/ml to be diluted and retested. If 
another kit was purchased those samples with concentrations higher than the 100 
ng/ml standard would be diluted and repeated. Those below the 3 ng/ml standard could 
not be concentrated and thus are false negatives; the ELISA gave positive results for 
each of the body fluids tested. The ELISA showed that ZA2G was not specifically 
expressed in saliva.  When calculating the sensitivity and specificity of the ZA2G ELISA 
(Table 6.2) using a lower level cut off of 50 ng/ml to discount the low saliva sample 
readings. The ELISA was shown to be 88% sensitive and 0% specific within the range 
of the samples tested. The sensitivity of the test could not be adjusted to account for 
only saliva samples producing positive results as the concentrations of ZA2G identified 
in the body fluid samples (Figure 6.7) were within the range of values given for the 
saliva samples (Figure 6.6). ZA2G was therefore eliminated as a candidate protein for 
characterising saliva. 
 
6.3.3 Confirmation of Specificity using a Dot Blot  
 
Where ELISA kits were unavailable, dot blots were used. The dot blot is a 
simple method for testing the specificity of antigens in different samples. Unlike a 
Western blot where proteins are separated based on molecular weight prior to 
incubation with antibodies, the exact protein band being detected cannot be 
ascertained using a dot blot, only whether or not the antigen is present in the sample or 
not. Advantages for this method are that is quicker and simpler to use than a Western 
blot. 
 Positive reactions were seen with both blood and menstrual blood for all 
primary antibodies tested. There are three factors which could be responsible for 
causing false positives within this dot blot experiment: 1) low specificity or non 
specificity of the primary antibody, 2) low specificity or non specificity of the secondary 
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antibody 3) reaction of endogenous enzymes within the body fluids reacting with the 
colour development substrate. 
6.3.3.1 Testing the Detection Limits of the Dot Blot with 
Recombinant Protein 
 
The lipocalin antibody gave problems throughout the dot blot procedures. It 
neither bound to lipocalin protein or to any of the proteins from body fluids, primary and 
secondary antibodies. The reagents were all working well. It was concluded that the 
antibody was not functional. 
 
6.3.3.2 Testing the Detection Limits of the Dot Blot with a Serial 
Dilution of Body Fluids  
 
In subsequent experiments the primary antibody was diluted with blocking 
buffer in order to lower the background of the blot.  A blot was performed using either 
saliva (Cystatin SA, Cystatin SN and Lipocalin-1) or vaginal fluid (SERPIN B1) in serial 
dilution (Figure 6.11). Once again all antibodies reacted except Lipocalin-1 (Figure 
6.11c) up to either a 1:50 (Figure 6.11d, SERPINB1) or a 1:100 (Figure 6.11a and b, 
Cystatin SA and SN respectively) dilution.  
 
6.3.3.3 Testing the Detection of the Dot Blot with Lipocalin 
Primary Antibody Direct to the Membrane 
 
The Lipocalin-1 antibody was raised in Goat, as was the SERPIN B1 antibody. 
Positive result bands were observed when SERPIN B1 was tested with both the 
recombinant protein (Figure 6.9d) and vaginal fluid (Figure 6.11d) in serial dilution. For 
these reasons it was thought that the primary-secondary antibody reaction was working 
efficiently but was further tested in order to be certain. 10 µL anti-human Lipocalin-1 
antibody was blotted against the anti-Goat secondary antibody (Figure 6.13). Bands 
were seen on the membrane confirming that there was not a problem with the 
primary/secondary antibody reaction. As no bands were identified with either the 
recombinant protein or saliva when tested with Lipocalin-1 antibody it was decided not 
to use this antibody any further as none of the positive controls revealed any bands.  
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6.3.3.4 Dot Blot Detection using a Range of Body Fluids 
 
When each antibody was tested against a panel of body fluids, numerous 
positive bands were observed of differing intensities for each blot (Figure 6.14). The 
volume of body fluid was initially kept constant at 10 µl as it was thought in a forensic 
scenario body fluids would more likely be in their native concentrated form. It was 
difficult to determine whether the positive reactions produced in the dot blot were due 
to the presence of the antigen in the body fluid itself or whether due to the same 
volume of each fluid being used, a bias was added to the experiment. So, although the 
antigen may be present it may be present in much smaller amounts in one fluid 
compared to another, as was demonstrated by the SCC ELISA (section 6.3.2.1). In 
order to determine the effects of the differing body fluid protein concentrations on the 
dot blot a protein assay was performed and the dot blots were repeated using 10 µg of 
protein in each body fluid (section 6.3.3.7) as opposed to a constant volume.   
 
6.3.3.5 Dot Blot Detection using Blood Samples with Direct DAB 
Development 
 
Prior to DAB addition, staining shown on the membrane was thought to be 
caused by Haemoglobin (Figure 6.17). When DAB was added directly to a membrane 
blotted with blood and menstrual blood samples in serial dilution without prior antibody 
incubation, negative staining and brown staining was shown (Figure 6.18). A reaction 
was being seen between the DAB and the blood samples. Blood samples are known to 
exhibit peroxidase activity due to the haemoglobin within them (Ahlquist and Schwartz. 
1975). The peroxidase activity of the haem group catalyses the change in oxidation 
state of a substrate within both blood presumptive tests LMG and Phenolphalein 
causing a colour change (Webb et al. 2006).  
Endogenous peroxidase within the blood and menstrual blood samples were 
thought to cause a false position reaction with DAB causing a colour change on the 
membrane (Figure 6.18).  
 
6.3.3.6 Hydrogen Peroxide Treatment of Blood Samples  
 
Endogenous peroxidase activity was inhibited in menstrual blood and blood 
samples using a 3% hydrogen peroxide solution in methanol and incubating at 37°C for 
1 hour with the lids off the Eppendorf tubes in order for any liberated oxygen to be 
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released (Li, Fan et al. 2007). Samples were blotted once again in serial dilution 
without antibody incubation (Figure 6.19) and only the neat samples showed positive 
reactions and these appeared less intense than the blood samples where no treatment 
had been performed.  
 
6.3.3.7 Testing the Detection of the Dot Blot with a Range of 
Body Fluids after Protein Quantification 
 
Quantification of body fluids showed that the protein concentration in the panel 
of fluids tested ranged from 0.181 mg/ml for urine to 9.09 mg/ml for menstrual blood. 
When the body fluid blot was repeated with 10 µg of each fluid, positive bands were 
once again shown in all of the body fluids for each antigen tested. Some of the 
antigens have been positively identified in other body fluids, for example Cystatin SN 
has been identified in tear fluid by immunoblot (Barka, Asbell et al. 1991) Lipocalin-1 
has also been found within tears by studying endonuclease activity (Yusifov, 
Abduragimov et al. 2008) but not in the fluids tested in this study. For this reason it is 
unclear whether the biomarkers are not specific to saliva or vaginal fluid and present 
within the other body fluids tested or whether the antibodies used are not specific 
themselves. 
 
6.3.3.8 Testing the Detection of the Dot Blot for Secondary 
Antibody Specificity 
 
As positive results were still given for all the body fluids tested with each 
antibody the specificity of the secondary antibody was tested. When the secondary 
antibodies were blotted directly with the body fluid panel positive bands were visible for 
all body fluids with anti-mouse IgG and for semen, menstrual blood, breast milk, 
vaginal fluid and urine with anti-goat IgG. Peroxide treatment seemed to enhance the 
blood and menstrual signal produced with anti-goat IgG.  
 
 
6.3.3.9 Testing the Detection of the Dot Blot for Secondary 
Antibody Specificity Reacting with Human IgG 
 
Human IgG was blotted and tested with both anti-mouse IgG and anti-goat IgG 
to test for specificity and cross reactivity with human IgG. Human IgG is present within 
all body fluids although at differing levels. In serial dilution with and without peroxide 
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treatment anti-goat IgG showed positive reactions with up to 1 µg of human IgG 
protein. The anti-mouse IgG was less reactive only producing a band with 10 µg of 
human IgG untreated but peroxide treatment enhanced the reaction with the antibody 
detecting as little as 1 µg of human IgG thus this secondary antibody was reliable if the 
samples were not treated with peroxidase prior to blotting. 
 
 
6.3.3.10 Testing the Detection of the Dot Blot for DAB 
Specificity  
 
No reaction was seen with DAB directly added to the membrane blotted with 
human albumin protein. This shows that DAB will not react to any given protein within a 
sample and is specifically reactive to peroxide. 
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6.4 Chapter Summary 
 
 In summary the findings from this chapter show that the SCC ELISA showed 
high levels of sensitivity and specificity whereas the Zn-α-2-Glycoprotein ELISA kit only 
showed high sensitivity, and no specificity in the body fluid samples tested. 
 The Lipocalin-1 primary antibody gave no reaction with  Lipocalin antigens in 
saliva samples or the recombinant Lipocalin-1 protein. Positive results were seen for 
the other three antibodies when tested against their fluid of origin and the recombinant 
protein specific for the antibody. 
 Although positive results were obtained for each antibody with the body fluid of 
origin when tested alongside a panel of body fluids false positives were also shown for 
nearly every body fluid type, due to cross species reactivity of the secondary antibody. 
When blood and menstrual blood samples were reacted with DAB alone without any 
antibodies a positive reaction was seen, this was overcome when the same experiment 
was repeated with the blood and menstrual blood samples undergoing a peroxide 
treatment. 
False positive reactions were shown with both secondary antibodies when blots 
were performed without the primary antibody incubation.  
The Goat secondary antibody was shown to react with human IgG showing a 
degree of cross reactivity which was not shown with the secondary mouse antibody. 
PBS was shown to be consistently negative throughout all the blots performed.  
A summary of the Dot Blot results is shown in Table 6.4. 
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Chapter 7 – Discussion 
 
7.1 Biomarker Suitability 
 
The ideal biomarker should be expressed exclusively within one body fluid type. 
No cross reactivity should be seen with other body fluids and the chosen marker should 
be expressed population wide. Biomarker expression should not be affected by 
external factors.  
 
7.1.1 Cystatin SA 
 
 Although positive bands were seen on the dot blot membrane for all the body 
fluids tested (Figure 6.22a) with the Cystatin SA antibody, weak positive results were 
also visible on the membrane when only the secondary Anti-Mouse IgG (Figure 6.24 a) 
was tested with the body fluids. This implies that the secondary antibody was binding 
non-specifically to a component of the body fluid, probably IgG. When blotted with 
human IgG this theory was confirmed as 10 µg of protein produced a positive band with 
the anti-mouse IgG antibody (Figure 6.27). The signal was enhanced by peroxide 
treatment showing a positive band with 1 µg of protein. Isemura et al. (1991) have 
shown immunoblots to produce bands representative of Cystatin SA in tears and 
seminal plasma but stated these could be non-phosphorylated cystatin S. The 
specificity of Cystatin antibodies within this study may have affected the results as the 
anti-human Cystatin SA antibody shows 100% cross reactivity with Cystatin SN and 
Cystatin S (R&D systems). 
 
7.1.2 Cystatin SN 
 
 Although positive bands were seen on the dot blot membrane for all the body 
fluids tested (Figure 6.22b) with the Cystatin SN antibody, weak positive results were 
also visible on the membrane when only the secondary Anti-Goat IgG (Figure 6.24 b) 
was blotted. When the secondary antibody was tested with the body fluid panel, 
positive bands were seen for semen, menstrual blood, breast milk, vaginal fluid and 
urine suggesting that the antibody was exhibiting non specific binding to a component 
of the body fluids. When blotted with human IgG protein this was confirmed as 5 µg of 
protein produced a positive band with the anti-goat IgG antibody (Figure 6.26). This 
showed that the secondary antibody exhibited cross reactivity with human IgG and 
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some of the signal produced in the body fluid dot blot (Figure 6.24b) could be due to 
this cross reactivity of the antibody. Once again this effect was enhanced by peroxide 
treatment. Cystatin SN secretion has been found exclusively in saliva (Hiltke, Lee et al. 
1999) but immunoblots have shown a positive reaction to anti-human cystatin SN in 
tears (Barka, Asbell et al. 1991). As mentioned previously (section 7.1.1) the specificity 
of Cystatin antibodies within this study may have affected the results. The anti-human 
Cystatin SN antibody showed 30% cross reactivity with Cystatin SA and 15% with 
Cystatin S. 
 
7.1.3.Lipocalin-1 
 
 As the Lipocalin-1 antibody did not produce positive bands with either 
recombinant Lipocalin-1 (Figure 6.9c) protein or with saliva (Figure 6.11c) the 
specificity of the antibody could not be tested further with other body fluids. Lipocalin 
has also been identified in tears (Yusifov, Abduragimov et al. 2008). 
 
7.1.4 ZA2G 
 
 Although ZA2G was identified successfully by ELISA in each saliva sample 
within the study, levels were variable. Cross reactivity was also seen in each of the 
body fluids within the panel tested. For this reasons ZA2G would not be a suitable 
forensic marker for saliva. Due to its universal expression this protein could be 
considered as a positive control for any test that was developed. Previous studies have 
confirmed the presence of ZA2G within human serum (Burgi and Schmid 1961), urine 
(Shibata and Miura 1982), semen, breast milk, sweat, and saliva (Ohkubo, Niwa et al. 
1990). 
 
7.1.5 SCCA /SERPIN B3 
 
 SCCA was identified in all but one of the vaginal fluid samples within this study 
by ELISA although the levels within each vaginal sample were variable. When the body 
fluid panel was used with the ELISA low levels were shown with saliva, urine and 
semen. Of these, the only fluid to show a reaction above the threshold seen with 
vaginal fluid was saliva. The only body fluid to give a reading similar to the vaginal fluid 
samples was menstrual blood which, due to its composition, was expected.  These 
results suggest that SCCA could be used as a marker for a fluid of vaginal origin. A low 
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level cut off would be recommended if this protein was selected as a marker for vaginal 
fluid to discount the low level positive results shown by the other body fluids tested. 
SCCA is expressed in normal squamous epithelia (Cataltepe, Gornstein et al. 2000) 
and hence likely to be found in body fluids containing these cells such as saliva, 
vaginal fluid. The acidic form of SCCA (SCCA1) has been found in the saliva (Kato 
1996). The presence of squamous epithelia in urine could be explained by 
contaminating skin cells deposited during collection. Epithelia cells have also been 
identified within semen samples and this could also be due to contamination from skin 
cells of the mucosal skin at the opening of the male urethra upon ejaculation. In order 
for SCCA1 to be used as a vaginal fluid marker, menstrual blood markers would have 
to be used in conjunction with it, as currently all that can be deduced from this ELISA is 
that the samples are of vaginal origin or not. Menstrual blood is easy to distinguish from 
vaginal fluid due to the presence of haemoglobin so this could be used a blood marker 
in conjunction with SCCA to distinguish between vaginal fluid and menstrual blood. 
 
7.1.6 Leukocyte Elastase Inhibitor/SERPIN B1 
 
 Although positive bands were seen on the dot blot membrane for all the body 
fluids tested (Figure 6.22c) with the SERPIN B1 antibody, weak positive results were 
also visible on the membrane when only the secondary Anti-Goat IgG (Figure 6.24b) 
was tested with the panel of body fluids. This suggests that the antibody was exhibiting 
non specific binding to a component of the body fluid. When the secondary antibody 
was tested with the body fluid panel positive bands were seen for semen, menstrual 
blood, breast milk, vaginal fluid and urine. As mentioned above (section 7.1.2). Cross 
reactivity with human IgG could account for some of the signal produced in the body 
fluid dot blot (Figure 6.22c). 
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7.2 Future Work 
 
7.2.1 Expression Analysis 
 
 In this study saliva and vaginal fluid were selected for protein expression 
analysis using 2DGE. Nine protein spots were successfully identified for each fluid type 
relating to 6 different proteins in both saliva and vaginal fluid. These protein spots were 
selected based on their position within the 2D gel and their universal expression across 
each of the saliva or vaginal fluid samples. It is impossible to make comparisons 
between the two different fluid types in this study through software analysis due to the 
different protein profiles of the samples and a lack of identical protein vectors between 
them.  
 Difference Gel Electrophoresis (DIGE) is a method used to make comparisons 
between up to three samples, each labelled with a fluorescent dye and run at the same 
time on one 2D gel (Marouga, David et al. 2005). It is capable of comparing two 
samples plus a control comprising both samples combined in equal amounts. Samples 
are pre-labelled with fluorescent cyanine dyes (Cy2, Cy3 and Cy5). Using DIGE would 
mean that two body fluids could be analysed in parallel together and comparisons 
between them would be easily made determining which proteins were unique to each 
fluid. As this is a relatively new technique the imaging software and scanning 
instruments are not easily accessible and the analysis would need to be outsourced.  
Finding differences between two body fluids is a small step in forensic body fluid 
identification, ideally body fluid markers for the whole range of body fluids encountered 
in forensic investigations would need to be made. Initially saliva and vaginal fluid were 
chosen for their applicability to a rape case, for this to be complete, semen would need 
to be added to this analysis.   
 Another gap in body fluid identification is determining the differences between 
venous blood and menstrual blood. It can be unclear in rape cases with vaginal 
bleedings being attributed to menstruation by the perpetrator which could actually be 
evidence of a violent assault (Bauer and Patzelt 2008). Although a lateral flow strip is 
available for blood identification (Independent Forensics) there is no published data for 
the results when tested with menstrual blood. 
 Other pH range strips could be tested to determine whether any potential 
markers lie outwith the pH range used in this study such as acidic proline-rich proteins 
(aPRPs). aPRPs have been identified as having expression specific to saliva 
(Schenkels, Veerman et al. 1995; Hardt, Thomas et al. 2005), therefore making them 
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suitable biomarkers. PRP's bind calcium ions maintaining mineral homeostasis and 
provide a protective and reparative environment for dental enamel which is important 
for the integrity of the teeth. These were not detected in this study as they have a pI of 
approx 4 calculated using the ExPASy Compute pI/Mw tool [online] and the most acidic 
pI used for spot analysis in this study was a strip with a lower limit of 5. Since staining 
with Coomassie blue R250 has also revealed that PRPs stain pink rather than blue 
(Hardt, Thomas et al. 2005), it would therefore be simple to identify these spots in a 
future experiment if run on another 2D gel with a more acidic pI range including pI 4.  
 
7.2.2 Verification of Protein Specificity 
 
 Firstly not all the proteins identified were suitable biomarkers due to universal 
expression in all body fluids and therefore not used for verification of specificity. Other 
proteins did not have commercial antibodies or ELISA kits available at the time of 
searching. Since this time an ELISA detecting Calgranulin B (Cellsciences) has been 
identified, further work could be performed testing this ELISA with the vaginal fluid 
samples and the body fluid panel to determine its suitability as a biomarker for vaginal 
fluid. This ELISA is primarily used for the detection of colon cancer by testing stools 
and therefore Calgranulin would be present in faeces. 
Of the verification tests performed, the commercial ELISA kits were more 
successful than the dot blots due to antibody specificity problems experienced with the 
dot blot. The SCCA ELISA could distinguish samples of vaginal origin (vaginal fluid and 
menstrual blood) from the other body fluids tested. To differentiate between vaginal 
fluid and menstrual blood further experiments would be required to identify menstrual 
blood markers which could be used in conjunction with the SCCA marker. Further 
experiments would need to look at whether the levels of SCCA decrease rapidly prior 
to menstruation as was shown with sample 10. This would require more samples to be 
collected from donors at this stage of the cycle and an ELISA being run with them. As 
the experiments determined both primary (cystatin SA and SN) and secondary 
antibody specificity was problematic in the dot blots performed.  
Further investigations would be necessary with different primary and secondary 
antibodies if available. 1D western blotting would ensure that antibodies bound to the 
correct molecular weight protein band in the gel representative of the protein 
biomarker, but both cystatin SA and Cystatin SN have similar molecular weights 
therefore the only way to determine between them would be by 2D western blotting due 
to their different pIs.  
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7.3 Conclusion 
 
There is a requirement for a sophisticated method of body fluid identification 
especially for vaginal fluid samples. Recent developments have produced a saliva test 
(RSID) with little cross reactivity with other body fluids although not commonly used in 
forensic laboratories (personal comment) whereas the more traditional and more 
commonly used method of Phadebas paper showed false positives with breast milk, 
pancreatic amylase and bacterial amylase.  
From these tests a new methodology for body fluid identification should be 
identified. Although a saliva test has been identified ideally all body fluids should be 
identified in a one step procedure rather than using separate strip tests for individual 
body fluids. The first stage in this development would be to identify protein biomarkers 
of body fluids. 
 The optimisation of saliva and vaginal fluid proteomic methods provided 
suitable experimental conditions. Sample extraction was performed from source or in 
PBS followed by acetone precipitation followed by protein concentration being 
determined by the RCDC protein assay. Electrophoretic conditions, using 7cm pH 5-8 
strips in conjunction and 12% polyacrylamide gels in the second dimension were used 
with SYPRO Ruby fluorescent gel stain (Invitrogen). Image analysis was performed by 
Prodigy samespots software.  
A total of 268 spots were identified in the saliva samples and 193 spots were 
identified in the vaginal fluid samples. Of these spots 19 saliva spots and 16 vaginal 
fluid spots found in each of the sample pools were analysed by LC-MS/MS. In both 
saliva and vaginal fluid samples 9 protein biomarkers were identified within saliva and 
vaginal fluid. Of the proteins identified there were some that were considered 
universally expressed; IgA, actin, IgG, superoxide dismutase and epidermal fatty acid 
binding protein. Those that were thought to be specific to saliva; zinc-α-2 glycoprotein, 
Cystatin SA, Cystatin SN and Lipocalin, and those thought to be specific to vaginal 
fluid; SERPIN B1, Leukocyte elastase inhibitor and Calgranulin B were found. 
The SCC ELISA showed high levels of sensitivity and specificity whereas the 
Zn-α-2-Glycoprotein ELISA kit only showed high sensitivity, and no specificity in the 
body fluid samples tested with expression being detected in each fluid tested. 
The Lipocalin-1 primary antibody was unsuccessful in identifying Lipocalin 
antigens in saliva samples as well as the recombinant Lipocalin-1 protein. Although 
positive results were obtained for each antibody with the body fluid of origin when 
tested alongside a panel of body fluids, false positives were also shown for nearly 
  251 
every body fluid type. False positive reactions with body fluids were shown with both 
secondary antibodies when blots were performed without the primary antibody 
incubation. The Goat secondary antibody was shown to react with human IgG showing 
a degree of cross reactivity which was not shown with the secondary mouse antibody. 
PBS was shown to be consistently negative throughout all the blots performed.  
From this it can be seen that further investigations would need to be performed 
in order to confirm the specificity of the biomarkers where dot blots were used for 
verification due to the lack of specificity of the antibodies used. The SCC ELISA was 
capable of distinguishing samples of vaginal origin (vaginal fluid and menstrual blood) 
from the other body fluid samples. The SCC ELISA could be therefore used in 
association with menstrual blood markers to identify vaginal fluid. 
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Appendix I 
 
Research participant information sheet 
 
“Identification of characteristic proteins for distinguishing between body 
fluids for forensic purposes” 
 
You are being invited to participate in a research study. Please take time to read 
the following information carefully and discuss it with others if you wish. Feel free 
to ask if there is anything that is unclear or if you would like any further 
information. You may take as long as you would like to decide whether or not you 
wish to take part. Thank you for reading this. 
 
What is the purpose of this study? 
 
This study intends to investigate two body fluids, namely saliva and vaginal fluid, in 
order to determine a way to identify a body fluid stain. Your name will not be 
available from our records.  It is often vital to know the source of a fluid in police 
work. By improving the current methods used by forensic scientists and police 
forces, it is hoped that crimes such as rape and murder would be easier to solve 
and prove in courts of law. 
 
Why have I been chosen? 
 
People chosen for this study are fit, healthy and living in the Aberdeen area. 
 
Do I have to take part? 
 
No. You are completely free to decide whether or not to take part in the study.  If 
you decide not to take part, this will not affect your treatment in any way.  If you 
do decide to take part you will be given this information sheet to keep and be asked 
to sign a consent form. If you do decide to take part you are still free to withdraw 
at any time without giving a reason. Should you wish to withdraw from the study 
any sample stored can be returned to you or destroyed on request. 
 
What will happen to me if I take part? 
 
If you decide to take part in this study, we will ask you to produce a sample of your 
saliva. The saliva sample will be less than a teaspoonful. Your participation in this 
study can end after one donation, however if you would like to donate again in the 
future, you can indicate this on the consent form overleaf. The research for this 
study will be carried out over a period of not less than three years, with all 
remaining samples being destroyed at the end of the study in not more than five 
years. 
 
Will my taking part in this study be kept confidential? 
 
Any sample you donate to this study will be treated confidentially and investigated 
anonymously. All data gathered from the study would be stored in accordance with 
the Data Protection Act (1998). The methods used for this study would not allow for 
any medical information to be gathered, and no information about your sample 
would be passed on to a third party under any circumstances. 
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Will the study benefit me? 
 
You will not benefit. 
 
 
 
What will happen to the samples I donate? 
Once samples have been analysed and upon completion of this study, samples will 
be destroyed.  
 
What will happen to the results of the research study? 
 
The results of the study would form the bulk of a research degree (PhD) thesis with 
the possibility of publication within an appropriate scientific journal. No names will 
be included in any report of the research results. The results of the study will be 
available to any interested participant, such as yourself. 
 
 
 
Contact for further information 
 
Mrs Louisa Vincini 
 
c/o The Robert Gordon University 
School of Life Sciences 
St Andrew Street 
Aberdeen 
AB25 1HG 
 
Tel: 01224262847 
 
Email: prs.vincini@rgu.ac.uk 
 
You will be given a copy of this information sheet and a signed consent form to 
keep. 
 
Thank you for taking part in this study. 
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Appendix II 
 
Research participant information sheet  
 
 “Identification of characteristic proteins for distinguishing between body 
fluids for forensic purposes” 
 
You are being invited to participate in a research study. Please take time to read 
the following information carefully and discuss it with others if you wish. Feel free 
to ask if there is anything that is unclear or if you would like any further 
information. You may take as long as you would like to decide whether or not you 
wish to take part. Thank you for reading this. 
 
What is the purpose of this study? 
 
This study intends to investigate two body fluids, namely saliva and vaginal fluid, in 
order to determine a way to identify a body fluid stain. Your name will not be 
available from our records. It is often vital to know the source of a fluid in police 
work. By improving the current methods used by forensic scientists and police 
forces, it is hoped that crimes such as rape and murder would be easier to solve 
and prove in courts of law. 
 
Why have I been chosen? 
 
You are attending the clinic Square 13 for an intimate examination. 
 
Do I have to take part? 
 
No. You are completely free to decide whether or not to take part in the study. If 
you decide not to take part, this will not affect your treatment in any way. If you do 
decide to take part you will be given this information sheet to keep and be asked to 
sign a consent form. If you do decide to take part you are still free to withdraw at 
any time without giving a reason. Should you wish to withdraw from the study any 
sample stored can be returned to you or destroyed on request. 
 
What will happen to me if I take part? 
 
If you decide to take part in this study, a sample of your vaginal fluid and/or saliva 
will be given. The vaginal fluid sample will be in the form of two swabs taken during 
your routine gynaecological examination and the saliva sample will be less than a 
teaspoonful. The research for this study will be carried out over a period of not less 
than three years, with all remaining samples being destroyed at the end of the 
study in not more than five years. 
 
Will my taking part in this study be kept confidential? 
 
Any sample you donate to this study would be treated confidentially and 
investigated anonymously. All data gathered from the study would be stored in 
accordance with the Data Protection Act (1998). The methods used for this study 
would not allow for any medical information to be gathered, and no information 
about your sample would be passed on to a third party under any circumstances. 
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Will the study benefit me? 
 
You will not benefit. 
 
 
 
 
What will happen to the samples I donate? 
 
Once samples have been analysed and upon completion of this study, samples will 
be destroyed.  
 
 
 
 
What will happen to the results of the research study? 
 
The results of the study would form the bulk of a research degree (PhD) thesis with 
the possibility of publication within an appropriate scientific journal. No names will 
be included in any report of the research results. The results of the study will be 
available to any interested participant, such as yourself. 
 
 
 
 
Contact for further information 
 
Mrs Louisa Vincini 
 
c/o The Robert Gordon University 
School of Life Sciences 
St Andrew Street 
Aberdeen 
AB25 1HG 
 
Tel: 01224262847 
 
Email: prs.vincini@rgu.ac.uk 
 
You will be given a copy of this information sheet and a signed consent form to 
keep. 
 
Thank you for taking part in this study. 
 
 
 
 
 
 
 
 
 
  
  257 
Appendix III 
 
Research participant consent form 
 
 
Project title: “Identification of characteristic proteins for distinguishing between 
body fluids for forensic purposes” 
 
 
Name of researcher : Louisa Vincini 
 
 
    Please initial box 
 
1.  I confirm that I have read and understood the information sheet  
dated.................(version...............) of the above study and have  
had the opportunity to ask questions. 
 
 
2.  I understand that my participation is voluntary and that I am    
free to withdraw at any time, without giving any reason, without  
my legal rights or medical treatment being affected. 
 
 
3.  I agree to take part in the above study. 
 
 
 
_______________________ _________     ______________ 
Name of participant   Date      Signature          M/F 
 
 
 
____________ ________________   ________________ 
Age   time sample taken  time since  
       eating/drinking/chewing gum 
 
 
 
__________________________  ____________ ______________ 
Name of person taking consent  Date   Signature 
(if different from the researcher) 
 
      
 
__________________________  ____________ ______________ 
Researcher     Date   Signature 
 
 
 
_____________________ 
Sample Number 
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Appendix IV 
 
Research participant consent form 
 
Project title: “Identification of characteristic proteins for distinguishing between 
body fluids for forensic purposes” 
 
 
Name of researcher : Louisa Vincini 
 
 
    Please initial box 
 
4.  I confirm that I have read and understood the information sheet  
dated.................(version...............) of the above study and have  
had the opportunity to ask questions. 
 
 
5.  I understand that my participation is voluntary and that I am    
free to withdraw at any time, without giving any reason, without  
my legal rights being affected. 
 
 
 
6.  I agree to take part in the above study. 
 
 
 
 
 
 
 
_______________________  _________  ______________ 
Name of participant    Date      Signature 
  
 
 
_______________________  _______________________________ 
Age       Stage of Menstrual Cycle 
 
 
___________________________________________ 
Form of contraception 
 
 
 
__________________________  ____________ ______________ 
Name of person taking consent  Date   Signature 
 
 
 
_______________ 
Sample Number 
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Appendix V 
 
Research participant consent form 
 
Project title: “Identification of characteristic proteins for distinguishing between 
body fluids for forensic purposes” 
 
 
Name of researcher : Louisa Vincini 
 
 
    Please initial box 
 
7.  I confirm that I have read and understood the information sheet  
dated.................(version...............) of the above study and have  
had the opportunity to ask questions. 
 
 
8.  I understand that my participation is voluntary and that I am    
free to withdraw at any time, without giving any reason, without  
my legal rights being affected. 
 
 
 
9.  I agree to take part in the above study. 
 
 
 
 
 
 
 
_______________________  _________  ______________ 
Name of participant    Date      Signature 
  
 
 
_______________________  _______________________________ 
Age       Type of sample donated 
 
 
_______________________ 
Sex 
 
 
__________________________  ____________ ______________ 
Name of person taking consent  Date   Signature 
 
 
 
_______________ 
Sample Number 
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Appendix VI – Spot Count Images 
 
 
 
 
 
 
268 Saliva spots identified by SameSpots software 
 
 
 
 
 
 
 
193 Vaginal spots identified by SameSpots software  
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Appendix VII – Hit Distribution Graphs 
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Appendix VIII – Total Ion Count Graphs 
 
IgG Controls 
 
 
Spot 1C 
 
 
Spot 2C 
 
TIC: from Sample 1 (08-34342 2c) of 08-34342 2c.wiff (Nanospray) Max. 2.5e9 cps.
5 10 15 20 25 30 35 40 45 50 55
378 770 1157 1548 1643 1684 1727 1767 1808 1846 1885
Time, min
0.0
2.0e8
4.0e8
6.0e8
8.0e8
1.0e9
1.2e9
1.4e9
1.6e9
1.8e9
2.0e9
2.2e9
2.4e9
2.5e9
In
te
n
s
it
y
, 
c
p
s
27.40
39.22
32.15
40.25
42.1831.21
30.24
34.16 36.30
25.55
44.10
58.58
50.96
56.9354.48
23.32
TIC: from Sample 1 (08-34343 4c) of 08-34343 4c.wiff (Nanospray) Max. 4.2e8 cps.
5 10 15 20 25 30 35 40 45 50 55
366 758 1138 1529 1789 1862 1901 1939 1977 2019 2066
Time, min
0.0
2.0e7
4.0e7
6.0e7
8.0e7
1.0e8
1.2e8
1.4e8
1.6e8
1.8e8
2.0e8
2.2e8
2.4e8
2.6e8
2.8e8
3.0e8
3.2e8
3.4e8
3.6e8
3.8e8
4.0e8
4.2e8
In
te
n
s
it
y
, 
c
p
s
30.91
39.44
31.86
58.22
41.72
46.56
37.53 43.78
34.44
48.62
55.81
28.16
55.24
27.11
25.38
24.90
19.71
  266 
 
 
 
 
Saliva 
 
 
 
 
Spot 6 
 
 
Spot 13 
 
TIC: from Sample 1 (08-34345 6s) of 08-34345 6s.wiff (Nanospray) Max. 3.5e8 cps.
5 10 15 20 25 30 35 40 45 50 55
374 766 1164 1550 1851 1963 2005 2051 2091 2132 2186
Time, min
0.0
2.0e7
4.0e7
6.0e7
8.0e7
1.0e8
1.2e8
1.4e8
1.6e8
1.8e8
2.0e8
2.2e8
2.4e8
2.6e8
2.8e8
3.0e8
3.2e8
3.4e8
3.5e8
In
te
n
s
it
y
, 
c
p
s
30.80
48.31
58.92
31.44 47.24
46.69
39.96
49.91
37.18
56.6036.00
52.57
27.51
53.10
24.86
23.35
16.21 22.19
TIC: from Sample 1 (08-34349 13) of 08-34349 13.wiff (Nanospray) Max. 6.5e7 cps.
5 10 15 20 25 30 35 40 45 50 55
405 809 1214 1616 1998 2335 2613 2965 3284 3664 4015
Time, min
0.0
5.0e6
1.0e7
1.5e7
2.0e7
2.5e7
3.0e7
3.5e7
4.0e7
4.5e7
5.0e7
5.5e7
6.0e7
6.5e7
In
te
n
s
it
y
, 
c
p
s
42.25
31.86
30.97
29.10
32.4326.08
32.88
43.78
55.7640.2133.68
43.9428.75 39.43
37.96
45.98
49.43
53.86
23.51
57.31
21.83
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Spot 27 
 
 
Spot 33 
 
 
 
 
 
 
TIC: from Sample 1 (08-34354 27) of 08-34354 27.wiff (Nanospray) Max. 5.3e7 cps.
5 10 15 20 25 30 35 40 45 50 55
405 808 1212 1615 1988 2309 2601 2934 3255 3642 3993
Time, min
0.0
5.0e6
1.0e7
1.5e7
2.0e7
2.5e7
3.0e7
3.5e7
4.0e7
4.5e7
5.0e7
5.3e7
In
te
n
s
it
y
, 
c
p
s
42.28
30.8625.84
43.36
32.04
30.34
30.09
32.46
28.75
43.79
7.03
32.63 44.06
46.25
34.8324.60 41.17
40.20
46.85
36.21 55.42
57.3123.48 54.74
23.11
21.25
12.632.78
TIC: from Sample 1 (08-34355 33) of 08-34355 33.wiff (Nanospray) Max. 5.7e7 cps.
5 10 15 20 25 30 35 40 45 50 55
405 809 1213 1615 1969 2249 2534 2872 3202 3583 3918
Time, min
0.0
5.0e6
1.0e7
1.5e7
2.0e7
2.5e7
3.0e7
3.5e7
4.0e7
4.5e7
5.0e7
5.5e7
5.7e7
In
te
n
s
it
y
, 
c
p
s
43.4228.70
25.66
30.01 42.31
43.71
33.50
57.0246.01
56.09
35.28 46.1341.09
36.58
39.26
46.36 57.7323.14 49.09 55.27
52.48
21.88
19.47
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Spot 34 
 
 
Spot 41 
 
 
 
 
 
 
TIC: from Sample 1 (08-34356 34) of 08-34356 34.wiff (Nanospray) Max. 2.4e8 cps.
5 10 15 20 25 30 35 40 45 50 55
376 743 1135 1527 1877 2022 2087 2143 2187 2227 2284
Time, min
0.0
1.0e7
2.0e7
3.0e7
4.0e7
5.0e7
6.0e7
7.0e7
8.0e7
9.0e7
1.0e8
1.1e8
1.2e8
1.3e8
1.4e8
1.5e8
1.6e8
1.7e8
1.8e8
1.9e8
2.0e8
2.1e8
2.2e8
2.3e8
2.4e8
In
te
n
s
it
y
, 
c
p
s
29.91
47.75
48.56
46.63
58.8945.81
44.81
57.16
36.47 40.89
33.95
55.57
27.29
25.54
22.86
16.3015.58
7.03
TIC: from Sample 1 (08-34358 41s) of 08-34358 41s.wiff (Nanospray) Max. 6.1e8 cps.
5 10 15 20 25 30 35 40 45 50 55
330 655 985 1314 1445 1485 1522 1563 1618 1676 1715
Time, min
0.0
5.0e7
1.0e8
1.5e8
2.0e8
2.5e8
3.0e8
3.5e8
4.0e8
4.5e8
5.0e8
5.5e8
6.0e8
In
te
n
s
it
y
, 
c
p
s
55.14
54.65
54.14
28.28
31.05
27.52 32.64
34.67
51.7526.96
46.4124.92
37.59 45.48
23.90 49.51
20.26
19.34
4.61
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Spot 43 
 
 
Spot 46 
 
 
 
 
 
 
TIC: from Sample 1 (08-34359 43) of 08-34359 43.wiff (Nanospray) Max. 6.0e8 cps.
5 10 15 20 25 30 35 40 45 50 55
337 675 1002 1315 1471 1513 1559 1611 1677 1735 1772
Time, min
0.0
5.0e7
1.0e8
1.5e8
2.0e8
2.5e8
3.0e8
3.5e8
4.0e8
4.5e8
5.0e8
5.5e8
6.0e8
In
te
n
s
it
y
, 
c
p
s
56.28
54.89
26.69
49.91
42.2028.04
43.17
24.35 32.01
36.61 41.04
43.88
TIC: from Sample 1 (08-34360 46) of 08-34360 46.wiff (Nanospray) Max. 4.6e8 cps.
5 10 15 20 25 30 35 40 45 50 55
299 607 936 1257 1410 1451 1497 1548 1612 1674 1713
Time, min
0.0
2.0e7
4.0e7
6.0e7
8.0e7
1.0e8
1.2e8
1.4e8
1.6e8
1.8e8
2.0e8
2.2e8
2.4e8
2.6e8
2.8e8
3.0e8
3.2e8
3.4e8
3.6e8
3.8e8
4.0e8
4.2e8
4.4e8
4.6e8
In
te
n
s
it
y
, 
c
p
s
57.45
56.39
26.59
53.82
42.90
30.46
50.5732.35 43.89
37.57
41.77
49.09
40.23
21.4119.4518.04
15.4710.916.29 7.514.14
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Spot 47 
 
 
Spot 59 
 
 
 
 
 
 
TIC: from Sample 1 (08-34361 47s) of 08-34361 47s.wiff (Nanospray) Max. 4.6e8 cps.
5 10 15 20 25 30 35 40 45 50 55
337 688 1040 1392 1504 1542 1584 1633 1697 1758 1795
Time, min
0.0
2.0e7
4.0e7
6.0e7
8.0e7
1.0e8
1.2e8
1.4e8
1.6e8
1.8e8
2.0e8
2.2e8
2.4e8
2.6e8
2.8e8
3.0e8
3.2e8
3.4e8
3.6e8
3.8e8
4.0e8
4.2e8
4.4e8
4.6e8
In
te
n
s
it
y
, 
c
p
s
56.82
54.77
26.71
32.51
53.04
33.70
34.71
31.39
36.55
43.09
44.1324.29
18.12
TIC: from Sample 1 (08-34364 59s) of 08-34364 59s.wiff (Nanospray) Max. 3.5e8 cps.
5 10 15 20 25 30 35 40 45 50 55
254 557 850 1136 1305 1366 1431 1486 1544 1593 1632
Time, min
0.0
2.0e7
4.0e7
6.0e7
8.0e7
1.0e8
1.2e8
1.4e8
1.6e8
1.8e8
2.0e8
2.2e8
2.4e8
2.6e8
2.8e8
3.0e8
3.2e8
3.4e8
In
te
n
s
it
y
, 
c
p
s
27.00
55.56
53.89
27.90
51.32
47.68
39.45
36.23
32.83
22.74
18.29
4.27
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Spot 66 
 
 
Spot 70 
 
 
 
 
 
TIC: from Sample 1 (08-34366 66) of 08-34366 66.wiff (Nanospray) Max. 3.0e8 cps.
5 10 15 20 25 30 35 40 45 50 55
307 596 917 1226 1433 1528 1600 1669 1731 1781 1821
Time, min
0.0
2.0e7
4.0e7
6.0e7
8.0e7
1.0e8
1.2e8
1.4e8
1.6e8
1.8e8
2.0e8
2.2e8
2.4e8
2.6e8
2.8e8
3.0e8
In
te
n
s
it
y
, 
c
p
s
27.69
56.9055.86
54.54
52.75
43.07
36.18
49.68
47.65
39.71
24.83 31.77 45.6834.80
3.92
1.76
TIC: from Sample 1 (08-34368 70) of 08-34368 70.wiff (Nanospray) Max. 1.5e8 cps.
5 10 15 20 25 30 35 40 45 50 55
398 796 1194 1568 1680 1752 1935 2274 2605 2998 3284
Time, min
0.0
1.0e7
2.0e7
3.0e7
4.0e7
5.0e7
6.0e7
7.0e7
8.0e7
9.0e7
1.0e8
1.1e8
1.2e8
1.3e8
1.4e8
1.5e8
In
te
n
s
it
y
, 
c
p
s
23.79
26.57
27.60
29.15
54.6821.63
39.42
30.8921.19
40.33
54.16
20.29
55.62
18.97 36.55 56.53
41.31 53.3643.8217.90
58.06
9.98
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Spot 72 
 
 
Spot 76 
 
 
 
 
 
TIC: from Sample 1 (08-34369 72) of 08-34369 72.wiff (Nanospray) Max. 3.1e8 cps.
5 10 15 20 25 30 35 40 45 50 55
307 610 897 1164 1262 1325 1383 1442 1500 1551 1589
Time, min
0.0
2.0e7
4.0e7
6.0e7
8.0e7
1.0e8
1.2e8
1.4e8
1.6e8
1.8e8
2.0e8
2.2e8
2.4e8
2.6e8
2.8e8
3.0e8
In
te
n
s
it
y
, 
c
p
s
24.56
58.17
55.93
54.18
53.36
51.73
50.40
45.7736.41
38.5821.70 31.36 35.56 43.9627.93
40.38
19.66
TIC: from Sample 1 (08-34372 76) of 08-34372 76.wiff (Nanospray) Max. 3.1e8 cps.
5 10 15 20 25 30 35 40 45 50 55
334 646 971 1276 1475 1550 1601 1657 1712 1761 1799
Time, min
0.0
2.0e7
4.0e7
6.0e7
8.0e7
1.0e8
1.2e8
1.4e8
1.6e8
1.8e8
2.0e8
2.2e8
2.4e8
2.6e8
2.8e8
3.0e8
3.1e8
In
te
n
s
it
y
, 
c
p
s
27.77
55.89
28.73
53.03
49.4947.3640.4532.05
31.1926.22 35.25 39.38
42.82
24.51
46.86
5.40
12.273.270.61
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Spot 79 
 
 
Spot 81 
 
 
 
 
TIC: from Sample 1 (08-34373 79) of 08-34373 79.wiff (Nanospray) Max. 3.6e8 cps.
5 10 15 20 25 30 35 40 45 50 55
294 628 928 1172 1285 1335 1383 1431 1476 1517 1554
Time, min
0.0
2.0e7
4.0e7
6.0e7
8.0e7
1.0e8
1.2e8
1.4e8
1.6e8
1.8e8
2.0e8
2.2e8
2.4e8
2.6e8
2.8e8
3.0e8
3.2e8
3.4e8
3.6e8
In
te
n
s
it
y
, 
c
p
s
27.94
56.47
40.81
28.87
52.73
47.3836.4634.7532.8525.03 46.1337.43
19.14
18.1311.69 12.381.96
TIC: from Sample 1 (08-34374 81s) of 08-34374 81s.wiff (Nanospray) Max. 8.2e8 cps.
5 10 15 20 25 30 35 40 45 50 55
321 622 923 1191 1324 1373 1411 1449 1494 1540 1579
Time, min
0.0
5.0e7
1.0e8
1.5e8
2.0e8
2.5e8
3.0e8
3.5e8
4.0e8
4.5e8
5.0e8
5.5e8
6.0e8
6.5e8
7.0e8
7.5e8
8.0e8
8.2e8
In
te
n
s
it
y
, 
c
p
s
30.89
27.55
36.62
35.20 55.13
39.3728.46
47.7224.43 44.40
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Spot 83 
 
 
Spot 85 
 
 
 
 
TIC: from Sample 1 (08-34375 83) of 08-34375 83.wiff (Nanospray) Max. 2.0e8 cps.
5 10 15 20 25 30 35 40 45 50 55
398 796 1194 1586 1705 1754 1888 2226 2586 2972 3273
Time, min
0.0
1.0e7
2.0e7
3.0e7
4.0e7
5.0e7
6.0e7
7.0e7
8.0e7
9.0e7
1.0e8
1.1e8
1.2e8
1.3e8
1.4e8
1.5e8
1.6e8
1.7e8
1.8e8
1.9e8
2.0e8
In
te
n
s
it
y
, 
c
p
s
27.65
26.60
24.07
29.57
23.60
30.73
21.89
55.11
31.2821.34
33.50
20.64
40.77 54.31
36.42
42.40 56.60
46.68
TIC: from Sample 1 (08-34377 85s - A) of 08-34377 85s - A.wiff (Nanospray) Max. 4.1e8 cps.
5 10 15 20 25 30 35 40 45 50 55
249 494 761 1032 1216 1279 1344 1399 1450 1495 1532
Time, min
0.0
2.0e7
4.0e7
6.0e7
8.0e7
1.0e8
1.2e8
1.4e8
1.6e8
1.8e8
2.0e8
2.2e8
2.4e8
2.6e8
2.8e8
3.0e8
3.2e8
3.4e8
3.6e8
3.8e8
4.0e8
In
te
n
s
it
y
, 
c
p
s
28.46
55.41
54.14
29.41
49.1647.20
26.39 35.6225.31 38.69
40.71 42.5131.07 34.40
12.48
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Spot 89 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TIC: from Sample 1 (08-34380 89) of 08-34380 89.wiff (Nanospray) Max. 2.8e8 cps.
5 10 15 20 25 30 35 40 45 50 55
245 465 716 934 1038 1100 1167 1223 1295 1348 1389
Time, min
0.0
2.0e7
4.0e7
6.0e7
8.0e7
1.0e8
1.2e8
1.4e8
1.6e8
1.8e8
2.0e8
2.2e8
2.4e8
2.6e8
2.8e8
In
te
n
s
it
y
, 
c
p
s
24.76
58.69
56.44
55.12
25.67
51.99
47.71
28.75 36.12
29.92 31.90
21.87
44.6842.42
24.04
10.72 17.04
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Vaginal Fluid 
 
 
 
 
Spot 6 
 
 
Spot 8 
 
 
 
TIC: from Sample 1 (08-34344 6v) of 08-34344 6v.wiff (Nanospray) Max. 3.5e8 cps.
5 10 15 20 25 30 35 40 45 50 55
365 756 1137 1504 1810 1964 2009 2052 2091 2134 2189
Time, min
0.0
2.0e7
4.0e7
6.0e7
8.0e7
1.0e8
1.2e8
1.4e8
1.6e8
1.8e8
2.0e8
2.2e8
2.4e8
2.6e8
2.8e8
3.0e8
3.2e8
3.4e8
3.5e8
In
te
n
s
it
y
, 
c
p
s
30.92
58.20
41.22 47.23
46.36
49.05
40.62 42.84
38.48
56.85
36.56
49.69
34.28
55.33
53.2428.07
26.66
22.0614.40 15.89
TIC: from Sample 1 (08-34347 8) of 08-34347 8.wiff (Nanospray) Max. 8.0e7 cps.
5 10 15 20 25 30 35 40 45 50 55
405 809 1213 1603 1949 2167 2384 2726 3049 3431 3737
Time, min
0.0
5.0e6
1.0e7
1.5e7
2.0e7
2.5e7
3.0e7
3.5e7
4.0e7
4.5e7
5.0e7
5.5e7
6.0e7
6.5e7
7.0e7
7.5e7
8.0e7
In
te
n
s
it
y
, 
c
p
s
41.49
30.77 31.8425.56
27.87
55.9142.52
32.85
55.19
34.62
37.63
23.10
40.39
43.32
46.10 56.65
47.10
51.2420.96
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Spot 14 
 
 
Spot 17 
 
 
 
TIC: from Sample 1 (08-34350 14) of 08-34350 14.wiff (Nanospray) Max. 7.9e7 cps.
5 10 15 20 25 30 35 40 45 50 55
405 809 1213 1615 1957 2188 2447 2759 3070 3450 3815
Time, min
0.0
5.0e6
1.0e7
1.5e7
2.0e7
2.5e7
3.0e7
3.5e7
4.0e7
4.5e7
5.0e7
5.5e7
6.0e7
6.5e7
7.0e7
7.5e7
7.9e7
In
te
n
s
it
y
, 
c
p
s
25.79
43.42
30.47
29.87
31.03
56.8742.2925.00
35.5031.89
43.74 55.9234.03
36.19
42.05
44.19
39.67
48.78
55.5723.32
45.52
58.2248.61 52.72
23.12
21.55
15.667.254.843.61
TIC: from Sample 1 (08-34351 17) of 08-34351 17.wiff (Nanospray) Max. 8.0e7 cps.
5 10 15 20 25 30 35 40 45 50 55
404 808 1212 1609 1939 2150 2368 2692 2992 3360 3706
Time, min
0.0
5.0e6
1.0e7
1.5e7
2.0e7
2.5e7
3.0e7
3.5e7
4.0e7
4.5e7
5.0e7
5.5e7
6.0e7
6.5e7
7.0e7
7.5e7
8.0e7
In
te
n
s
it
y
, 
c
p
s
26.14
27.38 30.00
32.01
43.4542.33
56.85
25.00
55.99
41.19
43.7436.90
23.42 39.91 45.95
58.2248.83
55.19
22.83
52.95
20.90
17.07
13.995.134.78
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Spot 19 
 
 
Spot 39 
 
 
 
TIC: from Sample 1 (08-34352 19) of 08-34352 19.wiff (Nanospray) Max. 8.6e7 cps.
5 10 15 20 25 30 35 40 45 50 55
404 807 1211 1613 1899 2062 2222 2525 2838 3208 3566
Time, min
0.0
5.0e6
1.0e7
1.5e7
2.0e7
2.5e7
3.0e7
3.5e7
4.0e7
4.5e7
5.0e7
5.5e7
6.0e7
6.5e7
7.0e7
7.5e7
8.0e7
8.5e7
In
te
n
s
it
y
, 
c
p
s
32.84
42.18
25.78
31.57
30.11
28.42
43.19
23.68
35.16
40.94
39.15 43.73
45.81
55.76
21.97 51.9946.30
17.53
14.12
TIC: from Sample 1 (08-34357 39) of 08-34357 39.wiff (Nanospray) Max. 6.2e7 cps.
5 10 15 20 25 30 35 40 45 50 55
405 809 1213 1616 1968 2250 2568 2921 3231 3623 3976
Time, min
0.0
5.0e6
1.0e7
1.5e7
2.0e7
2.5e7
3.0e7
3.5e7
4.0e7
4.5e7
5.0e7
5.5e7
6.0e7
6.2e7
In
te
n
s
it
y
, 
c
p
s
26.03
26.68
43.49
31.02
31.50
41.35
43.86
46.58
39.2423.09
56.00
32.76 38.95
33.96
49.3246.80
57.08
19.66
8.51
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Spot 53 
 
 
Spot 59 
 
 
 
TIC: from Sample 1 (08-34362 53) of 08-34362 53.wiff (Nanospray) Max. 1.2e8 cps.
5 10 15 20 25 30 35 40 45 50 55
393 791 1183 1564 1761 1890 2102 2408 2759 3065 3266
Time, min
0.00
5.00e6
1.00e7
1.50e7
2.00e7
2.50e7
3.00e7
3.50e7
4.00e7
4.50e7
5.00e7
5.50e7
6.00e7
6.50e7
7.00e7
7.50e7
8.00e7
8.50e7
9.00e7
9.50e7
1.00e8
1.05e8
1.10e8
1.15e8
1.20e8
In
te
n
s
it
y
, 
c
p
s
23.76
54.4327.52
26.57
33.66
28.45
39.23
45.94
53.54
40.07
30.81
38.97
52.8121.28
55.3236.31 40.99
51.6420.47 49.2642.88
18.54
8.17
TIC: from Sample 1 (08-34363 59v) of 08-34363 59v.wiff (Nanospray) Max. 1.7e8 cps.
5 10 15 20 25 30 35 40 45 50 55
393 791 1189 1547 1649 1692 1806 2136 2479 2848 3088
Time, min
0.0
1.0e7
2.0e7
3.0e7
4.0e7
5.0e7
6.0e7
7.0e7
8.0e7
9.0e7
1.0e8
1.1e8
1.2e8
1.3e8
1.4e8
1.5e8
1.6e8
1.7e8
In
te
n
s
it
y
, 
c
p
s
28.16
28.77
23.78
22.93
22.39
32.14
21.48
54.63
21.05 22.04
39.36
40.36
53.82
20.27
34.38
53.3940.69
55.10
17.88
46.76
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Spot 64 
 
 
Spot 73 
 
 
 
TIC: from Sample 1 (08-34365 64) of 08-34365 64.wiff (Nanospray) Max. 3.1e8 cps.
5 10 15 20 25 30 35 40 45 50 55
301 563 857 1155 1256 1310 1357 1409 1465 1512 1551
Time, min
0.0
2.0e7
4.0e7
6.0e7
8.0e7
1.0e8
1.2e8
1.4e8
1.6e8
1.8e8
2.0e8
2.2e8
2.4e8
2.6e8
2.8e8
3.0e8
3.1e8
In
te
n
s
it
y
, 
c
p
s
27.77
55.96
57.33
55.22
53.16
32.47
51.5239.71
48.8346.57
34.14 38.79
25.8024.55
41.07
22.39
20.20
7.02
2.08
TIC: from Sample 1 (08-34370 73) of 08-34370 73.wiff (Nanospray) Max. 4.2e8 cps.
5 10 15 20 25 30 35 40 45 50 55
399 797 1183 1490 1538 1576 1706 2018 2368 2748 3052
Time, min
0.0
2.0e7
4.0e7
6.0e7
8.0e7
1.0e8
1.2e8
1.4e8
1.6e8
1.8e8
2.0e8
2.2e8
2.4e8
2.6e8
2.8e8
3.0e8
3.2e8
3.4e8
3.6e8
3.8e8
4.0e8
4.2e8
In
te
n
s
it
y
, 
c
p
s
28.23
25.44
23.03
22.07
30.99
19.13
31.36
55.0733.63
40.46
54.2635.67 37.76
43.32 46.69
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Spot 74 
 
 
Spot 85 
 
 
 
TIC: from Sample 1 (08-34371 74) of 08-34371 74.wiff (Nanospray) Max. 3.6e8 cps.
5 10 15 20 25 30 35 40 45 50 55
298 615 919 1219 1368 1429 1486 1540 1599 1648 1689
Time, min
0.0
2.0e7
4.0e7
6.0e7
8.0e7
1.0e8
1.2e8
1.4e8
1.6e8
1.8e8
2.0e8
2.2e8
2.4e8
2.6e8
2.8e8
3.0e8
3.2e8
3.4e8
3.6e8
In
te
n
s
it
y
, 
c
p
s
25.61
55.8356.44
53.85
26.61
52.85
48.85
41.29 47.87
22.78 37.7634.72
33.69
29.48
44.15
1.78
TIC: from Sample 1 (08-34376 85v) of 08-34376 85v.wiff (Nanospray) Max. 3.6e8 cps.
5 10 15 20 25 30 35 40 45 50 55
289 531 814 1066 1200 1252 1307 1361 1415 1461 1500
Time, min
0.0
2.0e7
4.0e7
6.0e7
8.0e7
1.0e8
1.2e8
1.4e8
1.6e8
1.8e8
2.0e8
2.2e8
2.4e8
2.6e8
2.8e8
3.0e8
3.2e8
3.4e8
3.6e8
In
te
n
s
it
y
, 
c
p
s
26.43
56.03
55.20
27.37 52.61
24.47
37.85
50.7223.38 35.29 47.58
33.25
42.41
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Spot 86 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TIC: from Sample 1 (08-34379 86) of 08-34379 86.wiff (Nanospray) Max. 3.1e8 cps.
5 10 15 20 25 30 35 40 45 50 55
262 520 770 1026 1178 1239 1295 1355 1410 1461 1501
Time, min
0.0
2.0e7
4.0e7
6.0e7
8.0e7
1.0e8
1.2e8
1.4e8
1.6e8
1.8e8
2.0e8
2.2e8
2.4e8
2.6e8
2.8e8
3.0e8
3.1e8
In
te
n
s
it
y
, 
c
p
s
27.61
56.37
57.27
55.12
53.54
28.56
49.62
47.3025.66
38.06
34.68
24.67 31.38 41.85
10.4711.03
1.46
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Appendix IX- ELISA Standard Curves 
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With advances in DNA technology there has become a need for a sophisticated 
method of body fluid detection in forensic analysis. In this study, a two-
dimensional proteomics approach to identification was investigated. Human 
body fluids differ dramatically in function and composition. As protein 
expression is tissue dependent a proteomics approach seems viable and 
should show variation between fluid types. 
Body fluids studied were saliva, vaginal fluid and semen as these are most 
likely to be encountered in forensic labs. Clear differences were shown in the 
proteomic profiles of each body fluid when stained with SYPRO Ruby gel stain. 
These differences could be exploited in further experiments in order to find 
biomarkers for each fluid type.    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  304 
 
 
 
 
 
 
  305 
Poster Presentation at Joint conference of the Forensic Science Society 
with the Centre for Forensic investigation, University of Teeside & Body 
Fluids Forum- April 2008 
University of Teeside Middlesborough. 
A comparison of saliva detection methods.  
 
Louisa Vincini, Joanna McCurry, Theresa Wilson 
 
Prs.vincini@rgu.ac.uk 
School of Life Sciences, The Robert Gordon University, Aberdeen, AB25 1HG 
Scotland. 
 
 α-Amylase has traditionally been used to detect saliva stains using 
techniques such as Phadebas paper and the Iodine reaction. These tests 
cannot distinguish between isoforms of α-Amylase and hence cannot 
differentiate between salivary and pancreatic amylases. Recent developments 
have seen the introduction of detection kits which claim to offer a greater 
sensitivity and specificity; an immunochromatographic membrane strip test 
manufactured by Independent Forensics using antibodies specific to human 
salivary amylase, and the SALIgAE test from Abacus Diagnostics.  
 In this study we compared these kits with Phadebas paper, by analysing 
human body fluids such as saliva, semen, urine, blood, menstrual blood, sweat 
and vaginal secretions, saliva from several animals and mock casework 
samples as well as two commercially produced α-Amylase products. The data 
showed that the immunochromatographic strip test was the most sensitive yet 
showed some cross reactivity with sweat and semen stains. The SALIgAE test 
showed cross reactivity with urine and pancreatic α-Amylase.  We concluded 
that neither of these tests demonstrate the specificity claimed. 
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